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 Glial cell line-derived neurotrophic factor (GDNF) and neurturin (NTN) belong to a 
family of ligands (GFLs) that are known to be involved in many aspects of neurobiology, 
including neuronal differentiation, proliferation, survival and migration. GFLs activate 
downstream signaling through a multi-component receptor complex consisting of a preferred 
high-affinity GDNF family receptor alpha (GFRα) and co-receptors including Ret and/or 
neural cell adhesion molecule (NCAM). GFRα1 and GFRα2 have been identified as the 
preferred receptors for GDNF and NTN, respectively. Multiple alternatively spliced isoforms 
of the GFRα1, GFRα2 and Ret have been identified in the nervous system, but whether these 
isoforms serve distinct or redundant functions are not well addressed. The studies in this thesis 
are focused on unraveling the distinct biochemical and phenotypical effects of ligand activated 
GFRα1, GFRα2 and Ret receptor isoforms on neuronal cell differentiation and glioma cell 
migration.  
 GFRα1 is alternatively spliced into two isoforms: GFRα1a and GFRα1b. Upon ligand 
stimulations, GFRα1a induced neurite outgrowth in neuroblastoma cells via ERK1/2 and 
Rac1/Cdc42 activations. On the contrary, GFRα1b inhibited GFRα1a-mediated neurite 
outgrowth through the activation of RhoA-ROCK pathway. Compared to normal brain which 
expressed comparable levels of GFRα1 isoforms, human glioma specimens were found to 
predominately express GFRα1b. Interestingly, GFRα1b but not GFRα1a was required for 
GDNF-induced RhoA expression and migration of C6 glioma cells. These findings suggest the 
differential involvement of GFRα1 isoforms in neuronal differentiation and glioma motility. 
 Alternative splicing of GFRα2 results in at least three isoforms: GFRα2a, GFRα2b 
and GFRα2c. Upon ligand stimulations, GFRα2a and GFRα2c but not GFRα2b promoted 
CREB phosphorylation, sustained ERK1/2 activation and neurite outgrowth in PC12 cells. 
Interestingly, agonists of cAMP-PKA pathway cooperated with NTN to promote sustained 
ERK1/2 activation and neurite outgrowth through GFRα2b. Furthermore, cAMP-PKA 
signaling was found to be involved in GFRα2a and GFRα2c mediated neurite outgrowth. This 
vii 
 
study has not only identified the involvement of cAMP-PKA signaling in GFLs-induced 
neurite outgrowth but also provided novel insights into the functional difference of GFRα2 
isoforms. 
 Two major Ret isoforms, Ret9 and Ret51, produced by alternative splicing at C-
termini have been identified. GDNF signaling via GFRα1a was able to induce neuronal 
differentiation through both Ret isoforms. Intriguingly, Ret9 but not Ret51 regulated 
activation of FRS2α and Src. Ret9-mediated late ERK1/2 activation and neurite outgrowth 
were dependent on Src kinase activity. In addition, Ret9 and Ret51 regulated distinct gene 
expression profiles upon ligand stimulations. In this study, a novel Ret serine residue has been 
identified to be critical for Ret kinase activity and GDNF-induced neurite outgrowth in PC12 
cells. These results further demonstrate the functional differences and significance of Ret 
isoforms in GDNF-induced neurite outgrowth. 
 In the attempt to explore the effects of GFLs and microRNA (miRNA), a novel high 
performance quantitative real time PCR assay was developed. Using this assay, a number of 
miRNAs were found to be regulated by GDNF in human glioma cells, which may contribute 
to the modulation of glioma behaviors by GDNF signaling. 
 The results from this study highlight the functional diversity of GDNF receptor 
isoforms in regulating neuronal differentiation and glioma migration. The existence of 
multiple alternatively spliced isoforms of GFRα1, GFRα2 and Ret provides a paradigm shift 
of how this limited number of ligands and receptors can generate the pleiotropic effects by 
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1.1. Motivations of the study 
 
 Glial cell line-derived neurotrophic factor (GDNF) and neurturin (NTN) belong to a 
family of ligands (GFLs) that are known to be involved in many aspects of neurobiology, 
from cell proliferation, differentiation, migration, neurotransmitter release and neuronal 
excitability to neuronal regeneration. Because GFLs have protective and restorative effects on 
a variety of neurons in culture and animal models, it has raised hopes that GFLs could serve 
as therapeutics to treat neurodegenerative disorders. With great promise, both GDNF and 
NTN are currently in phase II clinical trials for Parkinson’s disease.  
 Homodimeric GFLs are known to activate downstream signaling by forming a multi-
component receptor complex consisting of a preferred high-affinity GDNF family receptor 
alpha (GFRα) and co-receptors including Ret and/or NCAM. Although GDNF and NTN 
transduce signal through its respective receptor GFRα1 and GFRα2, cross-talk between 
ligands and receptors is widely observed. Despite the clinical importance of GFLs in 
neurodegenerative diseases, the detailed molecular mechanisms of GDNF signaling is far 
from being fully deciphered. An important feature of GDNF signaling system is the 
combinatorial interactions of the multi-component receptor complex (receptors and co-
receptors), which may result in a plethora of diverse biological outcomes. Furthermore, the 
existence of multiple alternatively spliced isoforms of GFRα1, GFRα2 and Ret has been 
reported in the nervous system, but whether these isoforms serve distinct or redundant 
functions are not well addressed. The emerging view is that GDNF family ligands may 
regulate distinct signalling events and biological functions through specific interactions of 
receptor components and isoforms.  
 This thesis aims to better understand the distinct functions of alternatively spliced 
isoforms of GFRα1 (GFRα1a and GFRα1b), GFRα2 (GFRα2a, GFRα2b and GFRα2c) and 
Ret (Ret9 and Ret51) in regulating GDNF signaling. The focus is on GDNF and NTN-
induced signaling events (kinases/GTPases activations, gene expressions and microRNA 
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expressions) and phenotypic outcomes (neuronal differentiation and glioma migration) 
through these receptor isoforms. 
 
1.2. Organization of the thesis 
 
 This thesis is organized into six chapters (Chapters 3-8) based on specific scientific 
questions and findings. Chapter 3 reports the unexpected discovery that GDNF-induced cell 
signaling and neurite outgrowths are differentially mediated by GFRα1 isoforms, where 
GFRα1b inhibits GFRα1a-mediated neurite outgrowth through the activation of RhoA-ROCK 
pathway. Extending the studies on GFRα1 isoforms, Chapter 4 describes another 
unanticipated finding that GFRα1b but not GFRα1a is involved in GDNF-regulated RhoA 
expression and glioma cell migration. Chapter 5 reports the findings that differential 
neuritogenic activities of GFRα2 isoforms may partly be attributed to the differential 
modulation of cAMP-PKA signaling pathway, which is required for ligand-induced neurite 
outgrowth through all GFRα2 isoforms. Chapter 6 presents a study that demonstrates the 
involvement of distinct signaling pathways in Ret9 and Ret51-regulated GDNF-induced 
neurite outgrowth and gene expressions. In an effort to better understand Ret activation, 
Chapter 7 describes a study and presents evidence that Ser909 is a novel residue critical for 
Ret kinase activity and GDNF-induced neurite outgrowth. Lastly, Chapter 8 focuses on 
development of a novel high performance assay for quantification of microRNAs and the 
identification of GDNF-regulated miRNAs in human gliomas. 
 
1.3. List of related publications (published, submitted and in preparation) 
 
1. Wan G, Zhou L and Too HP. (2011) “Ret9 but not Ret51 activates Src in lipid rafts and 
requires Src for GDNF-induced gene expressions, ERK1/2 activation and neurite 
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2. Wan G*, Zhou L*, Lim QE, Wong YH and Too HP. (2011) “Cyclic AMP signalling 
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2.1. GDNF family of ligands (GFLs) 
 
 Glial cell line-derived neurotrophic factor (GDNF) is the prototype of a family of 
structurally related molecules that is a distantly related member of the TGF-β superfamily 
with conserved cystine knots. To date, four members of the GFLs [GDNF, NTN, Artemin 
(ART, also known as Enovin or neublastin), and Persephin (PSP)] have been identified in 
mammals. GDNF was originally purified from the conditioned media derived from a rat 
glioma cell-line (B49), which was previously shown to secrete potent trophic factors for 
cultured embryonic midbrain dopamine neurons (1). Similarly, NTN was purified from 
conditioned media derived from Chinese hamster ovary cells and shown to support the long-
term survival of superior cervical ganglion sympathetic cells in culture (2). Homology-based 
PCR screening was then used to identify PSP (3), and thereafter database searches identified 
ART (4), yet another GFL. A detailed and recent search of the human genome database 
(NCBI build 36.3) did not appear to reveal the existence of other GFLs. Orthologues of all 
four GFLs have also been reported in a variety of vertebrates including bony fishes but NTN 
is absent in clawed frog and PSP is absent in the chicken genome (5).  
 GFLs are encoded by single copy genes and the expressions of GFLs have been 
identified in many different regions of the nervous system, supporting the notion of its 
involvement as neurotrophic factors in the development, functional activity and maintenance 
of a variety of neuronal systems (6-9). Multiple transcripts of GDNF (10-16), ART (17)  and 
PSP (18) have been reported in different tissues. The expressions of some of these transcripts 
are tissue selective and specifically regulated by external stimuli (16,19). GFLs are 
biosynthesized and secreted as glycoproteins by a variety of tissues, including neurons 
(6,20,21). All the GFLs are produced in the form of precursors, preproGFLs. The signal 
peptide and the proGFLs are further processed by proteolytic cleavages, glycosylated and 
disulphide linked to produce the mature form of GFLs. The mature form of GDNF is 
anterogradely transported in axons as well as in dendrites to synapses and is involved in 
neuronal plasticity (22-26).  
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 Structurally, GFLs belongs to the family of cysteine-knot proteins sharing similar 
topologies and functions as homodimers (27). GFLs do not share high amino acid sequence 
homologies amongst each other, but all have seven conserved cysteine (Cys) residues (Fig. 
2.1). The crystalized form of GDNF contains an asymmetric unit of two antiparallel covalent 
homodimers and these dimers differ in the relative hinge angle between the “wrist” and 
“finger loops” within their respective monomers (28). While the overall topology of the GFLs 
is similar, detailed analyses of ART covalent homodimer compared to GDNF do show 
differences in the shape and possible flexibility of the elongated homodimer (29). A variety of 
studies have indicated that the two finger loops of GFLs interact directly with their respective 
co-receptors and that GFLs complexed to their cognate receptors resemble the structure of the 
GFL monomer (29-32). 
 
2.2. GDNF family of receptors (GFRs), co-receptors Ret and NCAM 
 
 The homodimeric GFLs are now known to activate downstream signaling by forming 
a canonical multi-component receptor complex consisting of a preferred high-affinity GDNF 
family receptor alpha (GFR) and the co-receptor, Ret (REarranged during Transformation) 
with a proposed stoichiometry of  GFL homodimer-(GFR)2-(Ret)2. 
 GFR1 was also known as GFRA1, GDNFR, GDNFR-ALPHA, GDNFRA, GFR-
ALPHA-1, MGC23045, RET1L, RETL1, TRNR1 or GDNFRA1. Similarly, GFR2 was also 
known as GFRA2, GDNFR-BETA, GDNFRB, GFR-ALPHA-2, NRTNR-ALPHA, NTNR-
ALPHA, NTNRA, RETL2 or TRNR2. To unify the various synonyms, a nomenclature to 
define the multi-components of this receptor complex was proposed (33). Hence, the 
component that binds the GFLs directly is known as the ‘’ subunit and the accessory 
component, Ret, as the ‘’ subunit. However, in recent publications, the latter term (‘’) has 




Fig. 2.1. Structures of GDNF-family ligands (GFLs). (A) Schematic representation of a homodimeric GFL with 
intra- and intermolecular disulphide bridges formed between cysteine residues designated by ‘C’. (B) Sequence 
alignment of human GFLs. The secondary-structural elements within the GFL structures are shown above the 
sequences by designations for alpha helices (coil) and beta strands (arrows). (C) RasMol representation of the 
GDNF monomer based on coordinates described [PDB ID 1AGQ; 51]. 
 
 Each GFL is known to preferentially bind and activate one GFR in vitro, and the 
activation of the multi-component receptor system shows some degree of promiscuity in their 
ligand specificities (Fig. 2.2) (34-38). GDNF preferentially binds to GFR1, NTN to GFR2, 
ART to GFR3 and PSP to GFR4. In addition, NTN and ART have been reported to also 
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Fig. 2.2. GFLs and receptors interactions. The canonical mechanism of GFLs signaling involves Ret activation 
by the binding of the homodimeric GFLs (GDNF, NTN, ART, PSP) with the cognate GFR receptors (GFR1-4). 
NCAM can also interact with GFR receptors independent of Ret in some cells. The arrows indicate the preferred 
ligand-receptor interactions and the broken arrows denote cross-talks of GFLs with GFR.  
 
 GFLs are also known to signal through Ret-independent signaling mechanisms and 
have been shown to modulate the functions of neural cell adhesion molecules (NCAM) 
through the binding with GFRs (40,41). Furthermore, a Ret and NCAM independent 
signaling pathway has been shown to be involved in GDNF promotion of differentiation and 
migration of cortical GABAergic neurons (42) and a recent study suggests the involvements 
of the Heparan sulfate proteoglycan syndecan-3 in GDNF signaling (43). Whether other GFLs 
utilize these mechanisms has yet to be determined. 
 In mammals, there are four GFR (GFR1 to 4) paralogues, and each is encoded by 
a single gene located on different chromosomes. GFR receptors are linked to the plasma 
membrane via a glycosyl-phosphotidylinositol (GPI) anchor and interact in cis with Ret of the 










cysteine residue arrangements (Fig. 2.3). Orthologues of all GFRα receptors are also present 
in several vertebrates (5,44).  
 
Fig. 2.3. Sequence alignment of human GFRα1-4. The GFRαs show low sequence homologies and conserved 
cysteines are boxed. 
 
 GFR is organized into three homologous cysteine-rich domains with C-terminal 
extensions of various lengths (35,45). Domain 2 (D2) is clearly involved in the binding of 
GFLs (31,32,38,46). Domain 3 (D3) stabilizes D2 in the binding of the ligands and D1 does 
not appear to be necessary for Ret binding of GFR1 (47) and is absent in GFR4 (35). 
However, direct chemical cross-linking and proteomic analyses of ligand-receptor 



























D1 of GFR1) contacted Ret at multiple sites and strongly supported the biological relevance 
of the N-terminal domains (48). Full length GFR1 has also been shown to be more 
biologically active than D1 truncated mutants and it is thought that the D1 domain may 
contribute to the optimal function of GFRα1 by stabilizing the interaction between GFRα1 
and GDNF (47). 
 Crystal structures have been obtained for truncated forms of GFR1 and GFR3. The 
crystal structure of the D3 of GFR1 was initially determined and used to model the D2 and 
from this the structure of D2/D3 of GFR2 was deduced (31). Recently, the heterotetrameric 
complex of GDNF dimer and the two GFR1 D2 and D3 domains have been solved (49). 
When compared to the heterotetrameric complex of homodimer of ART and GFR3-dimer 
(32), the GDNF-GFR1 complex showed some similarities in how the GFLs fingertips bind 
their respective receptor and that both the global structures of GFR1 and GFR3 are highly 
similar but not identical. These studies have provided a framework for the structural basis of 
ligand-receptor interactions and it is likely that all GFR share similar structures but differ in 
the details of the binding sites of GFLs and the interaction sites with Ret. Although the D1 
domain of the GFR is dispensible for ligand binding, it is not unreasonable to suggest that 
the differences in N-terminal sequences, found in multiple isoforms of GFR, may participate 
in modulating the interactions of GFLs with the different components of the receptor 
complexes. 
 Ret was originally identified as an oncogene activated by DNA re-arrangement in a 
3T3 fibroblast cell line transfected with DNA taken from human lymphoma cells (50,51). It 
encodes a receptor tyrosine kinase (RTK) and is a single-pass transmembrane protein with a 
cadherin-related motif and a cysteine-rich extracellular domain. Three isoforms (Ret9, Ret43 
and Ret51) with differing C-terminal sequences generated by alternative splicing have been 
identified. Ret is the only known receptor tyrosine kinase that does not bind its ligands 
directly and requires co-receptors for activation. Oncogenic Ret activation by mutations or 
rearragements is known to predispose to various cancers like multiple endocrine neoplasia 
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type 2 (MEN2A and MEN2B), papillary thyroid carcinoma (PTC) and medullary thyroid 
carcinoma (MTC) (52). In addition, loss-of-function mutations in Ret is closely linked to 
Hirschsprung’s disease (53).  
 The expression patterns of GFR and Ret in the nervous system are consistent with 
areas of where the neurons are responsive to GFLs innervations (54-68). Although Ret and at 
least one of the GFR are usually co-expressed, mismatch of the two components has been 
described in some brain regions (17,54,55,59-61,63,69-71). This Ret-independent GFRα 
expression is thought to play a role in the activation of Ret in a non-cell-autonomous fashion, 
by capturing diffusible GFLs and presenting them to neighboring Ret-expressing cells in 
trans (72). However, this mechanism appears not to be necessary for organogenesis and nerve 
regeneration in a transgenic mouse model (73). The expressions of Ret and GFR are 
generally low in the nervous system (55,56,63,74,75) but are known to undergo differential 
age-related changes, with maximal expressions in the early postanatal life (63,75-78). 
Changes in expressions have also been observed with physical trauma such as nerve 
transection and avulsion (79,80), ischemia (81-85), excitotoxic insult (74,86-88) and epileptic 
seizures (55,74,89,90), suggestive of a beneficial role of GFLs signaling in neurodegeneration. 
 
2.3. Molecular mechanism of GDNF-GFRα-Ret signaling 
 
 Upon GFLs stimulations in the presence of GFRαs, Ret undergoes dimerization and 
transphosphorylation of its intracellular tyrosine residues, a process that is required for the 
complete activation of Ret tyrosine kinase domains and downstream signaling. Mutations of 
Ret can result in auto-activation and autophosphorylation of Ret in the absence of ligand 
stimulation. Although most of Ret signaling mechanisms were elucidated with mutants of Ret, 
many of them were later found to be similar to ligand-induced Ret activations. Among the 
three better known Ret isoforms, Ret9 and Ret51 are major isoforms with well-characterized 
functions. Ret9 contains 16 tyrosine residues including ten in the kinase domains, two in the 
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juxtamembrane domain, one in the kinase insert and three in the carboxyterminal tail. Ret51 
contains two additional tyrosine residues in the carboxyl terminal (tyrosine 1090 and 1096). 
Autophosphorylations of Ret at tyrosines 905, 981, 1015, 1062 and 1096 were initially 
thought to recruit specific adaptor molecules GRB7/10 (91,92), Src (93), PLCγ 
(phospholipase Cγ) (94), Shc (Src-homologous and collagen-like protein) (95) and GRB2 
(96), respectively. With subsequent identifications of more Ret binding partners, it is likely 
that a single phosphotyrosine residue may serve as a competitive binding site, resulting in 
divergent signaling outcomes (Fig. 2.4).  
 
Fig. 2.4. Intracellular signaling pathways of activated Ret. Activation of Ret leads to phosphorylation of 
intracellular tyrosine and serine residues, which serve as docking sites for multiple adaptor molecules. Y, tyrosine; 







































































 Although the adaptors GRB7 and GRB10 were found to interact with activated 
EGFR/Ret chimera and Ret/PTC2 through the tyrosine residue corresponding to wild-type 
Ret tyrosine 905, there is as yet no evidence that ligand activated Ret can associate with 
GRB7/10 (91). It has become more evident that phosphorylation of tyrosine 905 is critical for 
intrinsic Ret kinase activity as mutation of this residue to phenylalanine drastically impairs 
autophosphorylation of both oncogenic (97) and ligand-stimulated Ret (98).  
 Mutation of tyrosine 981 has also been shown to impair Ret binding to Src through 
Src-SH2 domain and reduce GDNF-mediated survival of cerebellar granule neurons (93). 
Furthermore, c-Abl, a cellular homologue of Abelson murine leukemia virus, has been shown 
to interact with oncogenic Ret (Ret/PTC3) via Ret tyrosine 981, leading to the activation of 
ERK8 (99). However, the physiological significance of the interaction between Ret and c-Abl 
awaits further clarification. 
 Pleiotropy of Ret tyrosine residues in binding to multiple adaptors is further 
demonstrated by Ret tyrosine 1062. Phosphorylated tyrosine 1062 has been reported to bind 
to at least six families of adaptor molecules, including Shc, FRS2 (fibroblast growth factor 
receptor substrate 2), DOK1/4/5/6, IRS1/2 (insulin receptor substrate 1/2), Enigma and 
PTPRJ (tyrosine phosphatase J). Intriguingly, tyrosine 1062 is the key residue mediating the 
activations of RAS-ERK1/2 MAPK, p38 MAPK, JNK MAPK and PI3K-AKT pathways by 
Ret (100), consistent with the critical in vivo roles of Ret tyrosine 1062 in development of 
enteric nervous system and kidney organogenesis (101). Although a variety of signaling 
partners contributing to the versatile functions of Ret tyrosine 1062 has been reported, limited 
information is available on how selectivity of specific adaptor molecules is achieved upon 
GFLs stimulation. The contributions of cellular context and receptor isoforms to the observed 







2.4. Alternatively spliced isoforms of GDNF receptors 
 
 An interesting emerging view of the potential roles of the spliced isoforms of GFRα, 
Ret and NCAM is that the specific combinatorial interactions of these components may 
contribute to a multi-component signaling system to produce the myriad of observed 
biological responses.  
 Multiple alternatively spliced variants of GFRα1 (57,102,103) and GFRα2 (104,105) 
are differentially expressed. Similarly, alternatively spliced isoforms of Ret (106,107) and 
NCAM (108,109) have been reported. Alternative splicing is prevalent in many mammalian 
genomes and is a means of producing functionally diverse polypeptides from a single gene. 
Recently, in-depth analysis of diverse human tissue and cell line transcriptomes by deep 
sequencing of complementary DNA fragments showed that the extent of alternative splicing 
of human genes to be greater than an astonishingly 90% (110). Comparative genomic 
analyses demonstrated that the greatest amount of conserved alternative splicing occurs in the 
central nervous system (111).  In many systems, alternative splicing events have been shown 
to produce isoforms with distinct activities and biochemical properties and diverse biological 
functions (112). The existence of multiple alternatively spliced variants of the GFLs, GFRα 
and other co-receptors provide a shift in the paradigm of how this limited number of ligands 
and receptors can generate pleiotropic effects through combinatorial interactions of the 
various components.  
 Recently, the alternatively spliced isoforms of GFRα1 have been shown to exhibit 
distinct biochemical functions (66,113). The ligand activation of the GFRα2 isoforms was 
reported to differentially activate MAPK (ERK1/2) and AKT signaling, and regulated distinct 
early response genes. Furthermore, both GDNF and NTN induced neurite outgrowth through 
GFRα2a and GFRα2c, but not GFRα2b. Activation of GFRα2b inhibited neurite outgrowth 
induced by the other GFRα2 isoforms as well as GFRα1a and retinoic acid. The mechanism 
underlying the inhibitory effects of GFRα2b is RhoA-dependent (67). This study thus, 
provides the first piece of evidence of a dominant inhibitory activity of GFRα2b on neurite 
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outgrowth and distinct signaling mechanisms underlying the activation of spliced GFRα 
isoforms. It will be of interest to know whether other GFRα receptor isoforms may contribute 
to functional divergence of GDNF signaling in a similar manner. 
 The two major RET isoforms Ret9 and Ret51 were initially cloned from a human 
neuroblastoma cell line and bear differences at their C-termini (114). To understand the in 
vivo significance of each isoform, chimeric mouse-human monoisoformic Ret mice were 
generated and striking functional differences of these isoforms in organogenesis and embryo 
development were observed (115). While mice lacking Ret51 develop normally, mice lacking 
Ret9 show kidney hypodysplasia and defects in enteric innervation, similar to Ret knockout 
mice. Furthermore, Ret9 but not Ret51 is able to rescue the phenotype of Ret knockout mice. 
Interestingly, Ret51 but not Ret9 has been shown to promote the survival and tubulogenesis 
of mouse inner medullary collecting duct cells (107), suggestive of isoform specific roles in 
embryo development and organogenesis. However, a recent study using human 
monoisoformic Ret mice provides evidence that GDNF signaling through either Ret9 or 
Ret51 is sufficient for kidney organogenesis and mice viability (116). The relative importance 
of Ret isoforms in GDNF signaling deserves further investigation. 
 It is now clear that the differential expressions and distinct functions of GDNF 
receptor isoforms may at least in part, contribute to the diverse cellular and molecular effects 
















PART I: GDNF-INDUCED CELL SIGNALING AND NEURITE OUTGROWTHS 

















 GDNF is known to signal through a multi-component receptor system consisting of 
the glycosylphosphatidylinositol (GPI)-linked receptor GFR1, and the co-receptor Ret or 
NCAM (Chapter 2). The GDNF receptor complex can recruit various signaling modules and 
result in distinct cellular outcomes including proliferation, differentiation, survival and 
motility (117). Since both GFRα1 and Ret genes are alternatively spliced (102,114), the 
diverse and pleiotropic roles of GDNF may be mediated at least partly through the differential 
expressions and functions of alternatively spliced isoforms of the GDNF receptor complex. 
Currently, two alternatively spliced GFRα1 isoforms, GFR1a and GFR1b have been 
identified (102,103). These two isoforms are highly homologous, with a difference of only 
five amino acids (140DVFQQ144), which are absent in GFR1b. These 5 amino acids reside 
in the N-terminal Domain 1 (D1). Although domain 2 (D2) and 3 (D3) but not D1 are 
involved in ligand binding, direct chemical cross-linking and proteomic analyses of ligand-
receptor interactions showed that the residues at the distal end of the D1 contacted RET at 
multiple sites and strongly support the biological relevance of the N-terminal D1 (48). 
Therefore, it is not unreasonable that 5 amino acids in D1 may modulate the interactions of 
GFRα1 isoforms with GFLs and co-receptors. To date, most of the studies involving GFRα1 
were conducted with GFR1a and the contribution of GFR1b to the observed activities of 
GDNF is unclear.  
 GDNF, the preferred ligand of GFR1, has been shown to induce neurite outgrowth 
and branching morphology in various primary cultures and explants of sympathetic neurons 
(118), midbrain dopaminergic neurons (119), motoneurons (120), sensory neurons (121), 
enteric neurons (122) and similar effects were observed in vivo (123,124). GDNF has also 
been shown to promote morphological and biochemical differentiation in many 
neuroblastoma cell lines (125-127). However, the relative contributions of GFRα1 isoforms to 
the observed phenotypes in these studies are currently unknown. Interestingly, GFRα1a, 
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either acting in cis or in trans was able to mediate GDNF-induced neurite formation and 
axonal growth in both clonal cell lines (128,129) and primary neurons (72,130). Although 
GFRα1b exhibited distinct biochemical properties when compared to GFRα1a (66,113), the 
role of GFRα1b in GDNF-induced neurite outgrowth remains to be elucidated. Here, we 
uncovered distinct mechanisms of GFR1 isoforms in the regulation of GDNF-induced 
neurite outgrowth. GFR1a but not GFR1b induced neurite outgrowth when stimulated by 
GDNF or NTN, while GFR1b inhibited neurite outgrowth of GFR1a when co-expressed. 
Furthermore, we showed that these receptor isoforms modulate different RhoGTPase 
pathways. GFR1a promotes neurite outgrowth via activation of ERK1/2 and Rac1/Cdc42, 
while the inhibitory activity of GFR1b is RhoA-ROCK dependent. These findings not only 
reveal the distinct cellular functions of alternatively spliced GFR1 isoforms,  it also suggests 
that inhibitory activity of GFR1b may serve as a regulatory switch in neuritogenesis and 




3.2.1. GFRα1a and GFRα1b isoforms are expressed in human tissues and the central 
nervous system 
 To gain a better understanding of the possible physiological relevance of GFRα1 
isoforms, gene expression profiles of GFRα1 isoforms in various human tissues and different 
regions of central nervous system (CNS) were quantified using highly specific and sensitive 
quantitative real time PCR assays as previously designed for the quantification of mouse 
GFRα1 isoforms (66). Using a similar approach, GFRα1b was found to be the dominant 
isoform expressed in all the peripheral tissues examined (Fig. 3.1A). Interestingly, GFRα1b 
was found to be expressed at exceptionally high level in the adult liver, similar to that 
previously reported in mouse adult liver (66). In the substantia nigra and thalamus, GFRα1a 
was found to be expressed at significantly higher levels than GFRα1b, while the reverse was 
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observed with the expression of GFRα1b in the caudate nucleus, cerebral cortex, putamen, 
subthalamic nucleus, and spinal cord (Fig. 3.1B). Due to the lack of GFRα1 isoform-specific 
antibodies, it is unknown whether both GFRα1a and GFRα1b proteins are expressed in same 
cells. Together, these data showed the differential expression profiles of GFRα1 isoforms, 




Fig. 3.1. Differential expressions of GFRα1 isoforms in various human tissues and central nervous system. 
The expression levels of GFRα1 isoforms in various human adult and fetal tissues (A) and in various regions of 
adult central nervous system (B) were quantified by real-time PCR and normalized to GAPDH. The results were 
expressed as mean  S.E.M. (n = 3).  * p < 0.05; ** p < 0.01. 
 
3.2.2. Ligand activated GFRα1 isoforms induced ERK1/2 and AKT activations 
 We have previously generated Neuro2A transfectants stably expressing similar levels 
of GFRα1a or GFRα1b (66). These transfected cells showed specific expression of GFRα1a 
or GFRα1b, at comparable levels both in total cell lysates and on cell surface (Fig. 3.2A). 
GDNF or NTN treatment in both cell lines induced transient phosphorylation of ERK1/2 (Fig. 
3.2B). Both ligands were found to induce sustained phosphorylation of AKT in Neuro2A cells 
expressing GFRα1a or GFRα1b (Fig. 3.2B).  
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Fig. 3.2. Expression and activation of GFRα1 isoforms in Neuro2A. (A) Surface expression of GFRα1a and 
GFRα1b in Neuro2A cells. Surface proteins were labeled with biotin and extracted with streptavidin beads. Biotin-
labeled surface proteins and total cell lysates were probed with GFRα1, Ret and Transferin Receptor antibodies. (B) 
Activation of ERK1/2 and AKT by GDNF or NTN in Neuro2A cells expressing GFRα1 isoforms. Neuro2A cells 
stably expressing GFRα1a or GFRα1b were stimulated with 50 ng/ml GDNF or NTN, for the period of time 
indicated. Activations of ERK1/2 and AKT were examined by Western blotting. 
 
3.2.3. GFRα1a but not GFRα1b induced neurite outgrowths. The neurite outgrowth 
process is dependent on ERK1/2, Rac1 and Cdc42 activations 
 Both GDNF and NTN have previously been shown to regulate neurite outgrowth in 
various neuronal systems (131-133). However, the involvement of GFRα1b in neuritogenesis 
is not known. To investigate possible morphological changes induced by the activation of the 
GFRα1 isoforms, the transfectants were stimulated with either GDNF or NTN.  When 
stimulated with GDNF or NTN, cells expressing GFRα1a but not GFRα1b showed extensive 
neurite outgrowths (Fig. 3.3). Unexpectedly, cells expressing GFRα1b showed naïve 
neuroblast morphology upon ligand stimulations, comparable to cells transfected with control 
vector alone (Fig. 3.3A). These cells extended neurite-like structures when treated with 
retinoic acid, indicative of the potential for neurite outgrowth. GDNF and NTN have no 
neuritogenic effect on control vector transfected Neuro2A cells (data not shown). Increased 
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concentrations of GDNF were still unable to induce neurite outgrowth through GFRα1b, 
excluding the possibility that GFRα1b may have lower ligand affinity for neurite outgrowth 
(Fig. 3.3B). 
Fig. 3.3. GFRα1 isoforms mediate distinct neuritogenic activities. (A) Phase-contrast images of Neuro2A cells 
stably expressing GFRα1a or GFRα1b, treated with RA (5 µM), GDNF or NTN (50 ng/ml) for 72 h. (B) Dose-
response of GDNF-induced neurite outgrowth. Neuro2A cells expressing pIRES vector control, GFRα1a or 
GFRα1b were treated with RA or GDNF at indicated concentrations for 72 h. (C) Effects of U0126 on GDNF and 
NTN induced neurite outgrowth. Cells were pre-treated with 10 µM U0126 for 1 h and stimulated with GDNF or 
NTN (50 ng/ml) for 72 h. Percentage of cells differentiated was presented as Mean ± S.E.M. of at least three 
biological replicates. * p < 0.05. 
 
 Both GDNF and NTN activated ERK1/2 in Neuro2a cells expressing either GFRα1a 
or GFRα1b (Fig. 3.2B). It has been suggested that GDNF may promote survival and induce 
differentiation through AKT and MAPK respectively (128). Consistent with this notion, 
ligand induced neurite extension in GFRα1a cells was indeed MAPK (ERK1/2) dependent, 
sensitive to the MEK inhibitor, U0126 (Fig. 3.3C). The concentration of U0126 (5 µM) used 
did not affect the viability of these cells (data not shown).   
 Rho family small GTPases Rac1 and Cdc42 induce formation of lamellipodia and 
filopodia formation respectively and are involved in neurotrophic factor-induced neurite 












































































































neurite outgrowth, dominant negative mutants of Rac1 (Rac1-DN) and Cdc42 (Cdc42-DN) 
were transfected in Neuro2A cells expressing GFRα1a. Both Rac1-DN and Cdc42-DN 
inhibited GDNF, NTN and retinoic acid induced neurite outgrowth, suggesting GFRα1a 
mediated neuritogenesis is dependent on Rac1 and Cdc42 (Fig. 3.4). 
 
Fig. 3.4. GFRα1a mediated neurite outgrowth is dependent on Rac1 and Cdc42. Neuro2A cells stably 
expressing GFRα1a were transfected with eGFP vectors co-expressing Rac1-DN or Cdc42-DN. Transfected cells 
were stimulated with GDNF, NTN (50 ng/ml) or RA (5 µM) for 72 h. Percentage of eGFP positive cells bearing 
neurite after stimulations was presented as Mean ± S.D. of at least three biological replicates. ** p < 0.01, 
compared to non-treated control cells. 
 
3.2.4. GFRα1b inhibits the neuritogenic activity of GFRα1a 
 As Neuro2A cells expressing GFRα1b did not extend neurite upon ligand stimulation, 
it is tempting to hypothesize that GFRα1b may affect neurite outgrowth induced by ligand-
activated GFRα1a. Neuro2A transfectants co-expressing both GFRα1 isoforms 
(GFRα1a+GFRα1b) were established using a bicistronic vector. As controls, cells expressing 
GFRα1a or GFRα1b alone in the same bicistronic vector were generated. Similar to cells 
transfected with monocistronic vectors (Fig. 3.3), Neuro2A cells expressing GFRα1a but not 
GFRα1b or bicistronic vector alone extended neurites upon ligand stimulation (Fig. 3.5A). 
However, when stimulated with either GDNF or NTN, no significant neurite extension was 










































and NTN induced transient ERK1/2 activation and sustained AKT activation in these cells, 
similar to ligand stimulation of individual GFRα1 isoforms (Fig. 3.5B).  
 
 
Fig. 3.5. GFRα1b inhibits GFRα1a-mediated neurite outgrowth in Neuro2A cells. (A) Neuro2A cells stably 
expressing GFRα1a, GFRα1b, GFRα1a+GFRα1b or pIRES bicistronic vector control were stimulated with GDNF, 
NTN (50 ng/ml) or RA (5 µM) for 72 h. Percentage of cells differentiated was presented as Mean ± S.E.M. of at 
least three biological replicates. ** p < 0.01, compared to non-treated control cells. (B) Activation of ERK1/2 and 
AKT by GDNF and NTN in Neuro2A cells co-expressing GFRα1a and GFRα1b. Neuro2A cells stably co-
expressing GFRα1a and GFRα1b were stimulated with 50 ng/ml GDNF or NTN for the period of time indicated. 
Phosphorylation of ERK1/2 and AKT by GDNF and NTN was detected by Western blotting.  
 
 Similar finding was observed in NG108-15 cells which express endogenous Ret and 
GFRα1, but not GFRα2 (136). Using isoform-specific real-time PCR, these cells were found 
to express predominantly GFRα1a (Fig. 3.6A). To investigate the effect of GFRα1b in 
NG108-15 cells, GFRα1b was over-expressed at the level comparable to endogenously 
expressed GFRα1a (Fig. 3.6A). While GDNF and NTN induced neurite outgrowth in control 
NG108-15 cells transfected with an unrelated protein (eGFP), ligand treatment failed to 
induce neurite extension in cells transfected with GFRα1b (Fig. 3.6B,C). Regardless of the 










































cells were capable of neurite extension. Taken together, these results showed that the 
activation of GFRα1b inhibits neurite outgrowth induced by GFRα1a.  
 
 
Fig. 3.6. GFRα1b inhibits GFRα1a-mediated neurite outgrowth in NG108-15 cells. (A) Expression of GFRα1 
isoforms in wild-type and eGFP or GFRα1b transfected NG108-15 cells. (B) Percentage of differentiated cells 
treated with Forskolin (FK, 5 μM), GDNF or NTN (50 ng/ml), in NG108-15 cells transfected with eGFP or 
GFRα1b. Percentage of cells differentiated was presented as Mean ± S.E.M. of at least three biological replicates. 
** p < 0.01, compared to non-treated control cells. (C) Phase-contrast images of NG108-15 cells transfected with 
eGFP or GFRα1b, treated with FK, GDNF or NTN. 
 
3.2.5. Inhibition of neurite outgrowth by GFRα1b is dependent on RhoA-ROCK  
 RhoA, a member of Rho family small GTPases and the associated regulators are 
involved in formation of stress fiber and focal adhesions, antagonizing the effect of Rac1 and 
Cdc42 (134,135). As GFRα1a induced neurite outgrowth in Neuro2A is dependent on the 
activation of Rac1 and Cdc42, it was of interest to investigate whether inhibition of neurite 
outgrowth by GFRα1b may involve Rho signaling. Indeed, GDNF or NTN treatment of cells 


















































































pull down assay (Fig. 3.7A). Furthermore, GDNF induced Rho activation through GFRα1b 
was inhibited by pre-treatment of U0126 but not LY294002 (Fig. 3.7B). The involvement of 
Rho in GFRα1b inhibitory activities was further examined using RhoA dominant negative 
mutant (RhoA-DN) and Rho inhibitor, exoenzyme C3 transferase, in cells co-expressing both 
GFRα1 isoforms. GDNF or NTN was found to stimulate extensive neurite outgrowths in cells 
co-expressing GFRα1a and GFRα1b, when transfected with the RhoA-DN (Fig. 3.7C) or pre-
treated with exoenzyme C3 transferase (Fig. 3.7D).  
 
Fig. 3.7. Inhibition of neurite outgrowth by GFRα1b is dependent on Rho signaling. (A) GDNF and NTN 
induced Rho activation in Neuro2A cells expressing GFRα1b but not GFRα1a. Neuro2A cells transfected with 
GFRα1 isoforms or pIRES control were treated with LPA (10 µM), GDNF, or NTN (50ng/ml) for 5 min. GTP-
bound Rho was pulled down from cell lysates using GST–Rhotekin and immunoblotted for Rho. LPA served as a 
positive control for Rho activation. (B) GDNF induced Rho activation through GFRα1b was dependent on MEK-
ERK1/2 pathway. U, U0126 (5 µM); LY, LY294002 (10 µM). (C, D) Effects of dominant negative mutant of 
RhoA (RhoA-DN) and Rho inhibitor on inhibitory activity of GFRα1b in Neuro2A cells co-expressing both 
GFRα1 isoforms. Neuro2A cells stably co-expressing GFRα1a and GFRα1b were transfected with RhoA-DN (C) 
or pretreated with exoenzyme C3 transferase (D) and stimulated with RA (5 μM), GDNF or NTN (50 ng/ml). 
Percentage of cells differentiated was presented as Mean ± S.E.M. of at least three biological replicates. ** p < 
0.01, compared to non-treated control cells. 
 
 To gain a better understanding of the mechanisms underlying the inhibitory effects of 
GFRα1b, we examined the possible involvement of ROCK, an known effector of RhoA in the 
negative regulation of neurite outgrowth (137). Pre-incubation of ROCK inhibitor Y27632 
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either GDNF or NTN (Fig. 3.8D), suggestive of the involvement of ROCK. Y27632 treatment 
did not alter the neuritogenic activities of GFRα1a and GFRα1b when these two isoforms 
were expressed individually (Fig. 3.8B,C). Regardless of the transfectants examined, retinoic 
acid was found to induce neurite outgrowths, indicative that the cells were capable of neurite 
extension. Taken together, these observations indicate that GFRα1b activates RhoA-ROCK 
pathway to inhibit GFRα1a-mediated neurite outgrowths.  
 
Fig. 3.8. Inhibition of neurite outgrowth by GFRα1b is ROCK dependent. Neuro2A cells stably transfected 
with pIRES bicistronic vector control (A), GFRα1a (B), GFRα1b (C) or GFRα1a+GFRα1b (D) were treated with 
RA (5 µM), GDNF or NTN (50 ng/ml) with or without ROCK inhibitor Y27632 (10 µM). Percentage of cells 
differentiated was presented as Mean ± S.E.M. of at least three biological replicates. * p < 0.05; ** p < 0.01, 
compared to respective non-treated control cells. 
 
3.2.6. GFRα1b modulates ROCK downstream effectors LIMK1/2, cofilin and MLC2 
upon ligand stimulations  
 Activation of RhoA-ROCK pathway results in the phosphorylation of various ROCK 
effectors including LIMK, MLC, MLCP and CRMP2 (138). Phosphorylation and activation 
of LIMK by ROCK in turn induces phosphorylation and inactivation of cofilin, resulting in 
the inhibition of actin depolymerization (139). Phosphorylation of MLC induces assembly of 
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stress fibers and focal adhesion which results in the inhibition of neurite formation and neurite 
retraction (140). In this study, the phosphorylation profiles of LIMK1/2, cofilin and MLC2 in 
Neuro2A cells expressing GFRα1b was examined. Upon ligand stimulation, GFRα1b induced 
rapid phosphorylation of LIMK1/2, cofilin and MLC2, comparable to controls using LPA 
(Fig. 3.9A). Both GFRα1b and LPA mediated transient phosphorylation of MLC2, however, 
LPA induced phosphorylations of LIMK1/2 and cofilin were more sustained when compared 
to GFRα1b (Fig. 3.9A). Pretreatment of the cells with ROCK inhibitors Y27632 and H-1152 
significantly inhibited phosphorylation of LIMK1/2, cofilin and MLC2, indicative of ROCK-
dependent modulation of LIMK1/2, cofilin and MLC2 by GDNF and NTN through GFRα1b 
(Fig. 3.9B).  
 
 
Fig. 3.9. GDNF induces phosphorylation of LIMK1/2, cofilin and MLC2 through GFRα1b. Neuro2A cells 
stably expressing GFRα1b were stimulated with GDNF (50 ng/ml), NTN (50 ng/ml) or LPA (10 µM) in the 
presence or absence of ROCK inhibitors Y27632 (10 µM) or H-1152 (0.5 µM), for the period of time indicated. (A) 
GDNF, NTN and LPA induced phosphorylation of LIMK1/2, cofilin and MLC2 in Neuro2A cells expressing 
GFRα1b. (B) Phosphorylation of LIMK1/2, cofilin and MLC2 by GDNF, NTN and LPA (2 min) was inhibited by 




 This study demonstrated the differential tissue expressions and functions of 
alternatively spliced GFRα1 isoforms. GFRα1a promoted ligand induced neurite outgrowth 
through ERK1/2 and Rac1/Cdc42. Remarkably, GFRα1b, with the absence of five amino 
acids as compared to GFRα1a, activated RhoA-ROCK pathway and inhibited neuritogenic 
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 Using isoform-specific real-time PCR, the expression of GFRα1a was found 
significantly higher than GFRα1b in substantia nigra, consistent with the neuritogenic effect 
of GDNF in cells found in this region (141). Interestingly, except for fetal brain, all the other 
human peripheral tissues expressed significantly higher levels of GFRα1b than GFRα1a. 
These results are suggestive of physiological relevance of these GFRα1 isoforms. It is widely 
reported that GDNF signaling through GFRα1 and Ret induced neurite outgrowth in neuronal 
cultures from both central and enteric nervous systems (118,120-122,142). GDNF has also 
been shown to induce neurite outgrowths in human neural crest derived cells, neuroblastomas 
and pheochromocytomas (143,144). This is likely to be due to the activation of GFRα1a but 
not GFRα1b. Consistent with this suggestion is that GDNF induced neurite outgrowths has 
been reported with Neuro2A and PC12-Ret cells transfected with GFRα1a (128,129). 
Similarly, soluble or immobilized recombinant GFRα1a-Fc was able to mediate GDNF-
induced neurite outgrowth and axonal guidance of cultured nodose and sympathetic ganglion 
neurons (72,130).  
 This study showed for the first time that while GDNF or NTN induced neurite 
outgrowths in GFRα1a transfectants, no morphological change was observe in GFRα1b 
transfectants when stimulated with ligand. Cell-surface biotinylation study showed that both 
GFRα1a and GFRα1b were expressed at comparable levels on cell surface, excluding 
defective membrane localization of GFRα1b. Interestingly, GFRα1b appears to bind GDNF 
with higher or equal affinity to GFRα1a (113). Furthermore, high concentrations of GDNF 
did not induce neurite outgrowth of GFRα1b transfectants, suggesting that this inability to 
induce neurite outgrowth is unlikely to be due to sub-optimal GDNF stimulation. Neurite 
outgrowth mediated by GFRα1a was further demonstrated to be dependent on ERK1/2 and 
Rac1/Cdc42 activation, consistent with the roles of ERK and Rac1 in GDNF induced neurite 
outgrowth and lamellipodia formation (128,145). Unexpectedly, in cells co-expressing both 
GFRα1a and GFRα1b, GDNF or NTN was unable to induce neurite outgrowths, indicative of 
an inhibitory role of GFRα1b. It is unlikely that GFRα1b interacts with GFRα1a to inhibit 
GDNF signaling because GDNF stimulation of cells co-expressing both GFRα1 isoforms did 
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not show attenuation in either ERK1/2 or AKT signaling. Both Ret and NCAM are known co-
receptors for GDNF-GFRα1 signal transduction. While Ret-mediated GDNF signaling has 
been widely reported, NCAM has also been shown to be involved in GDNF induced axonal 
growth of primary neurons (41). The contributions of Ret and NCAM in the differential 
GFRα1 isoform binding and signal transduction observed in this study remain to be 
determined.  
 A likely intracellular mechanism underlying the neurite outgrowth inhibitory effects 
of GFRα1b involves the activation of Rho. The Rho GTPases family includes RhoA, Rac and 
Cdc42 which are known to be intimately involved in various processes involving actin 
cytoskeleton in eukaryotic cells, including neurite outgrowth and differentiation (135,146). 
While Rac and Cdc42 promote neurite and axonal outgrowth, RhoA and its downstream 
effector ROCK (Rho kinase) are known to be involved in neurite outgrowth inhibitory effects 
of Nogo-A, myelin-associated glycoprotein (MAG) (147) and lysophosphatidic acid (LPA) 
(148). Recent findings have further revealed that RhoA-ROCK mediates neurite outgrowth 
inhibition by reorganizing both actin network through MLC, LIMK and cofilin and 
microtubular network through Tau and MAP2 (149,150). It is interesting to note that GDNF 
was shown to induce Ret mediated phosphorylation of focal adhesion kinase, paxillin and 
p130C through the activation of Rho family GTPase and inhibited the outgrowth of neurites 
in TGW-I-nu cells (151). However, it is unclear if these Rho activities in these cells were 
regulated by GFRα1b, as the expressions of these spliced variants were not determined. 
Recently, GFRα2b, an alternatively spliced isoform of GFRα2 was found to inhibit neurite 
outgrowth in a RhoA but not ROCK dependent mechanism (67). This study further 
demonstrated that GFRα1b but not GFRα1a activated Rho upon ligand stimulation. 
Intriguingly, while GFRα1-mediated neurite outgrowth requires ERK1/2, Rac and Cdc42 
activation, GFRα1b-mediated Rho activation was also dependent on ERK1/2 activation. This 
is consistent with the notion that ERK plays a crucial role in regulation of Rho signaling (152). 
The critical roles of ERK1/2 in functions of both GFRα1 isoforms suggest the involvement of 
other distinct signaling pathways that act in concert to exhibit differential signaling outcomes. 
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Furthermore, inhibiting RhoA-ROCK pathway in cells co-expressing GFRα1 isoforms 
resulted in neurite outgrowths when stimulated by either ligand. GDNF and NTN also 
induced phosphorylation of various ROCK downstream effectors LIMK1/2, cofilin and 
MLC2 in cells expressing GFRα1b but not GFRα1a. These observations are consistent with 
the involvement of the Rho-ROCK pathway in the ligand dependent GFRα1b inhibition of 
neurite extension. 
 It is known that neurotrophic factor receptors regulate distinct neurotrophic signals 
through alternatively spliced receptor isoforms. TrkB isoforms displayed inhibitory actions on 
dendritic arborization, where the full-length TrkB increase proximal dendritic branching but 
truncated TrkB promoted distal dendritic elongation (153). Similarly, full-length TrkC 
enhanced elaboration of major axonal processes whereas truncated TrkC induced formation of 
protrusions and branching through distinct signaling pathways (154). Taken together, it is 
conceivable that some of the diverse cellular responses and activations of distinct signaling 
pathways by GDNF (155), may in part be due to the differential expressions and distinctive 
functions of the spliced GFRα1 isoforms. 
 In summary, this study provides the first evidence that GDNF or NTN exhibit distinct 
neuritogenic effects mediated through specific GFRα1 isoforms. GFRα1b inhibited GFRα1a 
mediated neuritogenesis through the RhoA-ROCK pathway. The interactions between the 
GFR1 isoforms in inducing neurite outgrowths may shed new insights into the complexity 
of GDNF signaling in the nervous system. The emerging view is that the combinatorial 
interactions of the spliced isoforms of GFRα1, Ret and NCAM, will invariably contribute 
















PART II: GDNF SIGNALING THROUGH GFRΑ1B BUT NOT GFRΑ1A IS 






 Glial cell line-derived neurotrophic factor (GDNF) was initially purified from 
conditioned medium of the rat glioma cell line and it supported the survival and 
differentiation of neuronal cells (1). Recently, both GDNF and its cognate receptor GFRα1 
were found to be overexpressed in human gliomas (156). Therefore, it is tempting to 
hypothesize that GDNF signaling through GFRα1 may play significant roles in human 
gliomas. 
 High-grade gliomas, the most common malignant brain tumours in adults, are 
characterized by their highly invasive nature and showed poor prognosis (157,158). The high 
mortality is partly attributed to the aggressive behaviors in migration and invasion, which 
causes tumor cells to infiltrate the adjacent brain regions and rendering it difficult for 
treatments (159-161). The unraveling of the molecular mechanisms underlying the migratory 
and invasive behaviors of glioma may not only provide useful diagnostic and prognostic 
markers but also candidate therapeutic targets. One of the key mechanisms contributing to 
glioma invasiveness is autocrine signaling where gliomas secrete soluble factors that 
transduce migratory signals through receptors expressed on the tumors (162,163). A number 
of growth factors are known to promote glioma invasion through autocrine loops, including 
transforming growth factor-alpha (164), heparin binding-epidermal growth factor (165), 
platelet-derived growth factor (166) and hepatocyte growth factor/scatter factor (167). It is 
likely that multiple autocrine signaling systems are involved in the maintenance of glioma 
invasiveness and that the identification of these can provide a more rational approach to the 
development of therapeutics. 
 Originally generated from rats exposed to N-nitrosomethylurea (168), the rat C6 
glioma cell line shares a number of similar characteristics with human glioblastoma (169,170). 
Currently, C6 glioma is widely used to elucidate mechanisms underlying the aggressive 
behaviors of malignant glioblastoma both in vitro and in vivo (171,172). Similar to human 
gliomas, C6 glioma was also found to overexpress GDNF and its receptors (173). 
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Furthermore, migratory behavior of C6 glioma and a low grade glioma cell line was 
positively correlated with their expression levels of GDNF and GFRα1 (173), suggesting that 
the autocrine GDNF signaling may be involved in the invasiveness of C6 glioma.   
 This study aimed to test the hypothesis that GFRα1 isoforms have distinct functions 
in glioma cell behaviors. It is first observed that human glioma samples expressed 
predominantly GFRα1b isoform. Specific functions of GFRα1 isoforms were investigated in 
C6 glioma cells, which expressed both GFRα1a and GFRα1b. In C6 cells, knockdown of 
either individual GFRα1 isoforms or total GFRα1 did not affect cell proliferation. 
Unexpectedly, knockdown of GFRα1b but not GFRα1a significantly induced cell elongation 
and inhibited cell migration and invasion. Furthermore, GFRα1b but not GFRα1a was 
required for RhoA expression and that RhoA was intimately involved in cell elongation and 
migration. Intriguingly, the alternative co-receptor NCAM but not the canonical co-receptor 
Ret was found to be involved in RhoA expression and migration of C6 glioma. These findings 
provide unanticipated and novel insights into the specific involvement of GFRα1b in 





4.2.1. Expression of GDNF and its receptor complexes in human glioma samples and C6 
glioma cells 
 The expression levels of GFRα1a and GFRα1b in normal human brain and human 
glioma samples were quantified by isoform-specific real-time PCR (Fig. 4.1). Human brain 
expressed comparable levels of GFRα1a and GFRα1b. Unexpectedly, GFRα1b was expressed 




Fig. 4.1. Expressions of GFRα1 isoforms in normal human brain and human glioma samples. Expression 
levels of GFRα1a (opened bars) and GFRα1b (filled bars) were quantified by isoform-specific real-time PCR and 
normalized to GAPDH. ** p < 0.01, compared to GFRα1a. 
 
 Similarly, the expression levels of GDNF and its receptors (GFRα1, GFRα2, Ret and 
NCAM) were examined in C6 cells using real-time PCR (Fig. 4.2). GDNF, GFRα1 and 
NCAM were highly expressed in C6 glioma cells. GFRα2 transcript was below detection 
limit (< 100 copies per µg of total RNA). Both GFRα1a and GFRα1b were expressed in C6 
cells at comparable levels. 
 
Fig. 4.2. Expressions of GDNF and its receptors in C6 glioma cells. The expression levels of the target genes 
were quantified by real-time PCR and normalized to GAPDH. GFRα1, Ret and NCAM but not GFRα2 were 
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4.2.2. Specific knockdown of GFRα1 isoforms in C6 cells using siRNA 
 In order to gain an insight into the specific functions of GFRα1a and GFRα1b, 
specific siRNA duplexed were designed to knockdown GFRα1 isoforms in C6 cells. As there 
is no unique nucleotide sequence in GFRα1b compared to GFRα1a, exon overlapping siRNA 
duplexes were designed. Three siRNA duplexes [#1, #2 and #3] were designed with 
sequences overlapping exon 4 and 6 of GFRα1b, which contain 5, 7 and 10 nucleotides within 
exon 6, respectively (Fig. 4.3A). Both siRNA duplexes #1 and #2 specifically knocked down 
the expression of GFRα1b but not GFRα1a with high efficiency (Fig. 4.3B). Although 
GFRα1b siRNA #3 exhibited some discrimination between GFRα1a and GFRα1b (p < 0.05), 
this siRNA only had knock down efficiency of about 50% against GFRα1b, and was therefore 
excluded from this study.  
 With similar strategy, two siRNA duplexes targeting exon 4 and exon 5 of GFRα1a 
were designed and found to efficiently knock down GFRα1a expression without affecting 
GFRα1b. Two siRNA duplexes (total GFRα1 siRNA) targeting C-terminal sequences shared 
by both GFRα1 isoforms were also designed to efficiently knock down the total levels of 






Fig. 4.3. Knockdown of GFRα1a and GFRα1b by isoform-specific siRNA. (A) Graphic representation of 
GFRα1a and GFRα1b exon organizations, positions of isoform-specific and total GFRα1 siRNAs. (B) Specific 
knockdown of GFRα1 isoforms or total GFRα1 by siRNAs. Expressions of GFRα1a (filled bars) or GFRα1b 
isoform (open bars) were specifically and efficiently knocked down by two siRNAs of each isoform (#1 and #2). 
Two siRNAs targeting common region of GFRα1 isoforms were also used to knock down the total levels of 
GFRα1. Luciferase siRNA was used as negative control. * p < 0.05, ** p < 0.01.  
 
4.2.3. Knockdown of GFRα1 isoforms does not affect cell proliferation 
 Proliferation of C6 cells was first examined after knockdown of GFRα1 isoforms. It 
is found that knockdown of either individual GFRα1 isoform or total levels of GFRα1 did not 
significantly alter the proliferative behaviors of C6 cells as evident from the following studies 
(Fig. 4.4). Firstly, C6 cells transfected with either control siRNA or GFRα1 siRNA had 
similar growth rates as indicated by the number of cells 24 h and 48 h post-transfection (Fig. 
4.4A). Secondly, C6 cells after GFRα1 knockdown were immunostained with ki-67 antibody, 
which reacts with a nuclear antigen in proliferating cells and widely used as marker for cell 
proliferation (174). The percentage of ki-67 positive cells was similar with cells transfected 
with either control siRNA or GFRα1 siRNA (Fig. 4.4B). Furthermore, no significant 
difference was observed with the cell cycle profiles of siRNA-transfected cells (Fig. 4.4C). 
























































shown). These results supported the notion that cell proliferation was not affected by the 
knockdown of GFRα1.  
 
Fig. 4.4. Knockdown of GFRα1 isoforms does not affect cell proliferation. C6 cells were transfected with 
control, GFRα1a , GFRα1b or total GFRα1 siRNAs (siRNA #1). Cells were analyzed 24 h later unless otherwise 
stated. (A) Cell numbers 24 h or 48 h after transfection of siRNAs were counted. (B) Ki-67 positive cells was 
immunostained with Ki-67 antibody and normalized to total number of cells. (C) Cell cycle profiles were analyzed 
by FACS.  
 
4.2.4. Knockdown of GFRα1b induces cell elongation and inhibits cell migration and 
invasion 
 C6 glioma cells in culture display flat polygonal morphology with multiple short 
processes. No significant difference in cell morphology was observed after transfection of 
control and GFRα1a siRNA. Interestingly, C6 cells transfected with GFRα1b siRNA and total 
GFRα1 siRNA exhibited distinct morphology with elongated processes as shown by 
fluorescent staining of cells with FDA (Fig. 4.5A). For quantitative analyses of the 
morphological changes, the cell processes were quantified by the elongation index (EI). This 
method has previously been applied to quantify NIH3T3 cell elongation upon serum 





























































































suggested that most control cells and cells with GFRα1a knockdown had EI less than 5. 
Interestingly, a large population of cells transfected with GFRα1b and total GFRα1 siRNA 
exhibited drastically elongated processes with EI of 5 to 15 (Fig. 4.5B). Identical results 
obtained using two different siRNA duplexes (#1 and #2) of both GFRα1 isoforms and total 
GFRα1, this data is suggestive of a specific role of GFRα1b but not GFRα1a in C6 cell 
behavior. 
 
Fig. 4.5. Knockdown of GFRα1b induces C6 cell elongation. C6 cells were transfected with control, GFRα1a, 
GFRα1b and total GFRα1 siRNAs and stained with FDA 48 h post-transfection. (A) Representative images of C6 
cells after FDA staining. White arrows indicate elongated processes of C6 cells. Scale bar, 50 µm. (B) 
Quantification of C6 cell elongation after GFRα1 knock down. Similar results were obtained with 2 different 
siRNA duplexes. ** p < 0.01, compared to control siRNA.  
 
 Because cell elongation may be the result of the failure in cell migration (176), it is 
possible that C6 cells transfected with GFRα1b siRNA may also display impaired cell 
migration. Cells transfected with GFRα1 siRNA were examined in wound healing and trans-
well migration assays. Indeed, cells with knockdown of GFRα1b and total GFRα1 did not fill 
the wound as rapidly as control and GFRα1a knockdown cells, indicative of a decrease in cell 
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migration were quantitatively analyzed using trans-well migration assays. Compared to 
control and GFRα1a knockdown cells, knockdown of GFRα1b or total GFRα1 resulted in 3-4 
fold decrease in the number of cells migrated across the trans-well membrane (Fig. 4.6B).  
 
Fig. 4.6. Knockdown of GFRα1b inhibits C6 cell migration. C6 cells were transfected with control, GFRα1a, 
GFRα1b or total GFRα1 siRNAs. (A) C6 cell migration after siRNA transfection was examined by wound healing 
assay. (B) Quantification of C6 cell migration by trans-well migration assay. Similar results were obtained with 2 
different siRNA duplexes. ** p < 0.01, compared to control siRNA. 
 
 C6 glioma cells are associated with various aggressive tumor behaviors including 
proliferation, chemoresistance, migration and invasion both in vitro and in vivo (172,177). We 
therefore further investigated whether knockdown of GFRα1b would affect cell invasion in 
vitro by matrigel invasion assay. Consistent with migration studies, C6 cells transfected with 
GFRα1b siRNA but not GFRα1a siRNA significantly inhibited cell invasion (Fig. 4.7A). 
Invasion of glioma cells is not only dependent on cell cytoskeletal and morphological 
alterations but also on extracellular activities such as integrin expressions and unbalanced 
matrix metalloproteinases (MMPs)/tissue inhibitors of metalloproteinases (TIMPs) activations 
(159). Interestingly, knockdown of GFRα1b did not seem to alter the expressions of various 
integrins (Fig. 4.7B) and MMPs/TIMPs (Fig. 4.7C). Furthermore, knockdown of GFRα1 
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MMP-9 in the gelatin zymography assay (Fig. 4.7D). Taken together, these findings 
suggested that GFRα1b but not GFRα1a was involved in glioma cell migration and invasion. 
 
Fig. 4.7. Knockdown of GFRα1b inhibits C6 cell invasion. C6 cells were transfected with control, GFRα1a, 
GFRα1b or total GFRα1 siRNAs. (A) C6 cell invasion was measured by matrigel invasion assay. ** p < 0.01, 
compared to control siRNA. Expression levels of integrins (B) and MMPs/TIMPs (C) were quantified by real-time 
PCR. No significant change in expression of these genes was observed. (D) Analysis of MMP2 and MMP9 activity 
of C6 culture medium by gelatin zymography.  
 
4.2.5. Knockdown of GFRα1b inhibits RhoA expression 
 Previous reports suggested that inhibition of small GTPase RhoA results in process 
elongation (178) and impaired migration of cultured astrocytes (179). It is possible that 
activation of RhoA may be inhibited by GFRα1b knockdown, resulting in C6 cell elongation 
and the impairment of migration. Using GST-Rhotekin pull-down assay, the level of GTP-
bound (active) RhoA was significantly reduced in cells transfected with GFRα1b and total 
GFRα1 but not GFRα1a siRNA (Fig. 4.8A). Surprisingly, the total levels of RhoA were also 
reduced with GFRα1b siRNA (Fig. 4.8A), suggesting that GFRα1b may regulate RhoA 
activation by modulating the expression of RhoA. It has been reported that RhoA activity is 
required for F-actin stress fiber formation (180,181). Knockdown of total GFRα1 or GFRα1b 
but not GFRα1a also dramatically impaired stress fiber formation (Fig. 4.8B), consistent with 
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Using real-time PCR, it is found that transcripts levels of RhoA and related Rho family 
GTPases Rac1 and Cdc42 were not affected by GFRα1 siRNA (Fig. 4.8C), indicating that 
regulation of the RhoA protein expression by GFRα1b is independent of RhoA transcription.  
 
Fig. 4.8. Knockdown of GFRα1b decreases RhoA protein expression and impairs stress fiber formation in 
C6 cells. (A) Active RhoA was extracted by Rhotekin pull-down assay. Both active and total RhoA expression 
were impaired by knock down of GFRα1b or total GFRα1 but not GFRα1a. Expression levels of the other Rho-
family GTPases Rac1 and Cdc42 were not affected by knock down of GFRα1 isoforms. (B) Effect of GFRα1 
siRNA (#1) on stress fiber stained by phalloidin-rhodamine. White arrows indicate extensive formation of stress 
fibers in cells. Scale bar, 5 m. (C) The transcript levels of RhoA, Rac1 and Cdc42 were quantified by real-time 
PCR in C6 transfected with GFRα1 siRNA (#1). The expression levels were normalized to control siRNA and 
presented as percentage expression.   
 
4.2.6. RhoA is required for C6 cell migration 
 To demonstrate the functions of RhoA in C6 cell migration, RhoA activation was 
suppressed by transfecting cells with RhoA dominant negative mutant (RhoA-DN) and RhoA 
siRNA. Compared to C6 cells transfected with wild-type RhoA (RhoA-WT), cells expressing 
RhoA-DN exhibited elongated morphology (Fig. 4.9A), which is further supported by 
quantification of elongation index of transfected cells (Fig. 4.9B). This observation is in 
congruence with the effect of GFRα1b knockdown in C6 cells (Fig. 4.5). Interestingly, 
expression of constitutively active RhoA (RhoA-CA) resulted in rounding of the C6 cells and 
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a significant reduction in cell elongation index, further suggesting the roles of RhoA in 
modulating cell morphology (Fig. 4.9A,B). The role of RhoA in C6 cell migration was further 
evaluated by knockdown of RhoA expression using siRNA. RhoA siRNA but not control 
siRNA abolished the expression of RhoA protein without affecting GFRα1 expression (Fig. 
4.9C). As expected, the knockdown of RhoA significantly inhibited C6 cell migration in 
trans-well migration assay (Fig. 4.9D). These results lend further support to the role of RhoA 
activity in C6 cell migration and suggested that GFRα1b modulate cell migration by 
regulating RhoA levels.  
 
Fig. 4.9. Inactivation of RhoA induces C6 cell elongation and inhibits cell migration. C6 cells were transfected 
with HA-tagged wild-type (WT), dominant negative (DN) and constitutively active (CA) RhoA constructs. (A) 
Representative images of C6 cells after immunostaining with HA antibody. White arrows indicate elongated 
processes of C6 cells. Scale bar, 50 µm. (B) Quantification of C6 cell elongation after transfection of RhoA 
constructs. ** p < 0.01, compared RhoA WT. (C) Western blot analysis showed efficient knockdown of RhoA 
expression using siRNA. (D) Knockdown of RhoA inhibited C6 migration in trans-well migration assay. ** p < 
0.01, compared to control siRNA. 
 
4.2.7. The reduction of cell migration and RhoA expression by GFRα1b knockdown are 
mitigated by overexpression of siRNA-resistant GFRα1b  
 siRNA rescue experiments were performed to verify that the observed effects of 
GFRα1 siRNA on C6 migration and RhoA expression were due to specific knockdown of 






















































on target sequence of total GFRα1 siRNA #2. These siRNA-resistant constructs were then co-
transfected with control siRNA or total GFRα1 siRNA. Transient transfection of siRNA-
resistant GFRα1a (1a-r) or GFRα1b (1b-r) resulted in an increase in both transcript and 
protein levels of GFRα1a or GFRα1b in C6 cells, respectively (Fig. 4.10A,C, left panels). As 
expected, co-transfection of total GFRα1 siRNA but not control siRNA resulted in efficient 
knockdown of both GFRα1 isoforms in cells transfected with control vector (Fig. 4.10A). 
However, in cells expressing 1a-r or 1b-r, total GFRα1 siRNA was only able to knockdown 
endogenous expression of GFRα1, which then resulted in specific expression of GFRα1a or 
GFRα1b, respectively (Fig. 4.10A). Resistance of siRNA knockdown with these constructs 
was further validated by Western blot analysis (Fig. 4.10C, top panel). It is worthy to note 
that only real-time PCR but not Western blot analysis could distinguish the relative 
expressions of GFRα1a and GFRα1b, due to extensive sequence homology.  
 
Fig. 4.10. Exogenous expression of siRNA-resistant GFRα1b rescues migration and RhoA expression of C6 
cell transfected with GFRα1 siRNA. C6 cells transfected with control or GFRα1 siRNA were further transfected 
with control (vec) or siRNA-resistant GFRα1a (1a-r) or GFRα1b (1b-r) constructs. (A) Relative expression of 
GFRα1a (filled bars) and GFRα1b (open bars) in the transfected C6 cells. (B) Quantification of C6 cell migration 
by trans-well migration assay. (C) Western blot analysis of GFRα1 and RhoA expressions in transfected C6 cells. 
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 These siRNA-resistant GFRα1 constructs allowed evaluation of whether inhibition of 
C6 cell migration and RhoA expression by GFRα1 knockdown could be restored by 
exogenous expressions of GFRα1a or GFRα1b. As expected, knockdown of total GFRα1 
inhibited cell migration when co-transfected with control vector in trans-well migration 
assays (Fig. 4.10B). Cell migration was specifically restored in cells co-transfected with 1b-r 
but not 1a-r (Fig. 4.10B). Furthermore, 1b-r but not 1a-r also restored the expression of RhoA 
in the presence of total GFRα1 siRNA (Fig. 4.10C). Therefore, the rescue experiments 
strongly supported the involvement of GFRα1b but not GFRα1a in RhoA expression and C6 
cell migration. 
 
4.2.8. Effect of GFRα1b is mediated through co-receptor NCAM 
 GDNF and GFRα1 are known to transduce signal through the canonical co-receptor 
Ret or alternative co-receptor NCAM. To gain an insight into the involvement of Ret or 
NCAM mediating the effects of GFRα1b in C6 cells, both co-receptors were specifically 
knockdown using siRNA duplexes. Expression of Ret and NCAM at both transcripts levels 
(Fig. 4.11A) and protein levels (Fig. 4.11D) were significantly reduced using these siRNA. 
As expected, knockdown of GFRα1 significantly inhibited cell migration and RhoA 
expression (Fig. 4.11B-D). Intriguingly, NCAM siRNA but not Ret siRNA inhibited cell 
migration in both wound-healing assay and trans-well migration assay (Fig. 4.11B,C). 
Furthermore, NCAM siRNA but not Ret siRNA partially inhibited the expression of RhoA 
(Fig. 4.11D). It has to be noted that due to the high endogenous expression of NCAM, 
incomplete abolishment of NCAM protein expression may explain the slight difference in the 
effects of GFRα1 siRNA and NCAM siRNA in cell migration and RhoA expression (Fig. 
4.11B-D). These results further supported the notion that GFRα1b may transduce signal 





Fig. 4.11. NCAM but not Ret mediates cell migration and RhoA expression in C6 cells. C6 cells transfected 
with control, GFRα1, Ret or NCAM siRNA. (A) Knockdown efficiency of GFRα1, Ret and NCAM siRNA in C6 
cells. The mRNA expression levels of GFRα1, Ret and NCAM were quantified by real-time PCR 24 h after 
transfection of control or target (GFRα1, Ret and NCAM respectively) siRNA duplexes. All three siRNA duplexes 
resulted in more than 70% knockdown of their respective targets at transcript levels. (B) C6 cell migration after 
siRNA transfection was examined by wound healing assay. (C) Quantification of C6 cell migration by trans-well 
migration assay. ** p < 0.01, compared to control siRNA. (D) Western blot analysis of GFRα1, Ret, NCAM and 




 In this study, isoform-specific siRNAs were successfully designed to knockdown the 
highly homologous GFRα1 isoforms specifically and efficiently in C6 glioma cells. It was 
rather unanticipated that GFRα1b but not GFRα1a was intimately involved in C6 glioma cell 
migration and invasion through the modulation of RhoA expression. Specific roles of 
GFRα1b were further supported by rescue experiments with siRNA-resistant GFRα1b. It is 
also interesting that alternative co-receptor NCAM but not Ret may play a significant role in 
GFRα1b mediated cell migration.  
Although previous report has shown that both GDNF and its receptor GFRα1 were 



























































are differentially expressed. It is worthy to note that due to high sequence homology of 
GFRα1 isoforms, quantitative analysis of the expression of the isoforms was practically 
impossible with existing antibodies and conventional PCR. Using isoform-specific real-time 
PCR, it is found that while human normal brain expressed comparable levels of GFRα1 
isoforms, human glioma samples expressed predominantly GFRα1b. This result suggests that 
GFRα1 isoform (especially GFRα1b) may play important functions in glioma biology.  
 In this study, C6 glioma cells were found to express high levels of GDNF, GFRα1 
and NCAM as previously reported (156,173,182). Ret was also expressed albeit at a lower 
transcript level. Interestingly, both GFRα1a and GFRα1b were found to be expressed at 
comparable levels. To address the specific functions of each GFRα1 isoforms, a number of 
exon-spanning siRNA duplexes were designed that targeted the unique exon junction of each 
isoform. Two of the siRNA duplexes were successful in knocking down each of the GFRα1 
isoform and the total levels of GFRα1. These isoform-specific siRNA duplexes provide 
valuable tools for functional studies of each GFRα1 isoform endogenously. 
 GDNF has been reported to act as a proliferating factor in C6 cells and treatment of 
antisense GFRα1 inhibited cell proliferation (183). Contrary to this report, we have found that 
the knockdown of either GFRα1 isoform with two different siRNA duplexes did not 
significantly affect cell proliferation, as measured by the total number of cells, the number of 
proliferating cells and cell cycle profiles. It is possible that differences in GFRα1 depletion 
methodologies may contribute to such discrepancies (184).  
 GDNF has been previously found to regulate migration of various cell types, 
including cortical GABAergic neurons (42), corneal epithelial cells (185), olfactory 
ensheathing cells (186), chondrosarcoma cells (187), pancreatic carcinomas (188,189) and 
Schwann cells (41). In addition to the finding that both GDNF and its receptors were highly 
expressed in gliomas, emerging evidence support the role of GDNF autocrine signaling in 
migration of glioma cells (173). However, the involvement of specific receptor components 
and the underlying signaling mechanisms were currently unknown.  
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 In this study, an interesting observation was made that knockdown of GFRα1b but 
not GFRα1a induced C6 cell elongation. It has been suggested that in response to cell 
migratory cues, cells polarize where the leading edge of the cell protrudes towards the 
direction of migration, and the rear edges of the cell contract to pull the cell forward (176). It 
is possible that the presence of leading edge protrusion with the failure of rear edge 
contraction may result in both cell elongation and impaired cell migration. Indeed, 
knockdown of GFRα1b but not GFRα1a inhibited C6 cell migration in both wound healing 
and trans-well migration assays. Furthermore, knockdown of GFRα1b impaired C6 cell 
invasion in matrigel invasion assay. This is the first report that showed glioma migration and 
invasion induced by GDNF signaling is mediated through a specific receptor isoform, 
GFRα1b. It is not uncommon that receptor isoforms exhibit distinct functions on tumor cell 
migration. For example, thromboxane receptor isoform beta (TP-b) but not TP-a promoted 
proliferation and migration of bladder cancer cells (190); interestingly, discoidin domain 
receptor-1 isoform a (DDR1a) but not DDR1b was found to be involved in glioma cell 
migration and invasion (191). It is possible that human gliomas may enhance GDNF 
autocrine migratory signaling via up-regulation of GFRα1b expression. 
 Glioma migration and invasion are multi-step processes that require integrated 
modulations of various intracellular and extracellular components, such as protein kinases, 
Rho family GTPases, integrins and MMPs/TIMPs (159,192). Although GFRα1b was 
involved in C6 cell invasion in vitro, knockdown of either GFRα1a or GFRα1b did not 
significantly affect the expressions and activities of MMPs/TIMPs or the expressions of 
integrins. It is thus likely that GFRα1b may be modulating intracellular events to facilitate C6 
cell migration and invasion. Rho family GTPases play pivotal roles in directional cell 
movement, whereby Rac and Cdc42 are involved in leading edge protrusion, RhoA modulates 
the retraction of the rear edge (193). In this study, knockdown of GFRα1b but not GFRα1a 
significantly reduced RhoA expression and stress fiber formation. Interestingly, regulation of 
RhoA expression by GFRα1b was not associated with transcriptional regulation of RhoA, 
suggesting that GDNF signaling through GFRα1b may either increase the translation or 
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stability of RhoA protein. It has been shown previously that combined LPA and PDGF 
signaling can trigger glioma cell migration through the stabilization of RhoA and 
tropomyosin expression (194). It is possible that GDNF signaling through GFRα1b may 
regulate RhoA expression in a similar mechanism. Furthermore, we found that inactivation of 
RhoA by RhoA-DN also induced cell elongation and knockdown of RhoA inhibited cell 
migration (Fig. 8), recapitulating the effects observed with knockdown of GFRα1b. 
Expression of RhoA protein has been found to be positively correlated with the degree of 
malignancy in astrocytomas (195). These data together suggested that regulation of RhoA 
protein expression may represent a novel mechanism in GFRα1b-mediated glioma migration 
and invasion. 
 Although GDNF-GFRα1 was known to transduce migratory signal through the 
canonical co-receptor Ret (185-189), the alternative co-receptor NCAM has also been shown 
to couple to GDNF-GFRα1 and modulate the migration of neuronal precursors in rostral 
migratory stream and Schwann cells (41,196,197). It is interesting to note that GFRα1b-
induced RhoA expression and glioma migration was likely mediated through NCAM but not 
Ret, suggesting the involvement of specific GDNF receptor complex in glioma migration. 
 In conclusion, this study provides the first evidence that GFRα1b, an alternatively 
spliced isoform of GFRα1, was involved in RhoA expression and cell migration in C6 glioma 
cells. The identification of GDNF-GFRα1b-NCAM-RhoA signaling conduit may shed new 
insight into the molecular mechanisms of glioma migration and may provide novel targets for 
















PART III: ACTIVATION OF CAMP-PKA SIGNALING IS A REQUISITE FOR GFL-
INDUCED SUSTAINED ERK1/2 ACTIVATION AND NEURITE OUTGROWTH 







In addition to GFRα1, both GDNF and NTN are known to signal through GFRα2 and 
regulate neurite outgrowth in various neuronal systems (67,132,198). To date, at least three 
alternatively spliced isoforms of GFRα2 (GFRα2a, GFRα2b and GFRα2c) have been 
identified (104,105). Our lab has recently shown that depending on the activations of specific 
GFRα2 isoforms, GDNF and NTN may promote or inhibit neurite outgrowth in 
neuroblastoma cells (67). Elucidating the molecular mechanism underlying the distinct 
ligand-induced functions of GFRα2 isoforms will provide novel insights into how GFLs may 
promote neurite outgrowth and neuronal regeneration.  
 Cyclic AMP (cAMP) is a second messenger that regulates key cellular responses in 
the nervous system such as neuronal survival, differentiation, axonal guidance and 
regeneration (199-203). Elevation of cAMP has been shown to overcome the inhibitory effect 
of myelin-associated inhibitory factors and promote regeneration of injured axons in a variety 
of neurons, including sciatic nerves (204), dorsal root ganglion (DRG) (205) and spinal cord 
neurons (202,206,207). It is known that elevation of intracellular cAMP can be induced by 
neurotrophic factors (208). NGF, BDNF and GDNF have been found to elevate cAMP to a 
threshold level that overcomes the inhibitory effects of myelin and results in neurite 
outgrowth in both cerebellar (209) and DRG neurons (205,210). The close link between 
cAMP and neurotrophic factor signaling is further supported by their cooperative effect in 
promoting neurite outgrowths. The co-administration of cAMP and neurotrophic factors is 
known to enhance adult retinal ganglion cell neurite outgrowth (211,212). Furthermore, 
trophic factors in muscle cell-conditioned medium requires the addition of only a membrane-
permeable cAMP analog for enhanced neurite outgrowth of adult rat spinal cord motoneurons 
in long-term cultures (213). Interestingly, the co-administration of a phosphodiesterase type 4 
inhibitor and dibutyryl cAMP (dbcAMP) along with GDNF has been shown to restore 
functional motor units of transplanted embryonic stem cells (214). The intimate interactions 
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of neurotrophic factors and cAMP signaling may have therapeutic benefits in promoting 
neurite outgrowth and neuronal regeneration. 
 Studies in primary neuronal cell cultures and the rat pheochromocytoma cell line 
PC12 have made significant contributions to the understanding of downstream cAMP 
signaling pathways in neurite outgrowth.  Although cAMP canonically signals through 
protein kinase A (PKA), cAMP signaling may also be transduced through the exchange 
protein directly activated by cAMP (Epac) (215,216). Both PKA and Epac were able to 
mediate cAMP-induced axonal regeneration in DRG neurons (210,217) and neurite extension 
in PC12 cells (218,219). It is well known that sustained activation of the MAPK ERK1/2 
plays a central role in cAMP-induced neuronal differentiation (220-224). As a novel guanine 
nucleotide exchange factor, Epac, was able to directly activate Rap1 and its downstream 
ERK1/2 pathway (225,226). However, PKA-mediated activation of Rap1 and ERK1/2 
requires Crk SH3 domain guanine nucleotide exchanger (C3G) (225). In addition to ERK1/2 
activation, PKA may mediate cAMP-induced neuronal differentiation through specific CREB 
phosphorylation and transcriptional activation (227-230). In view of these findings, 
unraveling the underlying mechanism of specific cAMP downstream pathways will be 
invaluable to the understanding of physiological interactions between cAMP and ligand 
activated GFRα2 isoforms. 
 In this
 
study, we unexpectedly identified cAMP signaling as an underlying 
mechanism contributing to differential neuritogenic activities of GFRα2 isoforms. 
Furthermore, we provide evidence that cAMP-PKA signaling is essential for ligand 
activations of GFRα2 to promote sustained ERK1/2 activation and neurite outgrowth, a 




5.2.1. GDNF and NTN induce CREB phosphorylation, sustained ERK1/2 activation and 
neurite outgrowth in PC12 cells expressing GFRα2a and GFRα2c but not GFRα2b 
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In this study, PC12 cells stably expressing both Ret9 with either one of the 
alternatively spliced GFRα2 isoform, GFRα2a, GFRα2b and GFRα2c were established and 
the transcript levels quantified by real-time PCR (Fig. 5.1A). The wild-type and PC12 cells 
carrying vector alone did not express either Ret or GFRα2 isoforms and were used as controls 
(Fig. 5.1A). Stably infected PC12 cells were then stimulated with GDNF, NTN or NGF. 
Interestingly, while NGF induced extensive neurite extensions in all the PC12 cell lines, 
GDNF and NTN promoted neurite outgrowth only in cells expressing GFRα2a and GFRα2c 
but not GFRα2b (Fig. 5.1B,C). This result is consistent with the previous report that GFRα2 
isoforms exhibited differential neuritogenic activities upon ligand stimulations (67) and 
suggests that ligand activation of GFRα2a and GFRα2c may regulate distinct signaling 
pathways compared to GFRα2b. 
 
Fig. 5.1. GDNF and NTN induce neurite outgrowth in PC12 cells expressing GFRα2a and GFRα2c but not 
GFRα2b. (A) Expression levels of Ret9 and GFRα2 isoforms in wild type (WT) and stably infected PC12 cells. 
PC12 cells were co-infected with mouse Ret9 and GFRα2 isoforms. The expression levels of Ret9 and GFRα2 
isoforms were quantified by real-time PCR and normalized to the expression levels of GAPDH. The results were 
expressed as mean ± S.E.M. (n = 3). (B) Ligand-induced neurite outgrowth in PC12 cells expressing Ret9 and 
GFRα2 isoforms. Cells were treated with GDNF, NTN or NGF (50 ng/ml) for 48 h. Error bars indicate mean ± 
S.D. of quadruplicate measurements. ** p < 0.01, compared with non-treated cells. (C) Phase-contrast images of 



















































































 To gain a better understanding of the downstream signaling pathways, we next 
examined the NTN-induced phosphorylation of CREB and ERK1/2 in PC12-GFRα2 cells 
over a period of 6 h (Fig. 5.2). It is interesting to note that GFRα2a and GFRα2c but not 
GFRα2b mediated NTN-induced CREB phosphorylation in a time-dependent manner (Fig. 
5.2A,B). Furthermore, NTN stimulation of both GFRα2a and GFRα2c induced a biphasic 
phosphorylation pattern of ERK1/2, which was sustained at least up to 6 h (Fig. 5.2A,C). In 
contrast, activation of ERK1/2 by NTN through GFRα2b was transient and was dramatically 
reduced after 5 min (Fig. 5.2A,C). These findings are in line with the observation that 
GFRα2a and GFRα2c but not GFRα2b mediated ligand-induced neurite outgrowth in PC12 
cells, possibly through a sustained level of ERK1/2 activation. 
 
Fig. 5.2. NTN promotes CREB phosphorylation and sustained ERK1/2 activation in PC12 cells expressing 
GFRα2a and GFRα2c but not GFRα2b. (A) Time course of CREB and ERK1/2 phosphorylation induced by 
NTN. PC12 cells expressing GFRα2 isoforms were stimulated with NTN (50 ng/ml) for the indicated periods of 
time. Phosphorylation levels of CREB and ERK1/2 were analyzed by Western blotting. Fold changes of 
phosphorylation levels of CREB (B) and ERK1/2 (C) were quantified by densitometry and presented as Mean ± 






























































5.2.2. cAMP signaling cooperates with GDNF and NTN to promote sustained ERK1/2 
activation, pERK1/2 nuclear translocation and neurite outgrowth via GFRα2b 
 Phosphorylation of CREB is a major biochemical event downstream of cAMP 
signaling pathway (227). Importantly, cAMP signaling was found to be required for NGF-
induced neurite outgrowth (218) and was able to synergize with EGF to promote neurite 
outgrowth in PC12 cells (222). We therefore hypothesized that cAMP signaling may similarly 
be able to cooperate with ligand-activated GFRα2b to promote neurite outgrowth. Indeed, 
while treatment of PC12 cells with various cAMP elevating agents alone (dbcAMP, FK and 
PACAP) only resulted in short neurite extensions, co-treatment of GDNF or NTN with these 
agents induced extensive neurite outgrowth in PC12 cells expressing Ret9 and GFRα2b (Fig. 
5.3).  
 
Fig. 5.3. Cyclic AMP elevating agents cooperate with GDNF and NTN to induce neurite outgrowth in PC12 
cells expressing GFRα2b. (A) Quantification of neurite outgrowth induced by various treatments. Cells were 
stimulated with GDNF or NTN (50 ng/ml) in the presence or absence of dbcAMP (100 µM), FK (10 µM) or 
PACAP (100 nM) for 48 h. Percentage of cells differentiated was presented as Mean ± S.E.M. of at least three 
biological replicates. ** p < 0.01, compared to dbcAMP, FK or PACAP alone. (B) Phase-contrast images of cells 
stimulated with GDNF or NTN in the presence or absence of FK for 48 h. NGF was used as positive control for 
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Fig. 5.4. Forskolin cooperates with NTN to promote sustained ERK activation required for pERK nuclear 
localization and neurite outgrowth in PC12 cells expressing GFRα2b. (A) Sustained ERK1/2 activation and 
(B) nuclear translocation of activated ERK1/2 were induced by co-treatment of NTN (50 ng/ml) with FK (10 µM). 
Phosphorylation levels of ERK1/2 were examined by Western blotting and fold changes over control were semi-
quantified. SOD-1 and PARP-1 served as specific markers for cytoplasmic and nuclear proteins, respectively. (C) 
Specific inhibition of late phase ERK1/2 activation. Cells were treated with NTN and FK for the indicated periods 
of time with (U0126) or without (DMSO) MEK inhibitor U0126. U0126 was added 1 h before (-1 h), together (0 
h), 1 h after (1 h) or 3 h after (3 h) NTN and FK stimulations. D, Effect of U0126 added at different time points on 
NTN and FK induced neurite outgrowth. Cells were incubated for 48 h from the time NTN and FK were added. 
Percentage of cells differentiated was presented as Mean ± S.E.M. of at least three biological replicates. U0126 
added 12 h after (12 h) NTN and FK stimulation has no inhibitory effect on neurite outgrowth. * p < 0.05, 
compared to NTN and FK treatment without U0126. 
  
 As ligand-induced neurite outgrowth through GFRα2a and GFRα2c was accompanied 
by sustained ERK1/2 activation (Figs. 5.1 and 5.2), we investigated if induction of neurite 
outgrowth by cAMP and NTN signaling through GFRα2b would also require sustained 
ERK1/2 activation. In PC12 cells expressing GFRα2b, treatment of FK resulted in transient 
ERK1/2 phosphorylation, similar to the observation with NTN stimulations (Fig. 5.4A).  Co-
treatment of cells with FK and NTN indeed promoted synergistic activation of ERK1/2 at 
later time points (Fig. 5.4A) and resulted in a prolonged ERK1/2 phosphorylation profile. The 
total level of ERK1/2 was not significantly increased with FK and NTN stimulations. 
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translocation of activated ERK1/2 at 6 h (Fig. 5.4B), a process critical for growth factor 
induced transcriptional activation and neuronal differentiation (231). These observations 
suggest that the late phase of ERK1/2 activation may play an essential role in neurite 
outgrowth induced by FK and NTN through GFRα2b. In order to examine the specific role of 
the late phase of ERK1/2, we incubated the cells with MEK inhibitor U0126 1 h before (-1 h), 
together (0 h), 1 h after (1 h) or 3 h (3 h) after the co-treatment of NTN and FK (Fig. 5.4C). 
As expected, pre-incubation with U0126 (1 h before) completely abolished ERK1/2 activation 
over 6 h period. Abolishment of ERK1/2 activation dramatically inhibited NTN and FK 
induced neurite outgrowth (Fig. 5.4D). U0126 added 1 h or 3 h after co-treatment of NTN and 
FK effectively inhibited ERK1/2 activation at 6 h. Specific inhibition of the late phase (6 h) 
ERK1/2 activation was sufficient to significantly block neurite outgrowth, supporting the 
notion that sustained ERK1/2 activation is required for NTN and FK induced neurite 
outgrowth. Interestingly, addition of U0126 at 12 h after NTN and FK stimulation was unable 
to inhibit neurite outgrowth, indicating that the activated ERK1/2 within 12 h of NTN and FK 
stimulations was sufficient to transduce neuritogenic signals in PC12 cells. 
 
5.2.3. Cooperation of cAMP signaling with NTN is mediated by protein kinase A (PKA) 
but not Epac 
 While the effects of cAMP have been mainly attributed to protein kinase A (PKA), 
Epac has been identified as an important downstream effector of cAMP signaling in signal 
transduction and transcriptional activations (232,233). We were therefore interested to 
determine the specific cAMP effector contributing to the cooperation of FK with NTN. The 
cAMP analogs 2-Me-cAMP and 6-Bnz-cAMP were used as specific agonists for activation of 
Epac and PKA, respectively. Interestingly, co-treatment of NTN with 50-200 µM of 6-Bnz-
cAMP significantly promoted neurite outgrowth in PC12 cells expressing GFRα2b in a dose 
dependent manner (Fig. 5.5A,B). In contrast, similar treatments with 2-Me-cAMP had little 
effects on neurite outgrowth. Both 2-Me-cAMP and 6-Bnz-cAMP at 200 µM induced 
transient ERK1/2 activation at comparable levels (Fig. 5.5C), indicating that 2-Me-cAMP was 
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biologically active. In agreement with the neurite outgrowth analyses, FK and 6-Bnz-cAMP 
but not 2-Me-cAMP cooperated with NTN to promote sustained ERK1/2 activation up to 6 h 
(Fig. 5.5D). The specific role of PKA was further supported by the observations that PKA 
inhibitor H89 significantly impaired both sustained ERK1/2 activation (Fig. 5.5E,F) and 
neurite outgrowth (Fig. 5.5G). These results strongly support the involvement of PKA but not 
Epac in the cooperation of cAMP signaling with NTN-GFRα2b to promote neurite outgrowth. 
 
Fig. 5.5. PKA but not Epac is the cAMP effector for cooperation of FK and NTN in PC12 cells expressing 
GFRα2b. (A) Dose-dependent cooperation of 6-Bnz-cAMP but not 2-Me-cAMP with NTN to induce neurite 
outgrowth. Cells were co-stimulated with NTN (50 ng/ml) and the indicated concentrations of FK, 2-Me-cAMP or 
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biological replicates. * p < 0.05 and ** p < 0.01, compared with NTN treatment alone. (B) Phase-contrast images 
of cells stimulated with NTN and 200 µM 2-Me-cAMP or 200 µM 6-Bnz-cAMP. (C) Transient activation of 
ERK1/2 by cAMP analogs. PC12 cells were stimulated with 200 µM 2-Me-cAMP or 6-Bnz-cAMP for indicated 
periods of time. Phosphorylation of ERK1/2 was examined by Western blotting. Blots were re-probed with eIF4E, 
serving as loading controls. (D) 6-Bnz-cAMP but not 2-Me-cAMP cooperated with NTN to induce sustained 
ERK1/2 activation. Cells were stimulated with NTN alone or together with 10 µM FK, 200 µM 2-Me-cAMP or 
200 µM 6-Bnz-cAMP for the indicated periods of time. Phosphorylation levels of ERK1/2 were analyzed by 
Western blotting. (E) Effect of PKA inhibitor H89 on sustained ERK1/2 activation induced by NTN and FK. Cells 
were co-treated with NTN and FK in the presence or absence of 10 µM H89 or 10 µM U0126 for the indicated 
periods of time. ERK1/2 phosphorylation was examined by Western blotting. (F) Fold changes of ERK1/2 
phosphorylation were quantified by densitometry and presented as Mean ± S.D. (n = 3). * p < 0.05, compared with 
NTN and FK treatment without H89. (G) Effect of H89 on neurite outgrowth induced by NTN and FK. Cells were 
co-treated with NTN and FK in the presence or absence of H89 for 48 h. Percentage of cells differentiated was 
presented as Mean ± S.E.M. of at least three biological replicates. ** p < 0.01, compared with NTN and FK 
treatment without H89. 
 
5.2.4. Forskolin and NTN-induced sustained ERK1/2 activation and neurite outgrowth 
via GFRα2b require de novo transcription and translation 
 Activation of gene transcription and regulation of protein synthesis are pivotal events 
to many of cAMP-mediated physiological processes (234). In PC12 cells expressing GFRα2b, 
we found that NGF and FK but not NTN promoted phosphorylation of CREB, expression of 
c-fos and phosphorylation of S6 ribosomal protein (Fig. 5.6), suggesting that transcriptional 
and translational activations may be regulated by cAMP signaling in these cells. We therefore 
examined whether activation of gene expressions is involved in FK and NTN induced 
sustained ERK1/2 activation and neurite outgrowth in PC12 cells expressing GFRα2b. Small 
molecule inhibitors Actinomycin D (ActD) and Cyclohexamide (Chx) were used to inhibit 
transcription and translation respectively. We found that ERK1/2 activation at 1 h and 6 h 
after FK and NTN stimulations was significantly inhibited after pre-treatment of ActD or Chx 
(Fig. 5.7A,B). Furthermore, these inhibitors significantly impaired neurite outgrowth induced 
by FK and NTN (Fig. 5.7C). These results suggest that cAMP signaling cooperates with 
NTN-GFRα2b signaling through activation of gene expressions that are required for both 






Fig. 5.6. Forskolin but not NTN regulates CREB phosphorylation, c-fos expression and S6 ribosomal 
protein phosphorylation in PC12 cells expressing GFRα2b. (A) Time-dependent CREB phosphorylation, (B) c-
fos expressing and (C) S6 ribosomal protein (S6RP) phosphorylation were induced by FK and NGF but not NTN. 
Cells were stimulated with FK (10 µM), GDNF (50 ng/ml), NTN (50 ng/ml), or co-stimulated with FK and GDNF 
or NTN for the indicated periods of time. Cells stimulated with NGF (50 ng/ml) served as positive controls. 
Phosphorylation levels of CREB and S6RP were examined by Western blotting. Blots were re-probed with Actin 
or eIF4E, serving as loading controls. Expression levels of c-fos were quantified by real-time PCR. 
 
 
Fig. 5.7. Forskolin and NTN induced sustained ERK1/2 activation and neurite outgrowth through GFRα2b 
requires de novo transcription and translation. (A) Effect of ActD and Chx on NTN and FK induced ERK1/2 
activation. Cells were treated with 50 ng/ml NTN and 10 µM FK in the presence or absence of 2 µg/ml ActD or 10 
µg/ml Chx for the indicated periods of time. (B) Fold changes of ERK1/2 phosphorylation levels were quantified 
by densitometry and presented as Mean ± S.D. (n = 3). * p < 0.05, compared with NTN and FK treatment without 
inhibitors at each time point. (C) Effects of ActD and Chx on NTN and FK induced neurite outgrowth. Cells were 
treated with NTN and FK in the presence or absence of inhibitors for 24 h. Percentage of cells differentiated was 
presented as Mean ± S.E.M. of at least three biological replicates. ** p < 0.01, compared with NTN and FK 
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5.2.5. cAMP and PKA signaling is involved in NTN induced neurite outgrowth in PC12 
cells expressing GFRα2a and GFRα2c 
 As NTN alone was able to promote CREB phosphorylation, sustained ERK1/2 
activation and neurite outgrowth in PC12 cells expressing GFRα2a or GFRα2c (Figs. 5.1 and 
5.2), we postulated that cAMP-PKA signaling would be similarly involved. We first 
demonstrated that late phase of ERK1/2 activation is critical to GFRα2a and GFRα2c 
mediated neurite outgrowth using the same experimental approach as Fig. 5.4C. NTN-
induced neurite outgrowth was significantly inhibited when U0126 was added 1 h before (-1 
h), together, 1 h after or 3 h after NTN stimulations (Fig. 5.8A). Addition of U0126 at 12 h 
after NTN treatment did not inhibit NTN-induced neurite outgrowth. As postulated, inhibition 
of PKA pathway with H89 significantly inhibited NTN-induced ERK1/2 activation (Fig. 
5.8B-D) and neurite outgrowth (Fig. 5.8E) in PC12 cells expressing GFRα2a or GFRα2c. 
Similarly, pre-treatment of ActD or Chx also significantly impaired NTN-induced ERK1/2 




Fig. 5.8. NTN induced sustained ERK1/2 activation and neurite outgrowth through GFRα2a and GFRα2c 
require cAMP-PKA signaling and de novo transcription and translation. (A) Effect of U0126 added at 
different time points on NTN induced neurite outgrowth. Cells were incubated for 48 h from the time NTN were 
added. U0126 added 12 h after (12 h) NTN stimulation has no inhibitory effect on neurite outgrowth. ** p < 0.01, 
compared to NTN treatment without U0126. (B) Effect of H89 on NTN induced ERK1/2 activation. Cells were 
stimulated with NTN (50 ng/ml) in the presence or absence of 10 µM H89 or 10 µM U0126 for the indicated 
periods of time. Phosphorylation levels of ERK1/2 were examined by Western blotting. Fold changes of ERK1/2 
phosphorylation in PC12 expressing GFRα2a (C) or GFRα2c (D) were quantified by densitometry and presented 
as Mean ± S.D. (n = 3). * p < 0.05, compared with NTN treatment without H89 at each time point. (E) Effect of 
H89 on NTN induced neurite outgrowth. Cells were treated with NTN in the presence or absence of H89 for 48 h. 
** p < 0.01, compared with NTN treatment without H89. (F) Effects of ActD and Chx on NTN induced ERK1/2 
activation. Cells were stimulated with NTN in the presence or absence of 2 µg/ml ActD or 10 µg/ml Chx for the 
indicated periods of time. Fold changes of ERK1/2 phosphorylation in PC12 expressing GFRα2a (G) or GFRα2c 
(H) were quantified by densitometry and presented as Mean ± S.D. (n = 3). * p < 0.05, compared with NTN 
treatment without inhibitors at each time point. (I) Effects of ActD and Chx on NTN induced neurite outgrowth. 
Cells were treated with NTN in the presence or absence of inhibitors for 24 h. ** p < 0.01, compared with NTN 
treatment without inhibitors. In these experiments, percentage of cells differentiated was presented as Mean ± 
S.E.M. of at least three biological replicates. 
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 Furthermore, in PC12 cells expressing GFRα2a or GFRα2c, co-stimulation of NTN 
and FK significantly enhanced the rates of neurite outgrowth from 24 h to 72 h, compared to 
treatment with NTN alone (Fig. 5.9). Interestingly, 6-Bnz-cAMP but not 2-Me-cAMP was 
able to enhance NTN-induced neurite outgrowth (Fig. 5.10). These findings demonstrate that 
cAMP-PKA signaling mechanism is intimately involved in the sustained ERK1/2 
phosphorylation and neurite outgrowth mediated by ligand-activated GFRα2 isoforms. 
 
 
Fig. 5.9. Forskolin enhances the rate of NTN induced neurite outgrowth in PC12 cells expressing GFRα2 
isoforms. (A) Time course of neurite outgrowth induced by NTN and FK. PC12 cells were stimulated with NTN 
(50 ng/ml), FK (10 µM) or co-stimulated with both NTN and FK for 24 h, 48 h and 72 h. Percentage of 
differentiated cells was presented as Mean S.E.M. of at least three biological replicates. (B) Phase-contrast images 












































































































Fig. 5.10. PKA but not Epac agonist enhances NTN induced neurite outgrowth of PC12 cells expressing 
GFRα2a and GFRα2c. PC12 cells expressing GFRα2a (A) or GFRα2c (B) were stimulated with 50 ng/ml NTN 
alone or together with 200 µM 2-Me-cAMP, 200 µM 6-Bnz-cAMP or 10 µM FK for 48 h. Percentage of cells 
differentiated was presented as Mean ± S.E.M. of at least three biological replicates. * p < 0.05 and ** p < 0.01, 
compared to NTN alone. 
 
5.2.6. cAMP and PKA signaling cooperates with NTN to promote neurite outgrowth in 
BE(2)-C cells 
 We next validated the contribution of cAMP-PKA signaling in NTN-induced neurite 
outgrowth in BE(2)-C, a human neuroblastoma cell line that endogenously expresses both 
GFRα2a and GFRα2b (67). We have previously shown that NTN was unable to induce 
significant neurite outgrowth in these cells, due to the inhibitory activity of GFRα2b (67). 
Similarly, FK, 2-Me-cAMP and 6-Bnz-cAMP also failed to promote neurite outgrowth in 
BE(2)-C cells. Interestingly, co-treatment of NTN with FK and 6-Bnz-cAMP but not 2-Me-
cAMP resulted in extensive neurite outgrowth in BE(2)-C cells (Fig. 5.11A,B), which 
recapitulated the specific synergistic effect of NTN and cAMP-PKA but not EPAC pathways 
in PC12 cells. Furthermore, we have previously shown that NTN was able to induce neurite 
outgrowth in BE(2)-C cells through GFRα2a, when GFRα2b was specifically knocked down 
(67). To examine if PKA signaling was involved in NTN-GFRα2a induced neurite outgrowth, 
BE(2)-C cells with GFRα2b knockdown were pre-treated with PKA inhibitors H89 and Rp-8-
Br-cAMPS before NTN stimulation. As expected, NTN promoted neurite outgrowth in cells 

























































even lowered doses resulted in significant toxicity in BE(2)-C cells, it was therefore excluded 
from the study. U0126 and the other PKA inhibitor Rp-8-Br-cAMP significantly reduced 
NTN-GFRα2a induced neurite outgrowth (Fig. 5.11C,D). These findings lend further support 
to the paradigm that cAMP-PKA signaling is essential for ligand-induced neurite outgrowth 
through GFRα2 isoforms. 
 
Fig. 5.11. Cyclic AMP and PKA signaling is required for NTN-induce neurite outgrowth in BE(2)-C cells. 
(A) Quantification of neurite outgrowth induced by NTN, FK and cAMP analogs. BE(2)-C cells were treated with 
10 µM FK, 200 µM 2-Me-cAMP or 200 µM 6-Bnz-cAMP in the presence or absence of 50 ng/ml NTN for 96 h. 
(B) Phase-contrast images of BE(2)-C cells stimulated with NTN, FK and cAMP analogs. (C) Quantification of 
neurite outgrowth induced by NTN in BE(2)-C cells with GFRα2b knockdown. BE(2)-C cells were transfected 
with either control or GFRα2b siRNA and treated with 50 ng/ml NTN in the presence or absence or 10 µM U0126 
or 200 µM Rp-8-Br-cAMPS for 96 h. (D) Phase-contrast images of control and GFRα2b knockdown BE(2)-C cells 
stimulated by NTN with or without inhibitors. Percentage of cells differentiated was presented as Mean ± S.E.M. 




 This study demonstrates the essential role of cAMP signaling in ligand-induced 
neurite outgrowth through GFRα2 isoforms (Fig. 5.12). While ligand activations of GFRα2a 
and GFRα2c mediate sustained ERK1/2 activation and neurite outgrowth, the ligand 
activation of GFRα2b requires cooperation of cAMP signaling to promote neurite outgrowth. 
Furthermore, the specific cAMP effector PKA, but not Epac, is required for transcription and 
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 GDNF and NTN are known to regulate neurite outgrowth through GFRα2 in various 
neuronal systems (67,132,198). GFRα2 is alternatively spliced into at least three isoforms 
(104,105), all of which are expressed in human nervous system (67). Recently, we have 
shown that NTN stimulations of GFRα2 isoforms induced similar ERK1/2 activations within 
30 min but resulted in distinct neuritogenic outcomes in neuroblastoma cells (67). Consistent 
with our previous report, ligand stimulations of GFRα2 isoforms resulted in similar early 
phase of ERK1/2 activation that peaked at 5 min in PC12 cells. Interestingly, GFRα2a and 
GFRα2c but not GFRα2b were able to mediate CREB phosphorylation, a late phase of 
ERK1/2 activation (~3 h) and neurite outgrowth upon ligand stimulations. Both 
phosphorylation of CREB and sustained activation of ERK1/2 are critical events required for 
neurite outgrowth in PC12 cells (229,235). These findings provide additional biochemical 
evidence for differential neuritogenic activities of GFRα2 isoforms.  
 
Fig. 5.12. A schematic illustration of cAMP-PKA signaling in GFL-induced neurite outgrowth through 
GFRα2 isoforms. Upon GFL (GDNF or NTN) stimulations, GFRα2a and GFRα2c promote sustained ERK1/2 
activation and neurite outgrowth. The late phase of ERK1/2 activation is dependent on cAMP-PKA signaling and 
de novo gene expression. Ligand-activated GFRα2b only induces transient ERK1/2 activation and requires 
























 Similar to ligand-activated GFRα2b, treatment with cAMP agonists alone activated 
only transient ERK1/2 phosphorylation and failed to induce significant neurite extensions in 
PC12 cells, consistent with previous observations (221,222,236,237). However, these cAMP 
agonists were able to cooperate with ligand-activated GFRα2b to induce a late phase of 
ERK1/2 phosphorylation and resulted in extensive neurite outgrowth. Intriguingly, sustained 
ERK1/2 activation and neurite outgrowth induced by ligand-activated GFRα2a and GFRα2c 
in PC12 cells were also dependent on cAMP signaling. Furthermore, in BE(2)-C cells 
endogenously expressing both GFRα2a and GFRα2b, NTN was able to cooperate with cAMP 
signaling to induce neurite outgrowth. In BE(2)-C cells with GFRα2b knocked down, NTN-
induced neurite outgrowth through GFRα2a was significantly inhibited by antagonist against 
cAMP signaling. Taken together, these results suggest that differential regulation of cAMP 
signaling may be the key event underlying the divergent effects of GFRα2b compared to 
GFRα2a and GFRα2c. 
 While the essential role of cAMP signaling in neurite outgrowth has been well 
established, the specific involvement of cAMP effectors PKA or Epac is still a subject of 
debate. Using chemical inhibitors, a number of studies have shown that PKA signaling is 
specifically required for PC12 neurite outgrowth induced by NGF (218,220,237), secretin 
(223) and panaxynol (225). These effects of PKA signaling are likely mediated through PKA-
dependent sustained ERK1/2 activation (220,223) and/or gene expressions (220,230,237,238). 
In addition, exogenous PKA signaling is able to cooperate with non-neuritogenic stimuli 
(EGF and KCl) to promote neurite outgrowth in PC12 cells (222,228,236). It is however 
worth to note that PKA signaling alone induced transient ERK1/2 activation and was 
insufficient to promote neurite outgrowth (219,221,222,237). Interestingly, PKA-mediated 
ERK1/2 activation can be prolonged in the presence of Epac signaling, resulting in neurite 
outgrowth in PC12 cells (219). Recent evidence suggests that cAMP-dependent neurite 
outgrowth in PC12 and DRG neurons may also be mediated by Epac (217,239,240). For 
example, Epac-Rit signaling is shown to be required for PACAP-induced PC12 
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differentiation (239,240). In this study, we have provided mounting evidence that PKA but 
not Epac signals downstream of cAMP to promote sustained ERK1/2 activation and neurite 
outgrowth through ligand-activated GFRα2 isoforms. The specific role of PKA is underscored 
by the observation that PKA agonist but not Epac agonist enhanced ligand-induced neurite 
outgrowth through GFRα2a and GFRα2c, in agreement with similar findings that FK, 
dbcAMP and PACAP enhanced NGF-induced neurite outgrowth (221,238,241). These results 
further support the notion that cAMP-PKA signaling plays a pivotal role in neurotrophic 
factor-induced neurite outgrowth and axonal regeneration (208).  
 Sustained activation of ERK1/2 is critical to neurite outgrowth of neuronal cells, 
including PC12 cells (231). Sustained ERK1/2 activation is thought to result in nuclear 
translocation of the activated ERK1/2 (220,235,242,243), a process important for neuronal 
differentiation and plasticity (231,244). Numerous studies have demonstrated the strong 
correlation between sustained ERK1/2 activation (up to 6 h) and neurite outgrowth in PC12 
cells (222,223,235,242,245-248). Consistent with these reports, ligand-induced neurite 
outgrowth through GFRα2 is accompanied by both activation and nuclear translocation of a 
late phase of ERK1/2 at 3-6 h. By specifically inhibiting ligand-induced ERK1/2 activation at 
1 h or 3 h onwards, we provide strong evidence that the late phase of ERK1/2 
phosphorylation is critical to neurite outgrowth mediated by GFRα2 isoforms. Interestingly, 
inhibiting ERK1/2 activation after 12 h of ligand stimulation failed to impair neurite 
outgrowth, suggesting that sustained ERK1/2 was able to transduce neuritogenic signals to 
downstream effectors within 12 h upon ligand stimulations.  
 It has been reported that cAMP signaling through PKA is required to promote 
sustained ERK1/2 phosphorylation (220,222,223), however, the underlying mechanism 
remains to be characterized. Recently, thrombin stimulation of vascular smooth muscle cells 
was found to result in a similar biphasic ERK1/2 phosphorylation and the activation of late 
phase of ERK1/2 required de novo transcription and translation (249). In the present study, 
we demonstrate that sustained ERK1/2 activation by ligand-activated GFRα2 was also 
dependent on PKA and de novo gene expression. Interestingly, PKA signaling induced CREB 
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phosphorylation, c-fos expression and S6 ribosomal protein phosphorylation, consistent with 
the roles of PKA in regulating de novo RNA and protein synthesis required for cAMP-
mediated neuronal differentiation (220,237,250). Although the detailed mechanism awaits 
further investigation, this study provides novel insights into functional interactions of cAMP-
PKA signaling, de novo gene expression and sustained ERK1/2 activation in GFRα2-
mediated neurite outgrowth. 
 In summary, this study clearly demonstrates an essential role of cAMP-PKA 
signaling in GDNF and NTN induced neurite outgrowth and suggests the cAMP-PKA 
signaling as the underlying mechanism contributing to the differential neuritogenic activities 
of GFRα2 isoforms. The findings on specific roles of PKA in promoting sustained ERK1/2 
activation and neurite outgrowth should shed new light on the molecular mechanisms 

















PART IV: RET ISOFORMS REGULATE GDNF-INDUCED NEURITE 







Ret is alternatively spliced to produce two major isoforms: Ret9 and Ret51 (106,107). 
Ret9 and Ret51 are identical except the C-termini, where the former has 9 and Ret 51 has 51 
unique amino acids. Despite extensive sequence identity at the N-termini, some but not all in 
vivo studies have shown that Ret9 and Ret51 exhibit significantly different non-neuronal 
functions. An early report using chimeric mouse-human monoisoformic Ret mice showed 
striking functional differences in organogenesis and embryo development (115). While mice 
lacking Ret51 developed normally, mice lacking Ret9 showed kidney hypodysplasia and 
defects in enteric innervation, similar to Ret knockout mice. Furthermore, Ret9 but not Ret51 
was able to rescue the phenotype of Ret knockout mice. This observation was not consistent 
with a recent study using human monoisoformic Ret mice where GDNF signaling through 
either Ret9 or Ret51 was sufficient for kidney organogenesis and viability (116). The relative 
importance of Ret isoforms in embryogenesis remains to be resolved. 
While the in vivo function of Ret isoforms remains controversial, in vitro studies 
suggest distinct cellular functions and molecular mechanisms of Ret9 and Ret51. Although 
both Ret isoforms share identical extracellular GFL and GFRα binding domains, Ret9 and 
Ret51 seem to function as independent signaling complex in cultured sympathetic neurons and 
neuronal cell lines (136,251). When stimulated by ligands, tyrosine 1062 in both Ret isoforms 
can associate with Shc, FRS2 and DOK adaptors, in a competitive manner. Interestingly, 
Enigma can only bind to Ret9 but not Ret51 through tyrosine 1062 (252). This could be due to 
the extended Ret9-specific 2 to 4 residues after tyrosine 1062 (Y1062 motif) that are required 
for Enigma interaction. Furthermore, Ret9 contains a PDZ domain binding site at its extreme 
C-terminus that is absent in Ret51. This Ret9 specific domain has been found to mediate 
interaction with Shank3, which is responsible for sustained RAS-ERK1/2 and PI3K-AKT 
signaling as well as epithelial tube formation (253). On the other hand, Ret51-specific tyrosine 
1096 can compensate for the functional capacity of tyrosine 1062 by direct association with 
GRB2 and downstream signaling pathways. This is consistent with the observations that 
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tyrosine 1062 is vitally important for Ret9-mediated signaling and in vivo function, whereas 
Ret51 function can only be abolished with both tyrosine 1062 and 1096 ablations (98,116,254). 
However, the presence of tyrosine 1096 in Ret51 also renders Ret51 more capable of binding 
to Cbl ubiquitin ligase and susceptible to proteasome-dependent degradation (255). Therefore, 
it is likely that Ret9 and Ret51 may mediate GDNF signaling through distinct mechanisms.  
The involvement of Ret isoforms in GDNF-induced neurite outgrowth and gene 
expressions remains largely unexplored. In the study described in this chapter, we demonstrate 
both shared and diverse functions of Ret isoforms in GDNF-induced signaling activations, 
gene expressions and neurite outgrowths. Both Ret isoforms were found to be expressed at 
human central nervous system (CNS). GDNF stimulation resulted in similar activation and 
lipid raft translocation of Ret isoforms and similar early signaling events. However, Ret9 and 
Ret51 were found to regulate distinct late gene expressions. Interestingly, Ret9 but not Ret51 
mediated GDNF-induced activation of FRS2α and Src. This study also provides evidence that 
Src activation was specifically required for Ret9-mediated late ERK1/2 activation, gene 




6.2.1. Both Ret9 and Ret51 are expressed in human tissues and central nervous system 
 To gain an insight into the physiological relevance of the Ret isoforms, the expression 
levels of Ret9 and Ret51 were quantified in various human tissues and regions of human 
central nervous system (CNS) using isoform-specific real-time PCR (Fig. 6.1). Both Ret 
isoforms were expressed at comparable levels in kidney, small intestine, heart and testis. Ret9 
was found to be expressed at higher levels than Ret51 in human fetal and adult brain (Fig. 
6.1A), similar to that reported in mouse brain (66). In the human CNS, Ret9 was 
predominantly expressed in spinal cord, thalamus, putamen, cerebral cortex and caudate 
nucleus. Interestingly, both Ret isoforms were highly expressed at comparable levels in 




Fig. 6.1. Expressions of Ret isoforms in various human tissues and central nervous system. The expression 
levels of Ret isoforms in various human adult and fetal tissues (A) and in various regions of adult central nervous 
system (B) were quantified by real-time PCR and normalized to GAPDH. The results were expressed as mean  
S.E.M. (n = 4).  * p < 0.05. 
 
6.2.2. Both endogenously expressed Ret9 and Ret51 are activated and translocated into 
lipid rafts upon GDNF stimulations 
 GDNF has previously shown to induce neurite outgrowth in NG108-15 and N2a-1a 
cells (Chapter 3). As both Ret isoforms were expressed in these cells, activation and lipid raft 
translocation of Ret9 and Ret51 were examined. After ligand stimulation, Ret9 and Ret51 
were immunoprecipitated using Ret9 or Ret51-specific antibodies. GDNF promoted Y1062 
phosphorylation of both Ret isoforms (Fig. 6.2A), suggesting that both Ret9 and Ret51 can be 
activated when they are co-expressed. Furthermore, immunoprecipation with isoform specific 
antibodies showed the pull-down only the cognate Ret isoforms, hence, Ret9-IP and Ret51-IP 
failed to pull-down Ret51 or Ret9, respectively. This is consistent with the notion that Ret9 
and Ret51 do not associate and may function as independent signaling complexes (136,251).  
 Lipid rafts are plasma membrane microdomains that are enriched in cholesterol, 
sphingolipids and certain proteins. It has been reported that ligand stimulation results in 
recruitment of Ret into the lipid rafts, which is critical for GDNF-induced neuronal 
differentiation and survival (256). GDNF-induced lipid raft translocation of Ret9 and Ret51 in 
NG108-15 (Fig. 6.2B) and N2a-1a (Fig. 6.2C) was examined by isolation of detergent (1% 
Triton X-100) resistant membrane (DRM). GDNF induced rapid lipid raft translocation of 
both Ret9 and Ret51 in NG108-15 and N2a-1a cells (Fig. 6.2B,C). In addition, GDNF induced 
































phosphorylation of the lipid-anchored adaptor FRS2α at both Y196 and Y436 residues (Fig. 
6.2C). The activated FRS2α was preferentially localized in lipid rafts, consistent with previous 
reports that FRS2 specifically interacts with active Ret within lipid rafts (72,257). However, 
the contributions of Ret9 and Ret51 in interaction with FRS2 are currently unknown.  
 
Fig. 6.2. GDNF induced activation and lipid raft translocation of both endogenous Ret isoforms in neuronal 
cells. (A) Both Ret9 and Ret51 were activated by GDNF in NG108-15 cells. NG108-15 cells were stimulated with 
50 ng/ml GDNF and the cell lysates were immunoprecipitated (IP) with Ret9 or Ret51 antibodies. Proteins from 
Ret9-IP, Ret51-IP and total cell lysate (TCL) were immunoblotted (IB) with pRet (pY1062), Ret9, Ret51 and total 
Ret antibodies. GDNF induced lipid raft translocation of both Ret9 and Ret51 in (B) NG108-15 cells and (C) N2a 
cells stabling expressing GFRα1a (N2a-1a). NG108-15 and N2a-1a cells were treated with 50 ng/ml of GDNF. 
The detergent soluble (SOL) and detergent-resistant membrane (DRM) fractions were immunoblotted with Ret9, 
Ret51, pFRS2α (pY196) and pFRS2α (pY436) antibodies. Transferrin Receptor (TrfR) and Flotinin-1 (Flot) served 
as markers for SOL and DRM fractions, respectively. Fig. 6.2B, closed arrow indicates Ret51 protein and open 
arrow denotes non-specific detection of DRM protein by Ret51 antibody in NG108-15 cells. 
 
6.2.3. Both Ret9 and Ret51 mediate GDNF-induced neurite outgrowth through ERK1/2 
and p38 MAPK pathways in PC12 cells 
 In order to study the specific functions of individual Ret isoforms, PC12 cells 
expressing GFRα1a were stably infected with retroviral vectors containing ORFs of mouse 
Ret9 or Ret51. Specific and similar levels of expressions of Ret9 or Ret51 were quantified by 
real-time PCR (Fig. 6.3A). Wild-type PC12 cells (PC12-WT) that did not express GFRα1 and 
Ret were used as controls. PC12-1a-Ret9 and PC12-1a-Ret51 cells expressed GFRα1a and 
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Ret9 or Ret51, respectively. NGF receptor TrkA was expressed at comparable levels in all the 
PC12 cell lines. As expected, NGF treatment induced extensive neurite outgrowth in PC12-
WT cells. GDNF treatment resulted in neurite outgrowth of both PC12-1a-Ret9 and PC12-1a-
Ret51 cells, suggesting both Ret isoforms were capable of promoting neuritogenesis upon 
ligand stimulations (Fig. 6.3B,C).  
 
Fig. 6.3. Ligand-induced neurite outgrowth in PC12 cells expressing GFRα1a and Ret9 or Ret51. (A) 
Expression of Ret9, Ret51, GFRα1a and TrkA in wild-type PC12 (PC12-WT), PC12 cells infected with GFRα1a 
and Ret isoforms (PC12-1a-Ret9 and PC12-1a-Ret51). The mRNA expression levels of Ret9, Ret51, GFRα1a and 
TrkA were quantified by real-time PCR and normalized to GAPDH. Ratios to GAPDH were presented in log scale 
and error bars represented S.E.M of four individual measurements. (B) Induction of neurite outgrowth by NGF in 
PC12-WT and GDNF in PC12-1a-Ret9 or PC12-1a-Ret51 cells. PC12 cells were stimulated with GDNF or NGF 
(50 ng/ml) for 72 h. Percentage of cells differentiated was presented as Mean ± S.E.M. of at least three biological 
replicates. ** p < 0.01, compared to non-treated control cells. (C) Phase-contrast images of PC12 cells stimulated 
with GDNF or NGF. 
  
 Consistent with the findings in NG108-15 and N2a-1a cells where both Ret isoforms 
are endogenously expressed (Fig. 6.2), GDNF induced lipid raft translocation of both Ret9 and 
Ret51 in PC12-1a-Ret9 and PC12-1a-Ret51 cells, respectively (Fig. 6.4A). As expected, 
GFRα1 is glycosylphosphatidylinositol (GPI) anchored and was preferentially localized to 
lipid rafts independent of ligand stimulations. GDNF signaling promotes activation of multiple 





















































































Ret51 mediated GDNF-induced activations of AKT, ERK1/2, JNK and p38 pathways with 
similar kinetics (Fig. 6.4B). Interestingly, while NGF induced a single phase of kinase 
activations peaked at 5-10 min (Chapter 5 and data not shown), GDNF-induced biphasic 
activations of MAPK pathways peaked at both 5 min and 6 h. Using small molecule inhibitors 
against PI3K-AKT (LY294002), MEK-ERK1/2 (U0126), JNK (SP600125) and p38 
(SB203580), both Ret9 and Ret51-mediated neurite outgrowths were found to be dependent 
on ERK1/2 and p38 MAPKs (Fig. 6.4C).  
 
Fig. 6.4. GDNF induced lipid raft translocation of Ret isoforms and activation of MAPK and AKT signaling 
pathways in PC12 cells. (A) GDNF induced lipid raft translocation of both Ret9 and Ret51 in PC12-1a-Ret9 and 
PC12-1a-Ret51 cells, respectively. (B) Time-dependent activations of ERK1/2, JNK, p38 MAPK and AKT 
pathways by GDNF in PC12-1a-Ret9 and PC12-1a-Ret51 cells. (C) Effect of various kinase inhibitors on GDNF-
induced neurite outgrowth in PC12 cells. PC12-1a-Ret9 and PC12-1a-Ret51 were pre-treated with DMSO (0.5%), 
LY294002 (10 µM), U0126 (10 µM), SB203580 (10 µM) or SP600125 (5 µM) for 1 h. The cells were then treated 
with 50 ng/ml GDNF for 72 h in the presence of inhibitors. Percentage of cells differentiated was presented as 
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6.2.4. Ret9 but not Ret51 mediates GDNF-induced activation of FRS2α 
 As GDNF induced FRS2α activation in lipid rafts in N2a-1a cells which endogenously 
express both Ret isoforms (Fig. 6.2C), we next examined if activation of FRS2α is 
differentially mediated by Ret9 and Ret51. Surprisingly, although both Ret9 and Ret51 were 
translocated to lipid rafts upon ligand stimulations, Ret9 but not Ret51 mediated time-
dependent phosphorylations of FRS2α (Fig. 6.5A). Furthermore, GDNF-induced 
phosphorylation of FRS2α was abolished in cells expressing Ret9-Y1062F mutant (Fig. 6.5B), 
consistent with the finding that Ret Y1062 serves as the docking site for FRS2α PTB domain 
(258,259).  
 
Fig. 6.5. GDNF-activated Ret9 but not Ret51 mediated FRS2α activation through Ret9-Y1062. (A) GDNF 
induced FRS2α phosphorylation at Y196 and Y436 through Ret9 but not Ret51. (B) GDNF-induced FRS2α 
phosphorylation is dependent on Ret9-Y1062. PC12-1a-Ret9(WT), PC12-1a-Ret51 (WT) or PC12-1a-
Ret9(Y1062F) cells were stimulated with 50 ng/ml GDNF for the indicated time periods. Phosphorylation of 
FRS2α was examined by pFRS2α (pY196) and pFRS2α (pY436) antibodies.  
 
6.2.5. Ret9 but not Ret51 mediates GDNF-induced activation of Src and requires Src for 
neurite outgrowth and late ERK1/2 activation 
 The non-receptor tyrosine kinase Src is also known to reside within lipid rafts and 
involved in GDNF-induced cell signaling, neurite outgrowth and neuronal survival (93,260). 
The activation and involvement of Src in Ret9 and Ret51-mediated neurite outgrowth was 
then investigated. NGF treatment of PC12 cells promoted rapid and transient phosphorylation 
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of Src at Y416. Interestingly, Ret9 but not Ret51 regulated time-dependent Src 
phosphorylation upon GDNF stimulations, which sustained for at least 3 h (Fig. 6.6A).  
 To examine the functional significance of Src activation in Ret-mediated neurite 
outgrowth, cells were first transfected with wild-type (WT) or dominant negative (DN) of Src. 
Src-DN effectively inhibited GDNF-induced neurite outgrowth in PC12-1a-Ret9 but not 
PC12-1a-Ret51 cells (Fig. 6.6B). Furthermore, Src inhibitors PP2 and SU6656 specifically 
inhibited Ret9 but not Ret51 mediated neurite outgrowth (Fig. 6.6C). In addition, as the 
putative Src binding site on Ret (93), Y981 was involved in Ret9 but not Ret51-mediated 
neurite outgrowth (Fig. 6.6D). These results strongly supported that Src is specifically 
activated by Ret9 and is required for Ret9-mediated neurite outgrowth. 
 
Fig. 6.6. GDNF-activated Ret9 but not Ret51 mediated Src activation and required Src for neurite 
outgrowth in PC12 cells. (A) Time-dependent activations of Src (pY416) by NGF in PC12-WT and GDNF in 
PC12-1a-Ret9 or PC12-1a-Ret51 cells. (B) Effect of Src-WT and Src-DN expressions on GDNF induced neurite 
outgrowth through Ret isoforms. PC12 cells were transiently transfected with eGFP control vector, Src-WT or Src-
DN vectors and stimulated with 50 ng/ml GDNF for 72 h. Percentage of eGFP positive cells bearing neurites twice 
the cell body length was presented as Mean ± S.D. of six biological replicates. ** p < 0.01, compared to eGFP 
control vector. (C) Effect of Src inhibitors on NGF or GDNF induced neurite outgrowth in PC12 cells. PC12 cells 
were pre-treated with DMSO (0.5%), PP2 (2 µM) or SU6656 (2 µM) for 1 h. The cells were then treated with NGF 
or GDNF (50 ng/ml) for 72 h in the presence of inhibitors. Percentage of cells differentiated was presented as Mean 
± S.E.M. of at least three biological replicates. ** p < 0.01, compared to ligand treatment without inhibitors. (D) 
Effect of Ret-Y981F mutant on GDNF-induced neurite outgrowth. PC12 cells expressing GFRα1a were transiently 
infected with wild-type (WT) or mutant Ret9 or Ret51. Cells were stimulated with 50 ng/ml GDNF for 48 h and the 














































































































 Both MEK-ERK1/2 and Src activations were required for Ret9-mediated neurite 
outgrowth (Fig. 6.4 and 6.6), the possible interaction between the two pathways were 
examined. MEK inhibitor U0126 inhibited both early (5-30 min) and late (12 h) activation of 
ERK1/2 by both Ret9 and Ret51 (Fig. 6.7A). Src inhibitor SU6656 inhibited early activation 
of ERK1/2 by both Ret isoforms. Interestingly, Ret9 but not Ret51-mediated late ERK1/2 
activation was inhibited by SU6656 (Fig. 6.7A). Similar results were obtained with another 
Src inhibitor PP2 (Fig. 6.7B), which further suggested Src was not required for Ret51-
mediated ERK1/2 phosphorylation from 8-12 h. Because ERK1/2 activation is required for 
both Ret9 and Ret51-mediated neurite outgrowth (Fig. 6.4), this result suggested that Ret9 but 
not Ret51 may promote Src activation that is required for the late phase of ERK1/2 activation 
and neurite outgrowth.  
 
Fig. 6.7. Src inhibitors SU6656 inhibits Ret9-mediated late phase ERK1/2 phosphorylation. (A) Effect of 
MEK and Src inhibitors on NGF and GDNF induced ERK1/2 phosphorylation in PC12 cells. (B) Fold changes of 
ERK1/2 phosphorylation levels. PC12-WT, PC12-1a-Ret9 or PC12-1a-Ret51 cells were pre-treated with DMSO 
(0.5%), U0126 (10 µM), SU6656 (2 µM) or PP2 (2 µM) for 1 h and stimulated with NGF or GDNF (50 ng/ml) for 
indicated time periods. Phosphorylation of ERK1/2 was examined by Western blotting and quantified by dot-blot. 
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6.2.6. Ret9 and Ret51 regulate similar early response genes but distinct late gene 
expressions in PC12 cells 
 To compared the gene expression profiles regulated by ligand-activated Ret9 and 
Ret51, microarray analyses were performed upon ligand stimulations for 30 min and 72 h. 
Both Ret9 and Ret51 regulated the same immediate early genes (IEGs: egr-1, c-fos, ier2, arc) 
upon ligand stimulations for 30 min (Table 6.1). This is consistent with the finding that Ret 
isoforms regulated similar activation of signaling pathways at early time points (Fig. 6.4B). It 
is interesting to note that NGF at the same time point regulated many more genes than either 
Ret9 or Ret51. Furthermore, Ret9 and Ret51 regulated these IEGs with similar kinetics over 
12 h (Fig. 6.8A,B). In addition, regulations of these IEGs by both Ret isoforms were inhibited 
by MEK and Src inhibitors (Fig. 6.8C,D). This finding is in agreement with the requirement of 
MEK and Src signaling in early activation of ERK1/2 by both Ret isoforms (Fig. 6.7). 
 
Table 6.1. Regulation of early gene expression by Ret isoforms at 30 min in PC12 cells. 
Genes Fold P-value Description 
PC12-1a-Ret9  (GDNF-30 min) 
Egr1 7.7 4.18E-05 early growth response 1 (Egr1), mRNA. 
c-fos 2.7 2.93E-04 c-fos oncogene (c-fos), mRNA. 
Ier2 2.1 9.95E-04 immediate early response 2 (Ier2), mRNA. 
Arc 2.0 2.19E-03 activity regulated cytoskeletal-associated protein (Arc), mRNA. 
PC12-1a-Ret51  (GDNF-30 min) 
Egr1 17.7 1.90E-06 early growth response 1 (Egr1), mRNA. 
c-fos 5.4 1.01E-04 c-fos oncogene (c-fos), mRNA. 
Ier2 2.9 9.60E-06 immediate early response 2 (Ier2), mRNA. 
Arc 2.9 8.74E-06 activity regulated cytoskeletal-associated protein (Arc), mRNA. 
PC12-WT (NGF-30 min) 
Egr1 23.1 1.15E-04 early growth response 1 (Egr1), mRNA. 
c-fos 8.5 1.41E-02 c-fos oncogene (c-fos), mRNA. 
Ier2 13.1 2.25E-04 immediate early response 2 (Ier2), mRNA. 
Arc 26.1 4.24E-05 activity regulated cytoskeletal-associated protein (Arc), mRNA. 
Junb 8.0 1.27E-06 Jun-B oncogene (Junb), mRNA. 
Btg2 6.7 4.04E-07 B-cell translocation gene 2, anti-proliferative (Btg2), mRNA. 
Klf2 4.3 2.08E-07 Kruppel-like factor (Klf2), mRNA. 
Maff 3.8 1.04E-06 
v-maf musculoaponeurotic fibrosarcoma oncogene family, protein 
F, mRNA. 
Zfp36 5.3 1.08E-05 zinc finger protein 36 (Zfp36), mRNA. 
Atf3 5.6 7.00E-06 activating transcription factor 3 (Atf3), mRNA. 
Fosl1 5.9 2.45E-08 fos-like antigen 1 (Fosl1), mRNA. 
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Dusp6 2.5 2.54E-03 dual specificity phosphatase 6 (Dusp6), mRNA. 
ChaC 2.6 1.33E-03 ChaC, cation transport regulator-like 1 (E. coli), mRNA. 
Okl38 2.4 5.21E-04 pregnancy-induced growth inhibitor (Okl38), mRNA. 
Srf 2.5 4.80E-04 similar to serum response factor (LOC501099), mRNA. 
Dusp5 4.6 7.30E-08 dual specificity phosphatase 5 (Dusp5), mRNA. 
Hes1 3.0 2.52E-06 hairy and enhancer of split 1 (Drosophila) (Hes1), mRNA. 
Gadd45g 3.2 2.05E-06 growth arrest and DNA-damage-inducible 45 gamma, mRNA. 
Errfi1 2.4 1.52E-04 ERBB receptor feedback inhibitor 1 (Errfi1), mRNA. 
Fold changes were quantified using real-time PCR. 
 
 
Fig. 6.8. Regulation of IEG expressions by Ret9 and Ret51. (A, B) Time course of IEG expressions regulated 
by (A) Ret9 or (B) Ret51. PC12 cells were stimulated with GDNG (50 ng/ml) for the indicated periods of time. (C, 
D) Effect of MEK and Src inhibitors on IEG expressions regulated by (C) Ret9 or (D) Ret51. PC12 cells were 
pretreated with DMSO (0.5%), U0126 (10 µM) or SU6656 (2 µM) for 1 h before stimulation with GDNF (50 
ng/ml) for 30 min. Expression levels of egr-1, c-fos, ier-2 and arc were quantified by real-time PCR. * p < 0.05 
and ** p < 0.01, compared to DMSO control. 
  
 Contrary to similar activation of IEG expressions, Ret9 and Ret51 regulated distinct 
gene expression profiles at late time point (72 h). Although Ret9 and Ret51 were expressed at 
comparable levels, Ret9 regulated expressions of more than 1,500 genes whereas Ret51 only 
regulated ~150 genes (list not shown). Gene-ontology analysis was then carried out with 
PANTHER database (261) and regulation of gene expressions by Ret9 or Ret51 were 
































































































Ret51 regulated 6 in which Proteolysis was the only common biological process up-regulated 
by both Ret isoforms (Table 6.2).  
Table 6.2. Genes involved in distinct biological processes were differentially regulated by 
Ret isoforms at 72 h in PC12 cells. 
Biological Process (BP) Number of genes overUnder p-value 
PC12-WT (NGF-72 h) 
   
Proteolysis 23 + 1.08E-04 
Cell cycle 83 - 4.81E-04 
Cell adhesion-mediated signaling 12 + 4.98E-03 
DNA replication 22 - 7.69E-03 
Immunity and defense 42 + 9.15E-03 
DNA metabolism 31 - 1.24E-02 
Extracellular transport and import 3 + 1.71E-02 
Nucleoside, nucleotide and nucleic acid metabolism 110 - 3.51E-02 
Cell cycle control 28 - 3.67E-02 
Lipid metabolism 2 + 4.21E-02 
PC12-1a-Ret9 (GDNF-72 h) 
   
DNA replication 37 - 4.72E-06 
DNA metabolism 61 - 6.08E-05 
Cell cycle 144 - 1.63E-04 
Proteolysis 53 + 1.04E-03 
Extracellular transport and import 5 + 4.55E-03 
Immunity and defense 72 + 1.11E-02 
Cholesterol metabolism 8 + 1.47E-02 
Phosphate transport 2 + 1.58E-02 
DNA repair 32 - 1.60E-02 
B-cell- and antibody-mediated immunity 6 + 2.21E-02 
Sensory perception 17 - 2.24E-02 
Nucleoside, nucleotide and nucleic acid metabolism 264 - 2.42E-02 
Purine metabolism 8 + 2.82E-02 
Nucleoside, nucleotide and nucleic acid transport 3 - 2.88E-02 
DNA recombination 8 - 3.37E-02 
Homeostasis 16 + 3.62E-02 
General vesicle transport 19 + 3.77E-02 
Steroid metabolism 11 + 3.84E-02 
Cell communication 58 + 4.00E-02 
Cell adhesion-mediated signaling 13 + 4.52E-02 
PC12-1a-Ret51 (GDNF-72 h) 
   
Proteolysis 11 + 1.69E-04 
Protein metabolism and modification 16 + 1.79E-04 
Cytokinesis 2 - 2.03E-02 
Endocytosis 2 - 2.03E-02 
Cell structure and motility 8 - 3.69E-02 
Cell structure 6 - 3.95E-02 




 Among those genes regulated by Ret9 and Ret51, 12 genes were found to be regulated 
by both Ret isoforms but not by NGF treatment (Table 6.3). For example, GDNF stimulation 
induced up-regulation of edg2, gale, ldlr and snf1lk through both Ret9 and Ret51 (Fig. 6.9). 
Interestingly, regulation of these genes by Ret9 but not Ret51 was inhibited by Src inhibitor 
(Fig. 6.9). These results suggested the differential roles of Ret isoforms in regulating gene 
expressions and highlighted the specific requirement of Src in Ret9-mediated gene expressions. 








Ankrd1 0.3 0.5 Ankyrin repeat domain 1 (cardiac muscle) (Ankrd1), mRNA. 
Bmp2 7.5 4.8 Bone morphogenetic protein 2 (Bmp2), mRNA. 
Chga 5.3 7.8 Chromogranin A (Chga), mRNA. 
Cited2 3.4 3.3 
Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 
(Cited2), mRNA. 
Edg2 3.9 4.2 
Endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor, 2 
(Edg2), mRNA 
Gale 7.5 4.1 Galactose-4-epimerase, UDP (Gale), mRNA. 
Pfpl 5732.7 396.2 Predicted: Similar to Pfpl protein (LOC502380), mRNA. 
Ldlr 9.4 3.8 Low density lipoprotein receptor (Ldlr), mRNA. 
Scd1 6.7 4.0 Stearoyl-Coenzyme A desaturase 1 (Scd1), mRNA. 
Serpinb2 66.9 115.3 Serine (or cysteine) proteinase inhibitor, clade B, member 2 (Serpinb2), mRNA. 
Slc16a3 7.2 3.0 Monocarboxylate transporter (Slc16a3), mRNA. 
Snf1lk 5.4 2.8 SNF1-like kinase (Snf1lk), mRNA. 




Fig. 6.9. Src inhibitor SU6656 inhibited Ret9-mediated gene expressions at 48 h. PC12-1a-Ret9 and PC12-1a-
Ret51 cells were stimulated with GDNF (50 ng/ml) in the presence DMSO (0.5%) or SU6656 (2 µM) for 48 h. 
Expression levels of (A) edg2, (B) gale, (C) ldlr and (D) snf1lk were quantified by real-time PCR. * p < 0.05 and 






















































































 In this study, Ret9 and Ret51 were found to regulate GDNF signaling through both 
shared and distinct molecular mechanisms (Fig. 6.10). Both Ret isoforms promoted GDNF-
induced neurite outgrowth and IEG expressions. Interestingly, Ret9 but not Ret51 mediated 
GDNF-induced FRS2α and Src activations. Furthermore, the late phase of ERK1/2 activation, 
late gene expressions and neurite outgrowth mediated by Ret9 but not Ret51 were dependent 
on Src kinase.  
 
Fig. 6.10. A schematic illustration of GDNF signaling mediated by Ret9 and Ret51. Ligand stimulations of 
Ret9 and Ret51 result in similar Ret lipid raft translocation, activation of MAPK pathways, IEG expressions and 
neurite outgrowth. Ret9 but not Ret51 mediates ligand-induced activation of FRS2α and Src, both of which are 
enriched in lipid rafts. Src kinase is specifically required for Ret9-mediated late phase of ERK1/2 activation and 
neurite outgrowth. In addition, ligand-activated Ret9 and Ret51 regulate distinct late gene expression profiles. Solid 
lines, based on results from this study; dotted line, based on previous publications. G, GDNF. 
  
 Using isoform-specific real-time PCR, the expression levels of Ret9 and Ret51 were 
first determined in human tissues and CNS. Similar to our previous report on mouse tissues 
(66), Ret9 was expressed at higher levels than Ret51 in human brain. Interestingly, in 























were highly expressed at comparable levels. The implication is that both Ret isoforms may 
play physiologically significant roles in neuritogenesis. Consistent with this notion, GDNF 
stimulation induced autophosphorylation and lipid raft translocation of both Ret9 and Ret51, 
in cells endogenously co-expressing both Ret isoforms. 
 A number of in vitro studies have suggested similar phenotypic outcomes of ligand-
activated Ret isoforms, although it is unknown whether Ret9 and Ret51 regulate these 
functions through similar or distinct mechanism. For example, both oncogenic Ret9 and Ret51 
promoted transformation of fibroblast cells with similar potency (262). In addition, both 
ligand-activated Ret9 and Ret51 mediated scattering of SK-N-MC neuroepithelioma cells and 
branching tubule formation of MDCK cells (254). It is thus not surprising that both Ret9 and 
Ret51 promoted GDNF-induced neurite outgrowth in this study. Furthermore, Ret9 and Ret51 
activated similar MAPK and AKT pathways and same IEG expressions in MEK-ERK1/2 and 
Src-dependent mechanism.  
 Both Ret9 and Ret51 were translocated to lipid rafts upon ligand stimulations; 
unexpectedly, Ret9 but not Ret51 regulated the activations of lipid raft-enriched adaptors 
FRSα2 and Src. It is well reported that FRS2 was required for FGF and GDNF-induced Src 
activation (263,264). In this study, the functional significance of Src in Ret9 but not Ret51 
was strongly supported by both Src dominant negative mutant and inhibitors. Furthermore, 
mutation of the putative Src-binding and activation site on Ret (Ret-Y981F) significantly 
inhibited Ret9 but not Ret51-mediated neurite outgrowth. It is interesting to note that the 
inhibition of Ret9-mediated neuritogenesis by Ret9-Y981F mutant was much less drastic 
compared to Src-DN and Src inhibitors. It is likely that in addition to Ret9-induced Src 
activation, the background activity of Src (as evident by high Src-pY416 level in non-
stimulated cells) may also contribute to Ret9 function. Although Src activity was required for 
both Ret isoforms to promote early ERK1/2 activation and IEG expressions, Src was only 
required for Ret9 but not Ret51-mediated late ERK1/2 activation. As ERK1/2 was critically 
involved in GDNF-induced neurite outgrowth, Ret9 but not Ret51 may require Src for 
sustained (both early and late) ERK1/2 activation and neurite outgrowth.  
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 In addition, ligand-activated Ret9 and Ret51 were found to regulate distinct late gene 
expressions (72 h). This finding is consistent with the previous report that oncogenic Ret9 and 
Ret51 mediated distinct gene expression patterns in HEK293 cells (265) and further 
suggestive of differential functions of Ret isoforms. Interestingly, some of the late genes (edg2, 
gale, ldlr and snf1lk) were regulated by both Ret isoforms and regulation of these genes by 
Ret9 but not Ret51 was dependent on Src activity. These results thus not only highlight the 
differential functions of Ret isoforms but also provide a list of candidate isoform-specific 
genes for further investigation. 
 The underlying mechanism on specific activations of FRS2α, Src and differential roles 
of Src in Ret9 but not Ret51 function remains to be elucidated. A novel but rather intriguing 
hypothesis is that activated Ret9 and Ret51 recruit different signaling adaptors for intracellular 
signaling. Although both Ret isoforms share a consensus PTB-binding motif (Φ-X-N-X-
pY1062) (266), Ret9 (1063GRI1065) and Ret51 (1063GMS1065) have distinct amino acid 
sequences after G1063. These isoform-specific residues have been implicated in differential 
binding of Ret9 and Ret51 to adaptor molecules (106,252,253,262). Interestingly, previous 
report demonstrated that while oncogenic Ret9 and Ret51 interacted with Shc-PTB equally 
well, Ret9 exhibited higher affinity to FRS2α-PTB compared to Ret51 (259). This is 
consistent with this study that Ret9 but not Ret51 regulated ligand-induced activation of 
FRS2α (Fig. 6.5). Other PTB-containing adaptor molecules such as Shc and DOK have been 
shown to interact with Ret and mediate GDNF signaling (95,129,267). Whether these adaptors 
are differentially regulated by Ret9 and Ret51 remains to be investigated. 
 In summary, the study in this chapter demonstrates the specific activation of FRS2α 
and Src by Ret9 but not Ret51 upon ligand stimulations. Src kinase activity was required by 
Ret9 but not Ret51 mediated late phase of ERK1/2 activation and neurite outgrowth. Together 
with the finding that Ret isoforms regulated distinct gene expression profiles, this study 
























 GFL stimulation results in Ret dimerization and autophosphorylation at multiple 
tyrosine residues, which are required for Ret activation and downstream signaling. Among the 
many identified Ret autophosphorylations residues, phospho-tyrosines 905, 981, 1015, 1062 
and 1096 were found to be important for Ret functions by recruiting specific adaptor 
molecules GRB7/10 (91,92), Src (93), PLCγ (phospholipase Cγ) (94), Shc (Src-homologous 
and collagen-like protein) (95) and GRB2 (96), respectively. In addition, phosphorylation of 
tyrosine 905 is also critical for intrinsic Ret kinase activity (97,98).  
 Although Receptor Tyrosine Kinases (RTK) exerts its effect through 
autophosphorylation of tyrosine residues, it is not uncommon that RTK functions can be 
regulated through phosphorylation of its serine residues (268-270). Recently, it has been 
demonstrated that intracellular cAMP, presumably through PKA, can induce Ret 
phosphorylation at serine 696 and regulate Rac activation and lamellipodia formation (145). 
Furthermore, GDNF-induced Ret serine 696 phosphorylation is important in Rac-mediated 
JNK activation and delaying cell cycle progression of neuroectodermal tumor cells (271) as 
well as migration of enteric neural crest cells (272), supporting the in vivo significance of Ret 
serine phosphorylation. Interestingly, PKCα promotes phosphorylation of threonine and 
predominantly serine residues of yet to be characterized sites has been reported to decrease 
Ret tyrosine phosphorylation (273). This is further suggestive of potential unrecognized roles 
of serine residues on Ret receptor tyrosine kinase. It is therefore of interest to identify and 
examine the contributions of serine residues on Ret in mediating GDNF signaling and 
function in the nervous system. 
 This study aims to identify novel Ret serine residues involved in GDNF-induced 
neurite outgrowth. Four highly conserved serine residues were predicted to be candidate Ret 
phosphorylation sites. Interestingly, this study identified serine 909 as a critical residue for 
Ret kinase activation and functions in GDNF-induced neurite outgrowth and proposed an 
interesting hypothesis that the negative regulation of Ret tyrosine phosphorylation by PKC 
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may be mediated through Ret-Ser909 phosphorylation resulting in conformational changes in 




7.2.1. Prediction and site-directed mutagenesis of potential Ret phosphorylation residues 
 Potential phosphorylation sites of Ret intracellular domain were predicted using five 
independent algorithms, including NetPhosK (274), PPSP (275), GPS (276), MotifScan (277) 
and KinasePhos (278). The four serine residues (S765, S811, S909 and S1034) predicted by at 
least four of the five algorithms were selected for further analysis (Table 7.1). Ret amino acid 
sequences from various species were extracted from GenBank and aligned with Vector NTI. 
All the four serine residues were found to be highly conserved among these species (Fig. 7.1).  
 






Predicted Kinases for potential novel Ret phosphosites 











S811 PKC PKC PKC PKC PKC 
S909 PKC PKC PKC - PKC 
S1034 CK2 CK2 CK2 CK2 CK2 
Note: DNAPK, DNA-dependent protein kinase; ATM, Ataxia telangiectasia mutated;  




Fig. 7.1. The predicted Ret serine residues are highly conserved among species. Ret protein sequences from 
different species were obtained from GenBank and sequence aligned using Vector NTI. The conserved serine 
residues S765, S811, S909 and S1034 were highlighted in red. Numberings of the serine residues are based on 
positions in human RET. 
 
7.2.2. Ser909 of Ret is critical for GDNF-induced neurite outgrowth in PC12 cells 
 Phosphorylation-deficient mutations of tyrosine or serine residues can be generated 
by substitutions with phenylalanine or alanine, respectively. To investigate the potential roles 
of these predicted phospho-serine residues in Ret function, phosphorylation-deficient 
mutations of these residues were performed on both human and mouse Ret. In parallel, 
phosphorylation-deficient mutants were also generated for known Ret phospho-residues 
including Y905, Y1015, Y1062 and S696.  
 PC12 cells expressing GFRα1a were transiently infected with retrovirus carrying both 
eGFP and wild type or mutant Ret isoforms. After infection, cells were then stimulated with 
GDNF for 48 h for neurite outgrowth analysis (Fig. 7.2). As expected, both Ret9 and Ret51 
promoted neurite outgrowth upon ligand stimulations. Interestingly, Y1015F and S696A 
S765         S811         S909          S1034
NP_065681   --------LLSEF--------YGSLR--------KRS-QG--------GLSEE
AAH04257   --------LLSEF--------YGSLR--------KRS-QG--------GLSEE
CAB46483   --------LLSEF--------YGSLR--------KRSQVG--------GLSEE
NP_066124   --------LLSEF--------YGSLR--------KRS-QG--------GLSEE
XP_543915   --------LLSEF--------YGSLR--------KRS-KG--------GLSEE
AAB33460   --------LLSEF--------YGSLR--------KRS-KG--------GLSEE
NP_990521   --------LLSEF--------YGSLR--------KRS-KG--------GLSEE
NP_001079092   --------LLSEF--------YGSLR--------KRS-KG--------GLSEE
AAD10845   --------LLSEF--------YGSLR--------KRS-KG--------ALSEE
CAG04714   --------LLSEF--------YGSLR----------------------ALSEE
CAA64146   --------LLSEF--------YGSLR--------KRS-KG--------SLSEE
NP_858048   --------LLSEF--------YGSLR--------KRS-KG--------SLSEE
CAA33787   --------LLSEF--------YGSLR--------KRS-QG--------GLSEE
NP_477044   --------LLSEF--------YGSLR--------KRS-RD-------------
NP_724317   --------LLSEF--------YGSLR--------KRS-RD-------------
NP_477045   --------LLSEF--------YGSLR--------KRS-RD-------------
XP_001357489   --------LLSEF--------YGSLR--------KRS-RD-------------
XP_319646   --------LLSEY--------YGSLK--------KKS-KD-------------
XP_001604533   --------LLSEY--------FGSLR--------KRS-KG-------------
XP_396123   --------LLSEY--------FGSLR--------KRS-KG-------------
XP_969283   --------LLSEY--------HGSLR--------KRS-KG-------------
BAC32032   --------LLSEF--------YGSLR---------------------------
NP_001074249   --------LLSEF--------YGSLR--------KKS-KG--------GLSEE
NP_033076   --------LLSEF--------YGSLR--------KKS-KG--------GLSEE
CAA48013   --------LLSEF--------YGSLR--------KKS-KG--------GLSEE
CAC10569   --------LLSEF--------YGSLR--------KKS-XG--------GLSEE
EDM02081   --------LLSEF--------YGSLR--------KKS-KG--------GLSEE
EDM02082   --------LLSEF--------YGSLR--------KKS-KG--------GLSEE
NP_036775   --------LLSEF--------YGSLR--------KKS-KG--------GLSEE
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mutations of both Ret9 and Ret51 did not affect ligand-induced neurite outgrowth, suggesting 
that these residues were not involved in neurite outgrowth in this study. Phosphorylation of 
Y905 has been shown to be critical for Ret kinase activity, it is thus not surprising that Y905F 
mutation abolished ligand-induced neurite outgrowth. It is worthy to note that Y1062F 
mutation of Ret9 but not Ret51 significantly inhibited neurite outgrowth. This is in agreement 
with the report that Y1096 presented in Ret51 but not Ret9 may compensate Y1062F 
mutation through direct binding of GRB2 and activation of downstream signaling pathways 
(116,254). Interestingly, S909A but not S765A, S811A or S1034A significantly inhibited 
ligand-induced neurite outgrowth in both Ret isoforms. Similar results were obtained when 
these Ret mutants were coupled to GFRα2a or GFRα2c (data not shown). 
 
Fig. 7.2. Mutations of known and predicted Ret serine residues (Ret mutants) and their effects on GDNF-
induced neurite outgrowth. PC12 cells expressing GFRα1a were transiently infected with Ret9 or Ret51 mutants. 
Cells were stimulated with 50 ng/ml GDNF for 48 h and the percentage of eGFP cells differentiated was presented 
as Mean ± S.D. of four biological replicates. ** p < 0.01, compared to GDNF-stimulated wild-type (WT) Ret. 
 
7.2.3. Ser909 is required for Ret autophosphorylation and intracellular signaling 
 As both S909 and Y905 are located at the activation loop of Ret kinase domain based 
on Ret crystal structure (Fig. 7.3), it is possible that S909 may be involved in Ret kinase 
activation.  









































Fig. 7.3. Crystal structure of active Ret. The activation loop (A-loop) is highlighted in red. The positions of 
S909 and pY905 are indicated by white arrows. The crystal structure is obtained from Protein Data Bank (PDB ID: 
2IVT). 
 
 To test this hypothesis, PC12 cells expressing GFRα1a were stably infected with 
wild-type (WT), Y905F, Y1062F or S909A mutants of human Ret9. Expression of both Ret9-
WT and Ret9-Y1062F induced Y905 autophosphorylation. However, Y905 residue was not 
phosphorylated in clones carrying Ret9-Y905F and Ret9-S909A (Fig. 7.4). Furthermore, 
ligand stimulation failed to induce Y1062 phosphorylation on Ret9-S909A mutant, similar to 
Ret9-Y905F and Ret9-Y1062F. In addition, GDNF-induced ERK1/2 phosphorylation was 
significantly inhibited with Ret9-S909A mutant as compared to Ret9-WT. Similar results 
were obtained with mouse Ret9 mutants (data not shown). These findings suggest that S909 is 








Fig. 7.4. Effects of Ret9 mutants on GDNF-induced signaling activations. PC12 cells stably co-expressing 
GFRα1a and Ret9 wild-type (WT), Y905F, Y1062F or S909A mutants were stimulated with 50 ng/ml GDNF for 
the indicated periods of time. Autophosphorylation of Ret at Y905 or Y1062 and activation of ERK1/2 and AKT 
was examined by Western blotting.  
 
7.2.4. Both S909A and S909D mutations inhibit Ret-mediated neurite outgrowth 
 To further examine whether Ret-S909 phosphorylation is required for Ret function, 
phosphomimetic mutation of Ret-S909 (S909D) was constructed. Surprisingly, S909D 
mutation abolished Ret-mediated neurite outgrowth upon ligand stimulation, similar to S909A 
mutation (Fig. 7.5). Ret with dual mutations of S909D and Y905E or Y905F also failed to 
mediate GDNF-induced neurite outgrowth (Fig. 7.5). As S909 resides in the Ret activation 
loop (Fig. 7.3), this unanticipated result suggested that genetic manipulations of S909 (S909A 
and S909D) may inhibit Ret kinase activation through conformational changes that may affect 
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Fig. 7.5. Effects of Ret9 double mutants at Y905 and S909 on GDNF-induced neurite outgrowth. PC12 cells 
expressing GFRα1a were transiently infected with Ret9 harboring single and double mutations at Y905 and S909. 
Cells were then stimulated with 50 ng/ml GDNF for 48 h and the percentage of eGFP cells differentiated was 
presented as Mean ± S.D. of four biological replicates. * p < 0.05 and ** p < 0.01, compared to non-treated control. 
 
7.2.5. Inhibition of PKC does not affect Ret activation 
 Ret-S909 was predicted to be phosphorylation site of protein kinase C (PKC) (Table 
7.1). As both S909A and S909D mutations abolished Ret function (Fig. 7.5), we next 
investigated the possibility that PKC activity is required for activation or inhibition of Ret 
function.  
 PKC inhibitors were used to examine the involvement of PKC in ligand-induced Ret 
activation as indicated by Ret-Y1062 phosphorylation. Firstly, the broad spectrum PKC 
inhibitor Gö6983 (5 µM) was used to inhibit all PKC isotypes, except for PKCζ and PKCµ. 
Interestingly, Gö6983 at 5 µM did not significantly inhibit Ret phosphorylation in either 
PC12-1a-Ret9 cells or N2a-1a and NG108-15 cells which endogenously expressed both Ret 
isoforms (Fig. 7.6A). In contrast, the Src/Ret inhibitor PP1 completely abolished GDNF-
induced Ret phosphorylation in these cells (Fig. 7.6A). As Gö6983 at higher dose (10-20 µM) 
inhibits PKCζ and Gö6976 at 1 µM inhibits PKCµ specifically (279,280), the possible 
involvement of the atypical PKCζ and PKCµ in Ret activation was investigated. In NG108-15 
cells, neither Gö6983 (20 µM) nor Gö6976 (1 µM) was able to inhibit GDNF-induced Ret 





































induced ERK1/2 activation. These results indicate that PKC activity does not affect Ret 
activation. Whether PKC is required for inhibition of Ret function remains to be determined. 
 
 
Fig. 7.6. Effects of PKC inhibitors on GDNF-induced Ret activation. (A) PC12-1a-Ret9, N2a-1a and NG108-
15 cells were stimulated with GDNF (50 ng/ml) in the presence of 5 µM Gö6983 or 2 µM PP1. (B) NG108-15 
cells were stimulated with GDNF in the presence of 1 µM Gö6976 , 1 µM Gö6983 or 20 µM Gö6983. The 




 In this study, a novel Ret serine residue S909 was identified to be critical for Ret 
kinase activation and downstream signaling. Unexpectedly, both phospho-deficient (S909A) 
and phosphomimetic (S909D) mutations of S909 abolished Ret-mediated neurite outgrowth 
upon ligand stimulations. S909A mutation inhibited Ret autophosphorylation and GDNF-
induced activation of downstream signaling pathways, including ERK1/2. As the predicted 






































induced Ret. The results presented here highlight a critical role of Ret-S909 residue in 
mediating Ret function and a testable hypothesis is proposed where an endogenous 
mechanism involving PKC may negatively regulate Ret activation by phosphorylation of Ret-
S909 residue (Fig. 7.7). 
 
Fig. 7.7. A schematic illustration of Ret-S909 function in GDNF signaling. (A) Genetic alterations of S909 
(S909A or S909D) result in conformation change of Ret activation loop which inactivates Ret, its downstream 
signaling and neurite outgrowth. (B) Hypothetically, post-translational modification of S909 results in similar 
inactivation of Ret function. Endogenous kinase PKCα negatively regulates Ret activation by phosphorylating Ret 
at S909. 
 
 Ligand-induced Ret autophosphorylation at Y905, Y1015 and Y1062 has been well 
reported (251). Phosphorylation of tyrosine 905 is critical for intrinsic Ret kinase activity as 
mutation of this residue to phenylalanine drastically impairs autophosphorylation of both 
oncogenic (97) and ligand-stimulated Ret (98). It is thus not surprising that Ret-Y905F 
mutation abolished ligand-induced tyrosine 1062 phosphorylation, ERK1/2 activation and 
neurite outgrowth. Although Ret tyrosine 1015 was first discovered in Ret/PTC2 as the 
binding site for PLCγ, which is required for its full oncogenic activity (94), phosphorylation 




























neuronal cells (136). However, in this study, Ret-Y1015F mutation did not significantly affect 
ligand-induced neurite outgrowth. Similarly, PLCγ inhibitor U73122 did not inhibit GDNF-
induced neurite outgrowth (data not shown). These results indicated that Y1015 may not be 
involved in GDNF-induced neurite outgrowth but does not rule out the possibility of the 
involvement in non-neuronal functions. A variety of signaling partners contribute to the 
versatile and critical roles of tyrosine 1062 in Ret function, including Shc, FRS2 (fibroblast 
growth factor receptor substrate 2), DOK1/4/5/6, IRS1/2 (insulin receptor substrate 1/2), 
Enigma and PTPRJ (tyrosine phosphatase J). Several reports have demonstrated the 
differential role of Y1062 in Ret9 and Ret51 functions. While transgenic mouse expressing 
Ret-Y1062F exhibited impaired kidney organogenesis and ENS development, mouse with 
Ret-Y1062F was largely normal (101). Similarly, Y1062F mutation of Ret9 but not Ret51 
inhibited GDNF-induced scattering of SK-N-MC neuroepithelioma cells and branching tubule 
formation in MDCK cells (254). These reports are consistent with the finding that Y1062F 
mutation of Ret9 but not Ret51 significantly inhibited GDNF-induced neurite outgrowth in 
PC12 cells (Fig. 7.2). Until recently, the potential contributions of serine residues in Ret 
functions have started to be investigated. Serine 696 was found to be phosphorylated by PKA, 
which negatively regulates phosphorylation of adjacent tyrosine 687 by enhancing the binding 
of protein-tyrosine phosphatase SHP2 to Ret, which in turn activates RacGEF and 
lamellipodia formation (145,281). Unexpectedly, S696A mutation did not affect Ret-mediated 
neurite outgrowth (Fig. 7.2), suggesting that S696 may exert its effect in a cell context 
dependent manner.  
 In an attempt to identify novel serine residues involved in Ret-mediated neurite 
outgrowth, prediction softwares for potential phospho-serine residues were employed. The 
four predicted serine residues were found to be highly conserved among various species, 
suggestive of potential conserved functions in Ret signaling. Interestingly, serine 909 but not 
the other serine residue was critical for Ret-mediate neurite outgrowth. However, it is possible 
that the other serine residues may be involved in distinct functions of Ret, such as 
proliferation, survival or migration. 
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 S909A mutation of Ret inhibited Y905 autophosphorylation, ligand-induced Y1062 
phosphorylation and downstream signaling activation (Fig. 7.4), suggesting S909 was critical 
for Ret tyrosine phosphorylation and kinase activity. Intriguingly, both Y905 and S909 are 
located at the A-loop (Fig. 7.3, Activation loop) that spans amino acids 896-916 (282). 
Recently, a germline mutation S904C within the A-loop has been identified in familial 
MEN2B patients and was implicated in aberrant Ret kinase activation (283). Therefore, it is 
likely that S909 may serve as a structural determinant critical for the active conformation of 
A-loop. Genetic alterations of S909 (both S909A and S909D) may result in conformational 
changes in A-loop and resulting in the inactivation of Ret (Fig. 7.7A).  
 PKCα was found to phosphorylate Ret serine residues, which drastically reduced 
tyrosine phosphorylation of oncogenic Ret (MEN2A) (273). The Ret serine phosphorylation 
by PKCα was implicated in the inhibition of Ret kinase activation and mitogenic signaling 
(273). Although it is speculated that PKC may phosphorylate Ret directly, the identities of 
these serine residues remain to be determined. Intriguingly, the Ret-S909 residue identified in 
this study was predicted to be phosphorylated by PKC based on the conserved R/K-X-pS-Φ-
R/K motif. Analyses of Ret crystal structures suggested S909 may be involved in active 
conformation of Ret A-loop. In agreement with this, S909 was required for ligand-induced 
Ret autophosphorylation and activation, downstream signaling and neurite outgrowth. In 
addition, PKC activity was not required for Ret kinase activation but it is possible that PKC 
may be involved in inhibition of Ret function. In view of these observations, we propose an 
endogenous regulatory mechanism where the phosphorylation of Ret-S909 by PKCα 
negatively regulates GDNF-induced Ret activation and functions (Fig. 7.7B).  
 In summary, this study has evaluated the involvement of both known and predicted 
Ret phosphorylation residues in GDNF-induced neurite outgrowth. A novel serine residue 
(S909) has been identified to be critical for Ret kinase activation and neurite outgrowth. The 
proposed molecular mechanism of S909 in negatively regulating the activation of Ret for 
















PART VI: DEVELOPMENT OF HIGH PERFORMANCE SMRT-QPCR ASSAY FOR 







 It is now known that microRNAs (miRNAs) are differentially expressed in 
glioblastomas as compared to normal brain and many of these dysregulated miRNAs are 
involved in glioblastoma growth, invasion and chemoresistance (284,285). Interestingly, 
GDNF and its receptors are highly expressed in human glioblastomas (Chapter 4) and GDNF 
has recently been shown to promote chemoresistance of human glioblastoma cell lines in vitro 
(286). In the continual effort to gain a better understanding the role of GDNF in neurobiology, 
it is reasonable to hypothesize that GFLs may regulate microRNA expressions in gliomas. 
 miRNAs are small non-coding RNAs (~22 nucleotides) that were discovered as 
important post-transcriptional regulators of gene expression in metazoans (287). While 
expression of miRNAs are critical in various physiological processes (288-291), 
dysregulation of miRNAs are implicated in pathologies of many human diseases such as 
cancer (292), muscle disorders (293) and neurodegeneration (294). Recently, mature miRNAs 
were found to be remarkably stable in blood, and thus hold great promise as potential non-
invasive biomarkers of human diseases (295,296). To date, hundreds of unique miRNAs have 
been identified in many species and each of these is predicted to regulate diverse target genes 
(297). With the continual discovery of more miRNAs by both in silico prediction and in vivo 
validation (298), profiling of miRNA expression remains an essential tool not only for 
assessment of distribution and regulation of miRNAs but also for identification of novel 
biomarkers and potential therapeutic targets. 
 Currently, mature miRNAs can be detected by either direct or indirect methods. 
Although direct detection methods (eg. fluorescent, colorimetric and electrical-based methods) 
can minimize variations introduced during sample measurements, these methods are limited 
by low assay sensitivity and poor discrimination among miRNA homologs (reviewed in 299). 
Indirect detection methods include primarily Northern blotting, microarray and reverse 
transcription PCR (RT-PCR). Although widely used, both Northern blotting and microarray 
are semi-quantitative and suffer from poor sensitivity and require large amounts of starting 
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RNA. Although microarrays offer high-throughput detection of miRNAs and the potential 
capability of absolute quantification (300), a recent study showed that real-time PCR remains 
superior in sensitivity and specificity in comparison (301). Recent attempts to measure 
miRNA with isothermal methods have met with some success but are labor intensive 
(302,303). To date, real-time RT-PCR remains the most sensitive and efficient method for 
quantification of RNA species. TaqMan probe-based real-time RT-PCR has been reported 
and widely used for efficient and specific detection of miRNAs. However, due to an 
additional probe hydrolysis step, TaqMan assays were not compatible with fast thermo-
cycling protocols for rapid detection of miRNAs. Furthermore, with the escalating 
identification of hundreds of candidate miRNAs by deep sequencing (304,305), design of 
TaqMan probe for each of the novel miRNA is not only cost-prohibitive but also technically 
challenging and faces practical difficulties (306). Attempts have been made to improve 
miRNA detection without reliance on fluorescent probes (307-309), however, these assays 
usually involved multiple sample processing steps (308) and suffered from limited dynamic 
range of detection (307) and/or poor specificity against homologous miRNAs (307-309). It is 
noticed that a consensus strategy of these assays and some other TaqMan assays (306,310) is 
to use universal or common reverse PCR primer and/or fluorescent probe for amplification 
and detection of multiple miRNAs. In these assays, specificity of real-time PCR is only 
achieved by the forward PCR primer, which is not sufficient for discrimination of many 
homologous miRNAs. Furthermore, it is yet to be determined whether these assays are 
capable of rapid, multiplexed and direct detection of miRNAs without RNA isolation.  
 This study presented a novel method termed stem-loop mediated reverse transcription 
and quantitative PCR (SMRT-qPCR) for rapid and robust quantification of mature miRNAs 
directly from cultured cells. This miRNA assay coupled stem-looped and deoxyuridine-
incorporated primer for RT with hemi-nested real-time PCR. SMRT-qPCR showed high 
dynamic range, efficiency and sensitivity of detection and excellent discrimination of target 
mature miRNA against its precursor form and homologous family members. Instead of using 
a fluorescent probe, the hemi-nested reverse PCR primer could drastically enhance the assay 
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specificity and allow quantification of subzeptomole amounts of miRNA using SYBR Green I 
under rapid thermo-cycling conditions. Using multiplexed miRNAs assays, six miRNAs were 
found upregulated by GDNF through MEK-ERK1/2 pathway in human glioblastoma cells. 
Furthermore, miRNAs can be efficiently quantified directly from 10 to 1000 cells using this 




8.2.1. Overview and performance of the SMRT-qPCR assay 
 This study presents a facile method for specific detection of mature miRNAs by 








 It is noticed that in a number of previous reports (306-312), the reverse PCR primers 
were designed to anneal directly to sequences in the RT oligonucleotide. To achieve 
specificity, a unique miRNA-specific fluorescent probe is required to discriminate the targets 
5’-UAGCUUAUCAGACUGAUGUUGA-3’
Stem-loop Reverse Transcription
Hemi-nested Fast-cycling Real-time PCR


















from nonspecific amplicons (311). In the case of some TaqMan-based assays, this specificity 
was compromised for the convenience of throughput by using one common probe for 
detection. It is possible that increased specificity can be achieved by designing a hemi-nested 
reverse PCR primer instead of using a common or universal reverse PCR primer. To test this 
hypothesis, mature miRNA was first reverse transcribed at 42°C by RT oligonucleotide which 
adopted a stable stem-loop secondary structure during RT. The cDNA sample was then 
amplified using a tagged forward primer (Pf) and a hemi-nested reverse primer (Pr), where 3-
5 nucleotides extend beyond the RT oligonucleotide. Amplification of the cDNA sample was 
monitored in real-time PCR using SYBR Green I. Optionally, RT oligonucleotide can be 
incorporated with deoxyuridine (dU) residues and the cDNA generated was subsequently 
treated with Uracil-DNA Glycosylase (UDG) at 37°C before amplification. To assist in the 
user defined designs of any real-time RT-PCR assays, a flow chart was presented in using 
hsa-miR-21 (hereafter miR-21) as an example (Fig. 8.2).  
 
 
Fig. 8.2. Flow Chart and example for designing SMRT-qPCR assay. 
 
  
Extract mature miRNA sequence (seq)
Design RT oligonucleotide
1. 5’ stem-loop tag seq (stem: 5-6nt; loop: ~11nt) without 
significant homology to sequences from species of 
interest (eg. homo sapiens)
2. 3’ miRNA-specific seq (6nt, reverse complementary to 
3’ of miRNA sequence)
3. Optionally, dU residue can be incorporated in the loop 
region.
Evaluate RT oligonucleotide (mfold)
1. Formation of stable stem-loop secondary structure at 
RT condition (∆G  -0.5 kcal/mol)
2. Does not form stable stem-loop secondary structure at 
PCR condition (∆G  -0.5 kcal/mol)
Reaction Conditions
RT: Na+ = 75 mM, Mg2+ = 3 mM, Temp = 42 C
PCR: Na+ = 50 mM, Mg2+ = 2.5 mM, Temp = 60 C
Design hemi-nested real-time PCR primer
1. Forward primer (Tm  58 C) with 5’ tag seq to increase 
Tm and 3’ miRNA specific seq (~12nt)
2. Reverse primer (Tm  58 C) with partial stem-loop tag 
seq (8-10nt) and miRNA specific seq (9-11nt, including 
6nt used in RT and 3-5nt 3’ protruding seq).













Minimum free energy of the structure= -3.82 kcal/mol

















∆GRT = -2.37 kcal/mol
∆GPCR = 0.19 kcal/mol
Forward Primer:
Reverse Primer:





 The performance of the SMRT-qPCR assay was first evaluated using miR-21 cDNA 
dilutions under both fast (10 s per cycle) and standard (75 s per cycle with 15 s denaturation 
and 60 s annealing/extension) thermo-cycling profiles. The assay exhibited excellent dynamic 
range and linearity under both cycling profiles (Fig. 8.3A,B), demonstrating the robustness of 
this assay for rapid detection of miRNAs. To evaluate the performance of both RT and PCR, 
synthetic miR-21 was diluted over 7 orders of magnitude (10
9
 to 100 copies per RT) and 
quantified by hemi-nested real-time RT-PCR. Excellent linearity of the standard curve 
suggested that the miR-21 assay had a wide dynamic range of at least 7 logs and was able to 
detect as few as 100 copies (subzeptomoles) per RT reaction (Fig. 8.3C,D).  
 
 
Fig. 8.3. Performance of miR-21 SMRT-qPCR assay. (A, B) miR-21 cDNA (108 to 10 copies) were amplified 
by real-time PCR assay under fast-cycling conditions compared to standard cycling protocol. (C, D) Dilutions of 
synthetic miR-21 miRNA (109 to 102 copies), (E, F) dilutions of total RNA from A172 cells (100 ng to 1 pg) and 
(G, H) total RNA isolated from dilutions of U251 cells (100,000 to 10 cells) were reverse transcribed with miR-21 
RT oligonucleotide. The cDNA samples (10% v/v) were amplified by real-time PCR along with non-template 
control (NTC). Amplification plots (A, C, E, G) and standard curves (B, D, F, H) of the assay were shown. 
























 The performance of this assay in detecting miRNA from total RNA samples was 
examined. Total RNA dilutions from 100 ng to 1 pg (Fig. 8.3E,F) and total RNA isolated 
from 100,000 to 10 cells (Fig. 8.3G,H) were quantified using miR-21 SMRT-qPCR assay. 
The standard curves again showed excellent linearity (Fig. 8.3F,H), suggesting that this assay 
was capable of detecting miRNAs from a minute amount (1 pg) of total RNA or from as few 
as 10 cells with high reliability. The capability of this assay in quantifying mature miRNA 
from total RNA without RNA fractionation was further supported by total RNA spike-in 
experiments. Here, 100 ng of total RNA from U251 cells, which did not contain let-7d and 
let-7e (data not shown), was spiked with varying amounts of synthetic let-7d or let-7e 
miRNAs. The presence of total RNA did not affect the quantification of mature let-7d/let-7e 
miRNAs (Fig. 8.4).  
 
 
Fig. 8.4. Quantification of synthetic let-7d and let-7e miRNA dilutions with U251 total RNA spike-in. 
Standard dilutions (109, 108 and 107 copies) of synthetic let-7d (A) or let-7e (B) were spiked with 100 ng of total 
RNA isolated from U251 cells. Control miRNA dilutions or total RNA spiked-in miRNA dilutions were reverse 
transcribed with let-7d or let-7e RT primers. The cDNA samples (10% v/v) were amplified by real-time PCR. 
Standard curves were plotted as Ct versus Log (Copies of miRNA per RT).  
 
 SMRT-qPCR assays for three other miRNAs (miR-24, miR-92 and miR-218) were 





 copies per RT) and RT-PCR efficiency (88%-100%). Furthermore, these 
assays showed specific amplifications of target miRNAs from both synthetic standards and 








Fig. 8.5. Dynamic range and efficiency of miR-24 (A, B), miR-92 (C, D) and miR-218 (E, F) SMRT-qPCR 
assays. Standard dilutions of synthetic miR-24, -92 and -218 were reverse transcribed with miRNA-specific RT 
oligonucleotide. The cDNA samples (10% v/v) were amplified by real-time PCR along with non-template control 
(NTC). Amplification plots (A, C, E) and standard curves (B, D, F) of the assay were shown. Standard curves were 





Fig. 8.6. Gel electrophoresis of SMRT-qPCR products. SMRT-qPCR assays were performed with 106 copies of 
synthetic miRNA (a), 10 ng U251 total RNA (b) or non-template control (c). U6 was amplified from 10 pg of 
U251 total RNA. The amplified products and the 25bp marker (M) were resolved by 4% agarose gel. Product sizes: 
miR-7 (37bp), miR-21 (38bp), miR-218 (36bp), let-7f (45bp), let-7g (42bp), let-7i (38bp) and U6 (94bp).  
 
 
8.2.2. Specific detection of mature against precursor miRNAs 
 The capability of the SMRT-qPCR assay in discriminating mature against precursor 
miRNAs were investigated using 9 mature miRNAs and their corresponding precursors (miR-
21, miR-7-1, miR-7-2, miR-218-1, miR-218-2, let-7f-1, let-7f-2, let-7g, let-7i). For 
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secondary stem-loop structures during RT (∆G  -0.5 kcal/mol). For better comparison, these 
stem-loop RT oligonucleotides and their corresponding linear RT oligonucleotides were 
designed to 1) differ by only 4-5 bases at 5’; 2) have identical GC content and similar Tm (< 
1°C difference) and 3) have identical 3’ sequence so that same primers can be used in PCR.  
 Same amount (10
9 
copies per RT) of mature miRNAs and pre-miRNAs were 
individually quantified using either stem-loop or linear RT and qPCR. Depending on the 9 
pre-miRNAs examined, mature miRNAs were detected 3 – 14 cycles (average ∆Ct of 8.7 
cycles) earlier than pre-miRNAs using stem-loop RT oligonucleotides. In contrast, the assays 
using linear RT oligonucleotides were less discriminative (average ∆Ct of 4.8 cycles) and 
failed in discriminating some mature miRNAs from their precursors such as pre-miR-21, pre-
let-7f-1 and pre-let-7i (Table 8.1).  
 
Table 8.1. Discrimination between mature and precursor miRNAs using stem-loop or linear 
real-time RT-PCR.  
miRNA Assay  Mature (Stem-loop RT)  Mature (Linear RT)  











miR-21  28.0  18.9  9.1  28.5  27.6  0.9  
miR-7-1 30.2  16.1 14.1  32.9  22.5  10.4  
miR-7-2 26.0  16.1 9.9  26.7  22.5 4.2  
miR-218-1  28.7  15.8  12.9  24.1  16.6  7.6  
miR-218-2  25.0  15.8 9.2  25.8  16.6 9.2  
let-7f-1  21.6  18.2  3.4  20.4  20.8  -0.4  
let-7f-2  26.8  18.2  8.6  26.9  20.8 6.1  
let-7g 26.8  18.6  8.2  27.1  21.7  5.4  
let-7i  21.7  18.6  3.1  20.9  20.9  0.0  
109 copies of each synthetic mature miRNAs or in vitro transcribed pre-miRNAs were reverse transcribed with 
either stem-loop or linear RT oligonucleotide and quantified using the same PCR primers. Discrimination between 
mature and precursor miRNAs was expressed as ∆Ct values (∆Ct = CtPrecursor – CtMature). 
 
8.2.3. Discrimination of human let-7 miRNA homologs 
 Several miRNA families (eg. hsa-let-7, hsa-miR-30) consist of highly homologous 
miRNAs which differ by only a single or a few nucleotides. The eight let-7 family miRNAs 
share up to 63.6% overall sequence identity, among which let-7a and let-7c, let-7a and let-7f, 
let-7b and let-7f differ only by a single nucleotide (Fig. 8.7A). In this study, SMRT-qPCR 
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assays for each let-7 miRNA were designed. Each assay was used to amplify all eight 
synthetic let-7 miRNAs and the relative detection was compared. Briefly, specific reverse 
transcription of each let-7 miRNA (10
9
 copies per RT) was first achieved using stem-loop RT 
oligonucleotide targeting the less homologous 3’ region. Discrimination of let-7 miRNAs was 
further improved by a miRNA-specific forward PCR primer and a hemi-nested reverse primer 
preferably with miRNA-specific 3’-terminal sequence. All of the eight let-7 assays showed 
excellent discrimination against homologous miRNAs with less than 1% non-specific 
detection, except for let-7a assay with 1.778% relative detection against let-7c (Fig. 8.7B). 
For let-7 miRNAs that differ by 2 nucleotides or more, these assays were able to specifically 
detect the target miRNA with less than 0.3% cross-target amplification. This result suggests 
that SMRT-qPCR assay was capable of discriminating highly homologous miRNAs at levels 
comparable to fluorescent probe-based real-time RT-PCR assays (311), with inexpensive 
SYBR Green I detection chemistry. 
 
 
Fig. 8.7. Discrimination of human let-7 homologs. (A) Sequence alignment of the eight let-7 family miRNAs. (B) 





miRNA real-time RT-PCR assay




let-7a 100.0 0.001 0.036 0.005 0.225 0.298 0.000 0.000
let-7b 0.002 100.0 0.248 0.002 0.001 0.001 0.000 0.000
let-7c 1.778 0.178 100.0 0.001 0.003 0.075 0.000 0.000
let-7d 0.072 0.000 0.000 100.0 0.000 0.000 0.000 0.000
let-7e 0.002 0.000 0.000 0.000 100.0 0.000 0.000 0.000
let-7f 0.029 0.000 0.000 0.002 0.002 100.0 0.000 0.000
let-7g 0.000 0.000 0.000 0.000 0.001 0.000 100.0 0.000






















8.2.4. Improved assay performance by dU-incorporated RT oligonucleotide and UDG 
treatment 
 Discrimination between certain highly homologous miRNAs can be further improved 
using a novel strategy involving uracil-DNA glycosylase (UDG) treatment. It is observed that 
the amount of RT oligonucleotides carried-over was able to serve as amplification primers 
during PCR, although with poorer efficiency (Fig. 8.8B,C). Interestingly, after treatment with 
UDG, dU-incorporated RT (dU-RT) oligonucleotide but not standard RT (dT-RT) 
oligonucleotide was not able to serve as reverse PCR primer (Fig. 8.8A-C).  
 
Fig. 8.8. Specificity of SMRT-qPCR assay using dU-incorporated RT oligonucleotides. (A-C) UDG treatment 
of dU-incorporated RT oligonucleotide prevented it from serving as PCR primer after RT. (A) Sequence of 
standard (dT) and dU-incorporated (dU) RT oligonucleotides for miR-21. Synthetic miR-21 (109 copies) were 
reverse transcribed with of dT (B) or dU (C) RT oligonucleotides. The cDNA samples (10% v/v) were then treated 
with (red amplification curves) or without UDG (blue amplification curves) and subjected to real-time PCR with 
both forward and reverse primers (+ Pr) or forward primer alone (- Pr). (D) Sequence comparison of dT and dU 
RT oligonucleotides. The dU residues are underlined. (E) Relative detection of let-7f miRNA by let-7a assay. 109 
copies of let-7a or let-7f were reverse transcribed using 100 nM or 250 nM of dT, dU1 or dU2 RT oligonucleotide. 
The cDNA samples (10% v/v) were treated with or without UDG and amplified using let-7a specific PCR primers. 
Non-specific amplification of let-7f miRNA was calculated and expressed as % of relative detection. Error bars 
indicate standard deviations of quadruplicate measurements. ** p < 0.01. 
 














































dT dU1 dU2 dT dU1 dU2
100 nM 250 nM
111 
 
 It is thus possible that discrimination between let-7 miRNA homologs may be further 
improved with similar strategy. Indeed, while standard (dT) RT oligonucleotide for let-7a 
showed relative detection of 0.03% against let-7f miRNA, let-7a RT oligonucleotides with dU 
incorporation at either loop (dU1) or stem (dU2) region were significantly less capable of 
cross-amplifying let-7f after treatment with UDG (Fig. 8.8D,E). Both the let-7a dT and dU 
RT oligonucleotides were able to prime reverse transcription of let-7a equally well (data not 
shown). 
 
8.2.5. Application of multiplexed assays to identify GDNF-induced miRNA expressions 
in U251 cells 
 SMRT-PCR assays were then designed and applied to identify GDNF-regulated 
miRNAs in U251 cells. A total of 26 miRNA were examined including 18 miRNAs (miR-7, -
10b, -15b, -21, -124, -128, -137, -139, -146b, -181a, -181b, -181c, -218, -221, -222, -425, -
451, -486) reported to be dysregulated in human glioblastoma (313) and the 8 let-7 family 
miRNAs. Twenty miRNAs (except for miR-137, -146b, -181c, -451, let-7d and let-7e) were 
found to be expressed in U251 cells (data not shown). Stimulation of the cells with GDNF 
induced time-dependent activation of ERK1/2 MAPK, which was inhibited by pretreatment 
of MEK inhibitor U0126 (Fig. 8.9). The temporal regulation of expressions of these 20 
miRNAs in U251 cells by GDNF was examined by SMRT-qPCR assays. Interestingly, 
GDNF stimulation induced time-dependent up-regulation of miR-7, -21, -218 (Fig. 8.10A) 





Fig. 8.9. GDNF-induced ERK1/2 activation in U251 human glioblastoma cells. (A) Time-course of ERK1/2 
activation by GDNF (100 ng/ml) in U251 cells. (B) GDNF-induced ERK1/2 activation was inhibited by pre-




Fig. 8.10. GDNF regulated miRNA expressions in U251 cells. Regulation of selected mature miRNAs (A, B) 
were quantified by SMRT-qPCR and expressed as fold changes to non-stimulated control samples. Error bars 
indicate standard deviations of triplicate measurements. ** p < 0.01, compared to non-treated samples. 
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 A multiplexed assay was designed for simultaneous reverse transcription of the 26 
miRNAs (corresponding to 24 RT oligonucleotides) and subsequent detection of individual 
miRNA by hemi-nested qPCR. Using this 24-plex assay, it is found that up-regulation of the 6 
miRNAs by GDNF was effectively inhibited by pre-treatment of the cells with U0126, 
suggesting that MEK-ERK1/2 signaling pathway was required for GDNF-induced miRNA 




Fig. 8.11. Multiplexed quantification of the six GDNF regulated miRNAs. Expressions of miR-7 (A), miR-21 
(B), miR-218 (C), let-7f (D), let-7g (E) and let-7i (F) was quantified by multiplexed SMRT-qPCR assays of 24 
miRNAs. Regulation of these miRNAs was expressed as fold changes to non-stimulated control samples. Error 
bars indicate standard deviations of triplicate measurements. ** p < 0.01, compared to non-treated samples.  
 
8.2.6. Direct and multiplexed detection of miRNAs in cell lysates 
 Direct detection of miRNA from cell lysates can avoid the time-consuming multi-step 
RNA isolation process and dramatically increase the throughput of the assay. SMRT-qPCR 
assays were then applied for direct and multiplexed quantification of miRNAs from 10 to 
100,000 cultured U251 cells in 96-wells. Isolated total RNA from these cells were used as 
controls for quantification. Similar to Fig. 8.3H, excellent linearity of the miR-21 and miR-
222 standard curves of isolated RNA controls suggested that miRNAs can be reliably 



























































































miR-21 and miR-222 can be detected equally well from lysates of 10-1000 cells using this 
multiplexed assay, as compared to isolated RNA controls. However, it is worthy to note that 
direct quantification of miRNAs was compromised with lysates from near confluent (10
4 
cells 
per well) or over confluent cell densities (10
5
 cells per well). Interestingly, no significant 
difference was observed in detection of miRNAs from cell lysates with or without RNase 
inhibitors, suggestive of remarkable stability of mature miRNAs. 
 
 
Fig. 8.12. Direct and multiplexed detection of miRNAs from cell lysates. U251 cells cultured in 96-wells at 
various density (10, 100, 1000, 10000 and 100000 cells per well) were directly lysed and reverse transcribed in 
reaction mixture containing 24 miRNA RT oligonucleotides. The cDNA samples (2.5% v/v) generated from 
isolated RNA or cell lysates were amplified by (A) miR-21 and (B) miR-222 real-time PCR assays. Standard 




 It is now known that miRNAs play important roles in modulating gene expression 
and it has been suggested that up to 60% of human genes are targeted by miRNAs (314). 
With the increase interest in the expression profiles of miRNAs, rapid, robust and cost-
effective methods for the detection of mature miRNAs are highly desirable. The SMRT-qPCR 
assays described herein were simple to design and showed excellent performance and 
provided the flexibility for the design of any miRNAs that may be identified in the future.  
 With synthetic miRNA targets, the SMRT-qPCR assays showed wide dynamic range 
of at least 7 logs, high sensitivity of as few as 100 molecules per RT (subzeptomoles) and 
high RT-PCR efficiency of greater than 90%. Besides relative quantification of miRNA 






miRNA expression from total RNA samples. In contrast to previously reported miRNA real-
time PCR assays which were performed under standard thermo-cycling profile of 45 to 75 s 
per cycle (307-311), SMRT-qPCR assay was capable of fast thermo-cycling (10 s per cycle) 
without modification of reaction mixtures. The fast-cycling capability of this assay may in 
part be attributed to the short amplicon (<50 bp) generated by hemi-nested primers and rapid 
fluorescence acquisition of SYBR Green I without the necessity of probe hydrolysis.  
 Specific and sensitive quantification of mature miRNA from total RNA samples 
usually requires size-fractionation and pre-amplification, respectively. It has been reported 
that besides additional sample handling steps, size-fractionation can result in consistent loss 
of miRNAs (315) and pre-amplification efficiency is significantly affected by number of A 
bases in miRNAs (316). With our miRNA quantitative assay, small amounts of total RNA (1 
pg to 100 ng) and total RNA isolated from as few as 10 cells can be efficiently detected 
without the need for fractionation or pre-amplification. Previously, Megaplex miRNA assays 
for simultaneous reverse transcription of 220 to 450 miRNAs has been applied to quantify 
miRNA expression from minute amount of total RNA or single cell (316,317). Because much 
lower concentration of RT oligonucleotide was used for each miRNA, pre-amplification was 
required prior to real-time PCR especially when starting total RNA is less than 350 ng. This 
study has demonstrated that multiplex of 24 miRNAs resulted in conclusions comparable to 
single-plexed assays without reduction of RT oligonucleotide concentration or the necessity 
of pre-amplification. Therefore, multiplex of relatively small number of miRNAs with this 
method could reduce sample and reagent requirement and yet allow reliable quantification of 
miRNAs. These multiplexed assays can further be used for direct quantification of miRNAs 
from cultured cells in 96-wells. Taken together, the method reported herein is capable of 
reliable, rapid and high throughput quantitative profiling of miRNA expressions not only 
from minute amounts of isolated RNAs but also directly from lysed cells without the need for 
laborious, time consuming methods of RNA isolation. 
 In this study, specific detection of mature miRNAs from precursors is achieved by 
RT oligonucleotides with stem-loop secondary structure. Although the expression levels of 
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precursor miRNAs often correlate with mature miRNAs (318,319), it is not uncommon that 
maturation of miRNA can be regulated whereby precursor miRNAs were expressed but their 
mature forms were undetectable (320-323). In order to discriminate between the regulations 
of miRNA processing and maturation, specific assays for both mature and precursor miRNAs 
are highly desirable. Stem-loop but not linear RT oligonucleotides were found to 
preferentially reverse transcribed mature but not precursor miRNAs. This strategy has been 
previously applied successfully for specific reverse transcription of sense strand of replicating 
retrovirus (324). It has been suggested that linear RT oligonucleotides should contain at least 
7 nucleotides of miRNA-specific sequence for efficient reverse transcription of mature 
miRNAs (307). The poor discrimination of mature against pre-miRNAs by linear RT 
oligonucleotides (with 6 miRNA-specific nucleotides) used in this study, is likely to be due to 
the inefficient reverse transcription of mature miRNAs, consistent with the previous finding 
(311). These results suggested that the stem-loop sencondary structure may stabilize the short 
base-pairing between RT oligonucleotide and the mature miRNA during reverse transcription. 
 MiRNAs are grouped into families (eg. let-7 family) based on identical seed sequence 
that spans 2-7 nucleotides at 5’ of miRNAs, which is a critical determinant of target 
recognition (325). Although miRNAs of the same family are likely to share some common 
targets and functions, specific members of the family may be involved in certain 
physiological processes and disease states. For instance, let-7b was found to be specifically 
up-regulated with age and responsible for the declined stem cell self-renewal (326). Low 
expression of let-7d was suggested as prognostic marker for head and neck squamous cell 
carcinoma (286), and let-7i was identified as a novel biomarker for human epithelial ovarian 
cancer (327). As such, specific and quantitative detection of these miRNAs is required for the 
development of biomarkers and for studies on the biogenesis of miRNAs. Previously, 
discrimination of let-7 homologs was achieved with TaqMan RT-qPCR assays, whereby after 
miRNA-specific RT, a common reverse primer was used for PCR and a miRNA-specific 
TaqMan probe was required for discrimination (311). Assays with similar strategy but 
without the use of fluorescent probes suffered from significantly poorer discrimination of the 
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let-7 homologs (307-309). We hypothesized and showed that specificity of the assays can be 
dramatically enhanced by a hemi-nested miRNA-specific reverse PCR primer and do not 
require the use of fluorescent probe. Using this method, all the let-7 miRNAs can be 
specifically detected using inexpensive SYBR Green I, with excellent discrimination, 
comparable and in some cases, superior to the TaqMan real-time RT-PCR (311).  
 The presence of excess RT oligonucleotides can serve as reverse primers during PCR, 
which will contribute to non-specific amplification. This is problematic especially when the 
forward primer in PCR can also hybridize to shared sequences (eg. cDNA from homologous 
miRNAs). A common practice to mitigate this problem is to reduce the carryover of RT 
oligonucleotides by diluting cDNA samples after RT. However, this approach will invariably 
reduce the assay sensitivity, especially with low abundance target miRNAs. For low 
abundance miRNAs, the assay is further improved by modifying the RT oligonucleotides with 
deoxyuridine residues and treating the cDNA with UDG prior to real-time PCR. UDG was 
first purified from E.Coli and found able to cleave uracil from uracil-containing DNA (328). 
Release of uracil residues results in apyrimidinic sites on the DNA, which can block the 
replication by DNA polymerase during PCR (329). It is likely that UDG treatment disabled 
the unused dU RT oligonucleotides from serving as PCR primers. This is a simple and 
attractive approach in situations where maximum specificity is desired or discrimination is 
difficult to achieve during RT (eg. let-7a and let-7f share identical 3’ sequences for RT 
priming). 
 The number of miRNAs (including human) in the public domain currently is more 
than 15,000 (MiRBase release 16; Sept 2010) and expected to increase with both in silico 
prediction and in vivo validation such as deep sequencing. With the continuous demand for 
miRNA expression analysis, the SMRT-qPCR assay presented in this study provides a high 
performance method for the rapid and reliable detection of functional mature miRNAs.  
 Using SMRT-qPCR assays for selected miRNAs, GDNF was found to regulate the 
expressions of miR-7, miR-21, miR-218, let-7f, let-7g and let-7i through MEK-ERK1/2 
MAPK signaling pathway. MiR-21 is well known to be elevated in many cancers and exhibit 
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oncogenic roles in tumor development (330). Recently, miR-21 has been shown to contribute 
to glioblastoma tumor resistance to chemotherapy (285). However, the roles of miR-7, miR-
218 and let-7 family miRNAs in glioblastoma chemoresistance or other aggressive behaviors 
are less understood. The functional significance of these GDNF-induced miRNAs remains to 
be investigated. Using the rapid and high throughput method developed herein, it is now 




















9.1. Conclusion  
 
 In this thesis, the distinct functions of alternatively spliced isoforms of GFRα1, 
GFRα2 and Ret in regulating GDNF signaling have been investigated. Using isoform-specific 
real-time PCR, the expression levels of GFRα1a, GFRα1b, Ret9 and Ret51 were first 
quantified in human tissues and central nervous system. Both GFRα1 and Ret isoforms were 
expressed in vivo, supportive of their physiological relevance in neuronal systems. 
 In neuronal cells, GFRα1a but not GFRα1b promoted ligand-induced neurite 
outgrowth through ERK1/2, Rac1 and Cdc42. GFRα1b inhibited GFRα1-mediated neurite 
outgrowth by activation of RhoA pathway. The distinct function of GFRα1 isoforms was 
further demonstrated in glioma cells, where GFRα1b but not GFRα1a was required for RhoA 
expression and glioma migration. This process is likely to be mediated by the alternative co-
receptor NCAM but not the canonical Ret. These findings highlighted distinct functions of 
GFRα1 isoforms in neuronal differentiation and glioma migration. 
 GFRα2 isoforms were also found to exhibit differential neuritogenic activities. 
GFRα2a and GFRα2c but not GFRα2b promoted activation of cAMP pathway, sustained 
ERK1/2 activation and neurite outgrowth upon ligand activations. Activation of cAMP 
pathway was required for GFRα2a and GFRα2c-mediated sustained ERK1/2 activation and 
neurite outgrowth. Addition of cAMP agonists synergized with ligand-activated GFRα2b to 
induce prolonged ERK1/2 activation and neurite outgrowth. The contribution of cAMP 
signaling to GDNF-mediated neurite outgrowth was dependent on PKA but not Epac and 
required de novo transcription and translation. These results not only demonstrate an essential 
role of cAMP-PKA signaling in GDNF and NTN induced sustained ERK1/2 activation and 
neurite outgrowth, but also suggest cAMP-PKA signaling as an underlying mechanism 
contributing to the differential neuritogenic activities of GFRα2 isoforms. 
 Although both Ret isoforms promoted ligand-induced MAPK and AKT activations 
and neurite outgrowth, Ret9 but not Ret51-mediated late ERK1/2 activation, late gene 
expression and neurite outgrowth was dependent on Src kinase activity. The differential 
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requirement of Src by Ret9 and Ret51 may be due to distinct recruitment of adaptor 
molecules to their pY1062 motifs. In addition, ligand-activated Ret9 and Ret51 regulated 
distinct gene expression profiles in microarray studies. These results revealed an additional 
level of complexity in GDNF signaling contributed by Ret alternatively spliced isoforms. 
 This thesis also reports the identification of a novel serine residue critical for Ret 
kinase activation and GDNF-induced neurite outgrowth. In addition, a novel high 
performance real-time PCR assay has been developed to quantify mature microRNAs and 
identify GDNF-regulated microRNAs in human gliomas. 
 It is now evident that GFLs signalings are involved in many aspects of neurobiology, 
from cell proliferation, differentiation, migration to neurotransmitter release, neuronal 
excitability and neuronal regeneration. The pleotropic roles of GFLs signalings in these 
diverse processes are likely to be attributed to its complex regulatory mechanisms, including 
ligand-receptor crosstalks, existence of receptor isoforms, alternative receptors and other cell 
surface modulators (Fig. 9.1). Ligand-receptor crosstalks have previously been reported, 
where GDNF and NTN exhibited distinct biochemical effects on cells expressing only GFRα1 
(136) and differentially regulated the expressions of specific microRNAs in cells expressing 
only GFRα2 (331). Alternative receptors for GFLs have recently been discovered including 
NCAM (41) and the heparan sulfate proteoglycan Syndecan-3 (43), which regulated GDNF 
functions in neuronal migration and neurite outgrowth under restricted conditions. The 
complexity of GFLs signalings is further contributed by the activities of cell surface 
modulators including Lrig1, Gas1 and Pcdh. The leucine-rich repeats and Ig-like domain 
protein Lrig1 does not bind directly to GDNF, but is capable of physically interacting with 
Ret and inhibiting its GDNF binding capacity (332). Similarly, GFRα related protein Gas1 
(growth arrest-specific protein 1) interacts and modulates Ret activity independent of GDNF 
(333). Recently, Procadherins (Pcdhs) were found to be phosphorylated by Ret, which 
stabilizes the activated Ret by inhibition of its degradation (334). Thus, the combinatorial 
interactions of GFLs, receptors and accessory molecules can produce a bewildering array of 




Fig. 9.1. An overview of GDNF signaling. The complexity of GDNF signaling system is contributed by ligand-
receptor crosstalks, the existence of receptor (GFRα) and co-receptor (Ret) isoforms, alternative receptors 
(Syndecan-3 and NCAM) as well as other cell surface modulators (Pcdh, Lrig1 and Gas1). The combinatorial 
interactions of these signaling components differentially regulate intracellular signal transduction and gene 
expressions, resulting in the diverse neuronal processes. 
  
 The work presented in this thesis highlighted the contributions of alternatively spliced 
receptor isoforms in functional diversity of GDNF signaling. The existence of multiple 
alternatively spliced variants of the GFLs, GFRαs and other co-receptors provides a shift in 
the paradigm of how this limited number of ligands and receptors can generate pleiotropic 
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9.2. Future studies 
 
9.2.1. Crystal structures of GFRα1 and GFRα2 isoforms 
 GFR is organized into three homologous cysteine-rich domains. Using truncated 
and chimeric GFR1 constructs, previous studies showed that D1 of both GFR1 and 
GFR2 is dispensable and does not appear to affect the ligand-binding specificity (38). The 
specificity was contributed by D2/D3 and perturbations of which affected the interactions 
between the ligand and receptor binding (47). Interestingly, a recent study suggested that the 
residues at the distal end of the N-terminus (residues 89-101 of D1 of GFR1) interacted with 
Ret at multiple sites, strongly supporting the biological relevance of the N-terminal domains 
(48). As both GFRα1 and GFRα2 isoforms differ at the extreme N-terminus (D1 or D1/D2), it 
is of great interest to determine the contribution of conformational changes in these isoforms 
to the observed diverse functions. Crystal structures of full length GFRα1 and GFRα2 
isoforms can be determined by X-ray crystallography, preferably in the ligand-bound status.  
 
9.2.2. Phosphorylation patterns of Ret coupled to distinct GFRα1 and GFRα2 isoforms 
 In this thesis, PC12 cells which do not express significant levels of GFRα, Ret and 
NCAM were used as one of the neuronal models. In these cells, Ret was able to couple to all 
GFRα2 isoforms and resulted in distinct phenotypic outcomes (Chapter 5). Ret activation 
induces dimerization and autophosphorylation of Ret intracellular residues, which bind to 
multiple adaptor molecules and transduce signaling activations. It is likely that activation of 
Ret by GFRα2 isoforms results in distinct Ret phosphorylation patterns that dictate the 
downstream signaling events and functional outcomes. Previously, mass spectrometry has 
been carried out to analyze the autophosphorylation residues in the intracellular domain of 
oncogenic Ret (282). Recent advances in phospho-residue analysis of membrane receptors 





9.2.3. In vivo functions of GFRα1 and GFRα2 isoforms 
 It is now clear that alternatively spliced isoforms of GFRα1, GFRα2 and Ret isoforms 
serve distinct functions as evident in in vitro studies, such as neurite outgrowth and glioma 
migration. An extension of the findings here is to examine the in vivo functions of these 
isoforms including neurogenesis, neuroregeneration and neurodegeneration. Although 
transgenic animal models for Ret isoforms have been developed by two independent groups, 
studies with these monoisoformic animals have reached controversial conclusions (115,116). 
Transgenic animal models can provide insights into the physiological functions of specific 
receptor isoform at organism level; however, it is important to be aware of the potential 
limitations due to animal genetic background and compensatory effects. 
 
9.2.4. The involvement of NCAM in GDNF functions 
 Since the identification of NCAM as the alternative co-receptor for GDNF-GFRα1 
signaling (41), the in vivo significance of NCAM in GDNF signaling remain controversial 
(42,337). In this thesis, NCAM but not Ret was involved GDNF-mediated RhoA expression 
and glioma migration (Chapter 4), clearly supporting the role of NCAM in GDNF signaling. 
However, in PC12 cells expressing GFRα and Ret but not NCAM, GDNF was able to 
promote neurite outgrowth. Whether and how NCAM is involved in GDNF-induced neurite 
outgrowth deserves further investigation. However, in view of the abundant and ubiquitous 
expression of NCAM in neuronal cells, it is also desirable to examine the contribution of 
NCAM to GDNF function in the presence or absence of Ret. 
 
9.2.5. The functional roles of microRNA in GDNF signaling 
 The development of microRNA quantification assays in this thesis (Chapter 8) can 
allow accurate profiling of microRNA expressions regulated by GDNF signaling. Although it 
is now well established that microRNAs serve critical roles in neuronal development and 
neurodegeneration (338,339), how microRNAs regulate the functions of neurotrophic factors, 
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including GDNF family ligands is not known. Recently, a number of microRNAs have been 
implicated in neuronal differentiation, dendritic plasticity and neuronal cell fate decision, such 
as miR-125b (340), miR-132 (341) and miR-273 (342). It is therefore interesting to 
investigate the regulation of these neuronal microRNAs by GDNF signaling and their 















CHAPTER 10  




10.1. Ligands and chemicals 
  
 Human recombinant GDNF, NTN and mouse recombinant NGF were purchased from 
Peprotech (Rocky Hill, NJ). The following chemicals were purchased from Sigma (Saint 
Louis, MO): Lysophosphatidic acid (LPA), All-trans retinoic acid (RA), Forskolin (FK), 
Dibutyryl cAMP (dbcAMP), Pituitary adenylate cyclase-activating peptide (PACAP), PKA 
inhibitor H89, Src inhibitor SU6656, PKC inhibitors Gö6976 and Gö6983, transcription 
inhibitor Actinomycin D and translation inhibitor Cyclohexamide. Rho inhibitor exoenzyme 
C3 transferase and ROCK inhibitor Y27632 were from Calbiochem (Gibbstown, NJ). ROCK 
inhibitor H-1152, p38 inhibitor SB203580, JNK inhibitor SP600125, Src inhibitor PP2 and 
Src/Ret inhibitor PP1 were purchased from Tocris (Bristol, UK). MEK inhibitor U0126 and 
PI3K inhibitor LY294002 were from Promega (Madison, WI). Rp-8-Br-cAMPS, 8-p-
chlorophenylthio-2'-O-methyl-cAMP (2-Me-cAMP) and N6-Benzoyl-cAMP (6-Bnz-cAMP) 
were from Biolog (Bremen, Germany). 
 
10.2. Plasmid construction and mutagenesis 
 
10.2.1. Overview of vectors 
 Cloning vector pGEM-T (Promega) was used to sub-clone templates for real-time 
PCR. Expression vector pIRESneo (Clontech, Palo Alto, CA) containing neomycin-resistance 
gene was used to clone genes for stable expression. pIRES-eGFP (Clontech) was used to 
clone genes for transient and co-expression of target genes and eGFP. Retroviral vectors 
pQCXIN, pQCXIP and pQCXIH (Clontech) carrying neomycin, puromycin and hygromycin-
resistance genes respectively, were used to clone GFRα1, GFRα2 and Ret isoforms for stable 
retroviral infection of PC12 cells. Retroviral vector pQCXI-eGFP, with eGFP replacing 
antibiotic-resistance genes, was used to clone Ret phospho-mutants for transient and 




10.2.2. Plasmid construction for real-time PCR standards 
 All templates were generated by reverse transcription (RT)-PCR using mouse, rat or 
human brain cDNA and subcloned into pGEM-T (Promega), unless stated otherwise. The 
complete open reading frame (ORF) of mouse GFRα1a (AF014117), GFRα1b (AF015172), 
GFRα2a (AF079108), GFRα2b (AF079107), GFRα2c (AF002701), human GFRα2a 
(NM_001495), GFRα2b (NM_001165038) and GFRα2c (NM_001165039) were generated by 
PCR and subcloned into pIRESneo (Clontech). ORF of mouse Ret9 (AY326397), Ret51 
(AF209436), GAPDH (NM_001001303) and human GAPDH (NM_002046) were subcloned 
into pGEM-T. Partial ORF encompassing the real-time PCR amplicons of mouse NCAM 
(NM_010875), rat GDNF (NM_019139), RPL19 (NM_031103), human GDNF 
(NM_199231), GFRα1a (NM_005264), GFRα1b (NM_145793), Ret9 (NM_020630), Ret51 
(NM_020630) and NCAM (NM_000615) were subcloned into pGEM-T. All clones were 
verified by DNA sequencing. XbaI and XmnI (Promega) were used to linearize pGEM-T and 
pIRESneo plasmids, respectively. Dilutions of the linearized plasmids served as standard 
templates in real-time PCR. 
 
10.2.3. Construction of expression plasmids 
 HA-tagged RhoA constructs were gifts from Dr. Low BC (Department of Biological 
Sciences, National University of Singapore). Src constructs (wild-type and dominant negative) 
were gifts from Dr. Wong YH (Department of Biochemistry, Hong Kong University of 
Science and Technology). Mouse Rac1, Cdc42 and Src were subcloned into pIRES-eGFP. 
Mouse GFRα1a and GFRα1b were subcloned into pIRESneo. Mouse GFRα1a, GFRα1b, 
GFRα2a, GFRα2b, GFRα2c, Ret9, Ret51 and human Ret9 were subcloned into retroviral 
vectors. Mouse and human Ret phospho-mutants were cloned into pQCXI-eGFP vector.  
 
10.2.4. Site-directed mutagenesis 
 To construct siRNA-resistant GFRα1 clones, three silent mutations were introduced 
to the target sequence of total GFRα1 siRNA #2. Briefly, the siRNA-targeting sequence 5’-
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GGTCTGTCAGCAACTGTCTTAAGGA-3’ in wild type GFRα1 was mutated into 5’- 
GGTCTTTCAGCAACTGCCTTAAAGA-3’ (mutations underlined) in siRNA-resistant 
GFRα1 clones using assembly PCR as described previously (343). The siRNA-resistant 
GFRα1a and GFRα1b sequences were cloned into pIRESneo vector.  
 To construct dominant negative mutants of Rac1 and Cdc42, ORF of wild type Rac1 
and Cdc42 were cloned into pGEM-T. Dominant negative mutants of Rac1 (T17N) and 
Cdc42 (T17N) were then constructed using Phusion
TM
 Site-Directed Mutagenesis Kit 
(Finnzymes, Finland) according to manufacturer’s instructions. Ret phospho-mutants (S696A, 
Y905F, Y981F, Y1015F, Y1062F, Y1096F, S756A, S811A, S909A, S1034A, S909D, 
Y905E/S909D, Y905F/S909D and Y905E/S909A) were constructed with similar strategy. 
 
10.3. Cell culture 
 
10.3.1. Mammalian cell lines and culture conditions 
 Neuro2A, NG108-15, BE(2)-C, Plat-E, C6, A172 and U251 were cultured in 
Dulbecco’s minimum essential medium (DMEM) supplemented with 10% heat-inactivated 
fetal bovine serum (FBS, Hyclone, Logan, UT). PC12 cells were cultured in DMEM 
supplemented with 10% FEB and 5% horse serum (HS, Hyclone). Plat-E cells were obtained 
from Cell Biolabs (San Diego, CA). All the other cell lines were purchased from American 
Type Culture Collection (ATCC, VA). Cells were cultured with 100 U/ml penicillin and 100 
mg/ml streptomycin and maintained in a 5% CO2 humidified incubator at 37°C.  
 
10.3.2. Transfection of expression plasmids 
 Neuro2A cells which express endogenous Ret and NCAM (66), were stably 
transfected with either mouse GFRα1a and GFRα1b or vector control, pIRESneo (Clontech) 
using Transfectin Reagent (BioRad, Hercules, CA) and selected with 0.8 mg/ml of G418 
(Promega), over a period of 2 months. Neuro2A cells stably expressing GFRα1 were 
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transiently transfected with dominant negative constructs of RhoA, Rac1 and Cdc42 using 
Transfectin and analyzed 48 h post-transfection.  
 NG108-15 which endogenously expresses GFRα1a and Ret but not GFRα1b and 
GFRα2 (136), were transfected with either eGFP or mouse GFRα1b in pIRESneo vector.  
 C6 cells were transiently transfected with HA tagged wild-type (WT), dominant 
negative (DN) and constitutively active (CA) constructs of RhoA using Transfectin.   
 
10.3.3. Transfection of small interfering RNA 
 Small interfering RNA (siRNA) duplexes specific for GFRα1a and GFRα1b were 
designed against the unique exon junctions. siRNAs for GFRα1a and GFRα1b were from 
Invitrogen (Carlsbad, CA); siRNAs for total GFRα1 and RhoA were from Integrated DNA 
Technologies (IDT, Coralville, IA), siRNAs for Ret (sc-156121) and NCAM (sc-156119) 
were from Santa Cruz Biotechnologies (Santa Cruz, CA); luciferase control siRNA was 
obtained from Sigma. Transient transfections of siRNA were carried out using Transfectin 
(Bio-Rad) according to manufacturer’s instructions. Briefly, C6 cells were plated to 80% 
confluency in complete medium without antibiotics for 24 h. Prior to transfection, Transfectin 
and the siRNA duplexes were diluted separately in serum-free DMEM for 5 minutes. The two 
mixtures were combined and incubated for 30 minutes at room temperature to enable complex 
formation. C6 cells were then added drop-wise with the transfection mixture at final siRNA 
concentration of 20 nM. Cells were assayed and analyzed within 3 days post- transfection. 
 For knockdown of GRRα2b in BE(2)-C cells, siRNA duplexes (Invitrogen) were used 
as previously described (67). Briefly, subconfluent cells (50–80%) were transfected with 
siRNA duplexes (20 nM) using Transfectin (Bio-Rad) for 24 h. Cells were pretreated with 10 
µM U0126 or 200 µM Rp-8-Br-cAMPS for 1 h before stimulation with 50 ng/ml NTN.   








Table 10.1. Target sequences of siRNA duplexes. 
 
Target gene siRNA target sequence (5’ to 3’) 
Luciferase control CGTACGCGGAATACTTCGA 
GFRα1a #1 CATATCAGATGTTTTCCAGC 
GFRα1a #2 TATCAGATGTTTTCCAGCAA 
GFRα1b #1 GTCCCGTTCATATCAGTGGA 
GFRα1b #2 CCCGTTCATATCAGTGGAAC 
GFRα1b #3 GTTCATATCAGTGGAACACA 
Total GFRα1 #1 GGAGCATGTACCAGAGCCTGCAGGG 




10.3.4. Transient and stable retroviral infection of PC12 cells 
 Plat-E cells were transfected with retroviral vectors (pQCXIN, pQCXIP, pQCXIH, 
Clontech) encoding GFRα1, GFRα2 and Ret isoforms using FuGene 6 (Roche, Germany). 
The supernatants of transfected Plat-E cells containing active retroviruses were used to infect 
PC12 cells in the presence of 8 µg/ml of polybrene (Sigma). Infected PC12 cells were 
selected for at least 1 month in complete medium supplemented with 0.4 mg/ml G418 (PAA, 
Austria), 1 µg/ml puromycin (Clontech) or 0.1 mg/ml hygromycin B (Invitrogen) for 
pQCXIN, pQCXIP or pQCXIH vectors respectively. For transient infection of PC12 cells 
with Ret phospho-mutants, Plat-E cells were transfected with retroviral vectors co-expressing 
eGFP and Ret mutants and the supernatants were used to infect PC12 cells in the presence of 
polybrene for twice in 10 h interval. Infected PC12 cells were analyzed 48 h post-infection.  
 
10.4. RNA preparations and reverse transcription 
 
10.4.1. Generation of mature and precursor microRNA 
 Mature miRNAs were synthesized by Proligo (Sigma) or IDT. T7 promoter 
sequenced tagged PCR primers were used to clone precursor miRNAs (Table 10.2). The 
purified PCR products were validated by sequencing and subjected to MEGAscript T7 
Transcription kit (Ambion, Austin, TX) for in vitro transcription of precursor miRNAs 
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according to manufacturer’s instructions. Both mature and precursor miRNAs were quantified 
by spectrophotometry and diluted to desired concentration to serve as standards. 
 
Table 10.2. Primer sequences for cloning and real-time RT-PCR of miRNA precursors. 
 
 
Primer Sequence  
miRNAs  Cloning (Forward)  Cloning (Reverse)  
miR-7-1  TAATACGACTCACTATAGGGTTGGATGTTG  CTGTAGAGGCATGGCCTGTGC  
miR-7-2  TAATACGACTCACTATAGGGCTGGATACAG  TGCGATGGCTGGCACCATTAG  
miR-218-1  TAATACGACTCACTATAGGGGTGATAATGTA  TGTAGAAAGCTGCGTGACGTTCC  
miR-218-2  TAATACGACTCACTATAGGGGACCAGTCGC TGCAGGAGAGCACGGTGCTTTCCG  
miR-21  TAATACGACTCACTATAGGTGTCGGGTAGC  TGTCAGACAGCCCATCGACT  
let-7f-1  TAATACGACTCACTATAGGGTCAGAGTGAG  TCAGGGAAGGCAATAGATTGTATAGTTATCTCC  
let-7f-2  TAATACGACTCACTATAGGGTGTGGGATGA  CGTGGGAAAGACAGTAGACTGTATAGTTATC  
let-7g  TAATACGACTCACTATAGGGAGGCTGAGGT  TGGCAAGGCAGTGGCCTGTACAGTT  
let-7i  TAATACGACTCACTATAGGGCTGGCTGAGG  TAGCAAGGCAGTAGCTTGCGCAGTTATCTC  
 
 
10.4.2. Total RNA extraction 
 Total RNA samples from human tissues and various regions of central nervous 
system were purchased from Clontech. Human glioma clinical samples were provided by Dr. 
Ng WH (Department of Neurosurgery, National Neuroscience Institute of Singapore). Total 
RNA from glioma samples and cultured cells was isolated with TRIzol reagent (Invitrogen) 
according to manufacturer’s instructions. The integrity of isolated total RNA was validated by 
denaturing agarose gel electrophoresis.  
 
10.4.3. Reverse transcription of mRNA and microRNA 
 For RT of mRNA, 2 µg of total RNA were reverse transcribed using 400 U of 
ImPromII reverse transcriptase and 0.5 µg random hexamer for 60 min at 42°C according to 
the manufacturer’s instructions (Promega). The reaction was terminated by heating at 70°C 
for 5 min. 
 For RT of miRNA, total RNA samples were treated with RNase-free DNase I 
(Promega) at 37°C for 30 min. The DNase was inactivated at 80 °C for 5 min. For RT of 
primary and precursor miRNAs, 100 ng of DNase I treated total RNA or dilutions of in vitro 
transcribed precursor miRNA standards were initially heated at 80°C in the presence of 150 
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nM of gene specific reverse primers for 5 min, snapped chilled on ice and reverse transcribed 
[1x buffer, dNTPs (10 mM), dithiothreitol (DTT), RNase inhibitor, Thermoscript (15 U)] as 
specified by the manufacturer (Invitrogen). The reverse transcription was carried out at 60°C 
for 45 min and terminated by a further incubation at 85°C for 5 min. For the detection of 
precursors, both RT and real-time PCR were carried out with pre-validated gene-specific 
primers as reported previously (344). 
 For RT of mature miRNAs, 100 ng of DNase I treated total RNA or dilutions of 
synthetic human mature miRNA standards were reverse transcribed using 100 U of Improm II 
(Promega) and 100 nM of either stem-loop or linear RT oligonucleotide in a total volume of 
10 µl for 30 min at 42°C. The reaction was terminated by heating at 70°C for 5 min. For 
multiplex RT of 24 mature miRNAs, 100 ng of DNase I treated total RNA samples were 
reverse transcribed using 400 U of Improm II and 100 nM of each RT oligonucleotide (2.4 
µM of total) in a total volume of 40 µl for 30 min at 42°C. The cDNA samples were then used 
for real-time PCR using miRNA-specific primers. Primers for both RT and real-time PCR 
were listed in Table 10.3. Linear RT oligonucleotides were listed in Table 10.4. 
 













Stem-loop CACCGTTCCCCGCCGTCGGTGTCAACA 86.2 -2.37 0.19 
Linear GACCCTTCGCGGCCGTCGGTGTCAACA 85.6 -0.16 1.21 
miR-7 
Stem-loop CACCGTTCCCCGCCGTCGGTGACAACA 86.2 -2.98 -0.55 
Linear GACCCTTCGCGGCCGTCGGTGACAACA 85.6 -0.16 1.21 
miR-218 
Stem-loop CACCGTTCCCCGCCGTCGGTGACATGG 87.1 -2.98 -0.55 
Linear GACCCTTCGCGGCCGTCGGTGACATGG 86.4 -0.16 1.21 
let-7f 
Stem-loop GCTCAGACAGAAGTCACACTGAGCAACTAT 71.0 -3.22 -0.20 
Linear CGAGAGTCAGAAGTCACACTGAGCAACTAT 70.9 -0.02 1.40 
let-7g 
Stem-loop GCTCAGACAGAAGTCACACTGAGCACTGTA 72.8 -3.22 -0.20 
Linear CGAGAGTCAGAAGTCACACTGAGCACTGTA 72.8 -0.02 1.40 
let-7i 
Stem-loop GCTCAGACAGAAGTCACACTGAGCACAGCA 77.2 -3.22 -0.20 
Linear CGAGAGTCAGAAGTCACACTGAGCACAGCA 77.2 -0.50 1.17 
 
The most stable secondary structure was adopted to calculate ∆G for linear RT oligonucleotides. Sequence 








miRNAs  RT  PCR Forward  PCR Reverse  
let-7a  GCTCAGACAGAAGTCACACTGAGCAACTAT  GGGCGGTGAGGTAGTAGG  GAAGTCACACTGAGCAACTATACAAC  
let-7b  GCTCAGACAGAAGTCACACTGAGCAACCAC  Same to let-7a  CACACTGAGCAACCACACAAC  
let-7c  GCTCAGACAGAAGTCACACTGAGCAACCAT  Same to let-7a  TCACACTGAGCAACCATACAAC  
let-7d  GCTCAGACAGAAGTCACACTGAGCACTATG GCGGGCGGAGAGGTAGT  GTCACACTGAGCACTATGCAAC  
let-7e  GCTCAGACAGAAGTCACACTGAGCACTATA  CGGGCGGTGAGGTAGG  AGAAGTCACACTGAGCACTATACAAC  
let-7f  Same to let-7a  CGGGCGGTGAGGTAGTAGA  AGAAGTCACACTGAGCAACTATACAAT  
let-7g  GCTCAGACAGAAGTCACACTGAGCACTGTA  CGGGCGGTGAGGTAGTAGT  AAGTCACACTGAGCACTGTACAAA  
let-7i  GCTCAGACAGAAGTCACACTGAGCACAGCA  CGGGCGGTGAGGTAGTAGT  CACACTGAGCACAGCACAAA  
miR-24  CACCGTTCCCCGCCGTCGGTGCTGTTC  CCCGCCTGGCTCAGTTC  CCGTCGGTGCTGTTCCTG  
miR-92  CACCGTTCCCCGCCGTCGGTGCAGGCC  CCCGCCTATTGCACTTGTC  GTCGGTGCAGGCCGGG  
miR-10b  GACCGTTCCCCGCCGTCGGTCCACAAA  CCGCCGTACCCTGTAGAA  CGTCGGTCCACAAATTCG  
miR-221 CACCGTTCCCCGCCGTCGGTGGAAACC  CGGGCAGCTACATTGTCTG  CGTCGGTGGAAACCAGCA  
miR-222 CACCGTTCCCCGCCGTCGGTGACCCAG  CGGGCAGCTACATCTGG  CGTCGGTGACCCAGTAGC  
miR-21 CACCGTTCCCCGCCGTCGGTGTCAACA  CCCGCCTAGCTTATCAGACTG  GCCGTCGGTGTCAACATCA  
miR-486-5p  CACCGTTCCGCGCCGTCGGTGCTCGGG  CGCCGTCCTGTACTGAGCT  GTCGGTGCTCGGGGCAG  
miR-451 CACGGAACCCCGCCGACCGTGAACTCA  CGCCGAAACCGTTACCAT  GCCGACCGTGAACTCAGTAAT  
miR-15b CACCGTTCCCCGCCGTCGGTGTGTAAA  CCGCCGTAGCAGCACATC  CCGTCGGTGTGTAAACCATG  
miR-146b-5p  CACCGTTCCCCGCCGTCGGTGAGCCTA  CGGGCGTGAGAACTGAATT  CGTCGGTGAGCCTATGGA  
miR-128 CACGGAACCCCGCCGACCGTGAAAGAG  GGCGTCACAGTGAACCG  CGACCGTGAAAGAGACCG  
miR-181c CACGGAACCCCGCCGACCGTGACTCAC  CCGCCGAACATTCAACCT  CGACCGTGACTCACCGAC  
miR-181a Same to miR-181c  CGCCGAACATTCAACGC  Same to miR-181c  
miR-181b CACGGAACCCCGCCGACCGTGACCCAC  CCGCCGAACATTCATTGC  GACCGTGACCCACCGAC  
miR-425 GACCGTTCCCCGCCGTCGGTCTCAACG  GGGCGAATGACACGATCAC  CGTCGGTCTCAACGGGAG  
miR-7 CACCGTTCCCCGCCGTCGGTGACAACA  CGCCCTGGAAGACTAGTGAT  CCGTCGGTGACAACAAAAT  
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miR-124 CACCGTTCCGCGCCGTCGGTGGGCATT  CATACCTAAGGCACGCGG  GTCGGTGGGCATTCACC  
miR-137 CACCGTTCCCCGCCGTCGGTGCTACGC  CCGCCGTTATTGCTTAAGAA  CGTCGGTGCTACGCGTAT  
miR-139-5p  CACCGTTCCCCGCCGTCGGTGCTGGAG  CCGCCTCTACAGTGCACGT  CGTCGGTGCTGGAGACAC  
miR-218 CACCGTTCCCCGCCGTCGGTGACATGG  TCGGGCTTGTGCTTGATCT  CCGTCGGTGACATGGTTAG  
 
 
Table 10.5. Details of primers for real-time PCR. 
 
Gene Species Forward primer (5’ to 3’) Reverse primer (5’ to 3’) Amplicon size 
(bp) A. GDNF receptor complexes 
GDNF mmu, rno TGAAGTTATGGGATGTCGTGG TTGGAGTCACTGGTCAGCG 154 
GFRα1a mmu, rno CATATCAGATGTTTTCCAGCA TGGT(A/G)CAGGGGGTGATGTAGG 128 
GFRα1b mmu, rno CAGTCCCGTTCATATCAGTGGA TGGT(A/G)CAGGGGGTGATGTAGG 123 
GFRα1-GPI mmu, rno GCCAGCCAGAGTCAAGGTCT GCCAATCAGTCCCGAGTAGG 83 
GFRα2a mmu GCCTCTTCTTCTTTTTAGACGAA TGTCGTTCAGGTTGCAGGCCT 495 
GFRα2b mmu GCCTCTTCTTCTTTTTAGGTGAG TGTCGTTCAGGTTGCAGGCCT 180 
GFRα2c mmu GCCTCTTCTTCTTTTTAGGGACA TGTCGTTCAGGTTGCAGGCCT 96 
GFRα2-GPI mmu, rno TGTCATCACCACCTGCACATC AGGCCAAGGTCA(C/G)CATCAGG 200 
Ret9 mmu, rno CCCCTGGTGGACTGTAACA GTAAATGCATGTGAAATTCTACC 95 
Ret51 mmu, rno CCCCTGGTGGACTGTAACA TCGGCTCTCGTGAGTGGTA 128 
Ret-TK2 mmu, rno TCAATCAGAGCCTGGACCATA GGAGGAAGA(C/T)GGTGAGCA 82 
NCAM mmu, rno TGTCAAGTGGCAGGAGATGC GGCGTTGTAGATGGTGAGGGT 138 
GDNF hsa TCACTGACTTGGGTCTGGG TCAAAGGCGATGGGTCTGC 175 
GFRα1a hsa CATATCAGATGTTTTTCAGCAAGTGGA CAGACATCGTTGGACACGCT 150 
GFRα1b hsa TGGTCCCATTCATATCAGTGGA CAGACATCGTTGGACACGCT 145 
GFRα2-GPI hsa CAGTGACAGTACCAGCTTGGG    AAGGCCTGTTTCAGCATCAG 228 
Ret9 hsa GGATTGAAAACAAACTCTATGGTAGA AGGAAGGATAGTGCARAGGGGAC 83 
Ret51 hsa AAACAAACTCTATGGCATGTCAGAC CGCTGAGGGTGAAAGCATC 142 
NCAM hsa CAGCAGCGGATCTCAGTGGT CATCACACACAATCACGGCA 226 
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B. Rho GTPases 
RhoA rno ACTGGTGATTGTTGGTGATGG CACATAAACCTCTGGGAACTGG 85 
Rac1 rno CCCTCTCCTACCCGCAAAC TTCTCAATCGTGTCCTTATCATCC 178 
Cdc42 rno GGCTGTCAAGTATGTGGAGTG ACCTGCGGCTCTTCTTCG 113 
C. Integrins 
Itga2 rno CTCTCCTGTATGACGCTGAAC AATGTGGATGGTTACTGATGCC 188 
Itga3 rno ACTCCGTCCTATCGTCATCAC CTGTCGCACTTGTTGTCTGG 177 
Itga5 rno CTTCGGTTCACTGTTCCTCATC TCACGGCTTCAGGCTTGG 172 
Itga6 rno CCGCCGCTCAGAATATCAAG AAGCACAGCCAGGAGGATG 122 
Itgav rno ATTCGGTGCCATCTCAAATCC AGCATTTACGGTGACAACAGG 185 
Itgb1 rno AGTGAACAGCAACGGTGAAG AATCAGCAGCAAGGCAAGG 133 
Itgb3 rno CCTGGTGGTCCTGCTGTC TGGCTCTGGCTCGTTCTTC 134 
D. Matrix metalloproteinases (MMPs)/tissue inhibitors of metalloproteinases (TIMPs) 
Mmp2 rno TTTGTTTGCCCTTTGCTGTTTG AGCCGATGACTTGGTTCTCC 198 
Mmp9 rno GCCAACTATGACCAGGATAAGC TTGCCCAGGAAGACGAAGG 116 
Mmp13 rno TGCGGGAATCCTGAAGAAGTC AAGTTTGCCAGTCACATCTAAGC 94 
Mmp14 rno GTCATCTGCTTCTCTTCCATCC CAATCTTTCCACCTCCAAATATGC 173 
Mmp16 rno CCCTCTTGCCTCCTGACAC GACACAATGCTTCTCGCTCTG 124 
Timp1 rno TCCTGGTTCCCTGGCATAATC ATCTGATCTGTCCACAAGCAATG 151 
Timp2 rno TTACCCTCTGTGACTTTATTGTGC CATTGATGCTCTTCTCTGTGACC 183 
E. Genes regulated by NGF or GDNF in PC12 cells 
Egr1 rno TTAGAGCACGATGAGGAAGAGG CAGTAGGTAACCGCAGCATTC 160 
c-fos rno CGTCTTCCTTTGTCTTCACCTAC CCTGCCTTCTCTGACTGCTC 149 
Ier2 rno GAATCTCAGGGTCGGACTCTC CACGCAAGGCAACAGGAAG 153 
Arc rno TCAGCACAGAGCCCAGTTC GCACAGCAGGTAAGGTCAGG 103 
JunB rno TGTAGTCCCTCCCGTCTGG CTCTCAACTCAAGCGTCTGC 195 
Btg2 rno TCTCCTGTCCCTTCCGTCTG CCTCCATTATATCTGCCTTATAGCC 147 
Klf2 rno GCCGTCCTTTGCCACTTTC ACGCTGTTTAGGTCCTCATCC 105 
Maff rno CGTCGCACACTCAAGAACC GCTCGGACTTCTGCTTCTG 91 
Zfp36 rno CCCTCGGAAACTCTGGTCTC AATGGCTTTGGCTATTTGCTTTG 168 
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Atf3 rno TGTGCTACTCTGTGCTGACC GGACTTTGTGCCTTCGTTCTG 130 
Fosl1 rno TAGCAGCAGCAGTGGTGAC AAGGAGATGACAACGGGTAGC 111 
Dusp6 rno AACAGCCAGCCTTCCTTCC TGATGCCAAACTCTTCCAACAC 100 
Chac rno GCAGAGAAGGAGGCGAAGTAG GCAGACAGACAGAGGGATAAGG 140 
Okl38 rno CAAGGTGGGAGCAGTAGCC TGGTGAAAGGTTAGGTCTGAGG 123 
Srf rno CCTCAACTCGCCAGACTCTC CTTCAGTGTGTCCTTGGTTTCC 139 
Dusp5 rno GCAGCAAAGTAGGAGCAAGC TGAAGTGACAGAGGACAGAGAC 128 
Hes1 rno GCCAATTTGCTTTCCTCATCCC CCCGCTGTTGCTGGTGTAG 80 
Gadd45g rno GCGATGTTGCCTGGAGAGC TGCTTGCTGAGTCACACCTG 190 
Errfi1 rno CAGAGACAGAGCAGCGAAGG ACAGGCAGCAGGTAATGGC 195 
Ankrd1 rno CGTGGGTGAATGGTGTCTAATC AGCAGTGAGAATCCAGAGAAGG 120 
Bmp2 rno TTGTATGTGGACTTCAGTGATGTG TGGTTGGTGGAGTTCAGGTG 125 
Chga rno ACACAGCCAACAATACCCAATC CTCTTTCTCCTCCTCCTCTTCC 176 
Cited2 rno CTTAGTGATAGAGATGGGTTTGGAC GGGCAGGGAGGGTGATTTC 166 
Edg2 rno TCGCCAGAGGACTATGAGAATG ACCCAGCACAATGACCACAG 100 
Gale rno GACTACGCTACGGAGGATGG GCTTCTTCAAGGCTGCTATATGG 88 
Pfpl rno AACTCCACAACTCTGTATTGATGAC GGCAAGGTAAATCTTAACTGTAGGG 116 
Ldlr rno CAGTGTCCTCCCAAGTCCAAG GTTCCTCAGCCGCCAGTTC 155 
Scd1 rno AGGGCAGTTCTGAGGTGATTAG TTATGGCAGTGAGTAGGTAGGC 191 
Serpinb2 rno GTTCCTGTTGCTTCCTGATGAG CAGAATGGGCTTGAGTTCGTAG 181 
Slc16a3 rno CACACTTAGGAGACAACACGAC AGACAGAGATATGGAGGATTGGC 153 
Snf1lk rno TAGGGTAGAGGTGTCAGGGAAG GAGAACGAAGGTGTTTGGATGG 99 
F. Reference genes 
GAPDH mmu, rno ACCACGAGAAATATGACAACTC(A/C)C CCAAAGTTGTCATGGATGACC 100 
GAPDH hsa AAACCTGCCAAATATGATGAC ACCTGGTGCTCAGTGTAG 92 




 For direct RT of mature miRNA without RNA isolation, U251 cells in 96-well plate 
at various cell densities (10 to 10
5
 cells per well) were washed once with phosphate-buffered 
saline (PBS), lysed and reverse transcribed directly in the wells with 40 µl of RT mixture 
containing 0.5% Triton X-100 (Thermo Fisher Scientific, MA), 400 U Improm II (Promega) 
and 100 nM of each RT oligonucleotide (2.4 µM of total) in the presence or absence of RNase 
inhibitor SUPERase-In (1 U/µl, Ambion) for 30 min at 42°C. For comparison, total RNA 
from the identical densities of cells were isolated and reverse transcribed in the same RT 
mixture. 
 
10.5. Quantitative real-time PCR assays and DNA microarray 
 
10.5.1. Quantification of mRNA expressions 
 The gene expression levels were then quantified by real-time PCR using gene specific 
primers listed in Table 10.5. Real-time PCR were performed on iCycler iQ or CFX96 (Bio-
Rad) in a total volume of 25 µl in 1X XtensaMix-SG (BioWORKS, Singapore), containing 1 
µl of cDNA sample, 2.5 mM MgCl2, 100 nM of each primer, and 1.25 U KlearTaq DNA 
polymerase (KBiosciences, UK). Real-time PCR was carried out after an initial denaturation 
for 10 min at 95°C followed by 40 cycles of 30 s denaturation at 95°C, 30 s annealing at 60°C 
and 30 s extension at 72°C. Fluorescent detection was carried out at the annealing phase. The 
threshold cycles (Ct) were calculated automatically using the iQ5 or CFX Manager softwares 
(Bio-Rad). Absolute real-time PCR quantifications of GDNF receptor complexes (Group A in 
Table 10.5) were carried out simultaneously with linearized plasmid standards. The levels of 
gene expression were interpolated from standard curves and normalized to the expressions of 
GAPDH in the same samples. RPL19, instead of GAPDH was used as reference gene for 
gene expressions in PC12 cells. Fold changes of the other genes (Groups B-E in Table 10.5) 
in treatment samples in relative to control samples after normalization were calculated using 
the equation 2





10.5.2. Quantification of microRNA expressions 
 Real-time PCR for precursor miRNA and U6 snRNA was performed according to 
previous reports (319,344). Fast thermo-cycling of miRNA cDNAs was performed after 10 
min initial denaturation at 95°C followed by 50 cycles of 5 s denaturation at 95°C and 5 s 
annealing/extension at 60°C. One µl of each cDNA sample was subjected to real-time PCR in 
a total volume of 25 µl in 1X XtensaMix-SG
TM
 (BioWORKS, Singapore), containing 2.5 mM 
MgCl2, 100 nM of each primer and 1.25 U KlearTaq DNA polymerase (KBiosciences). The 
threshold cycles (Ct) were calculated automatically using the CFX manager software (Bio-
Rad). Where applicable, all miRNA expression levels were normalized to U6 snRNA 
expression.  
 In some cases, cDNA samples treated with 5 U UDG (New England Biolabs, 
Beverley, MA) at 37°C for 10 min. The reaction was inactivated at 95°C for 10 min and 
subjected to real-time PCR. 
 
10.5.3. Calculation of assay efficiency and specificity 
 Efficiency and specificity of real-time RT-PCR were determined as previously 
described (65). Briefly, 10-fold dilutions of miRNA were subjected to real-time RT-PCR. 
Standard curve of the miRNA were obtained by plotting Ct vs Log (copies) of synthetic 
miRNA dilutions. Assay efficiency was calculated by (10
1/S
 – 1)  100%, where S was the 
slope of the standard curve. For calculation of specificity, identical amounts (10
9
 copies per 
RT) of perfectly matched miRNA and mis-matched miRNAs were quantified by real-time 
RT-PCR. ∆Ct was then calculated as Ctperfectly matched miRNA – Ctmis-matched miRNA. Relative detection 
of mis-matched miRNAs was then calculated by 10






10.5.4. DNA Microarray 
 PC12 cells were seeded on 25 cm
2
 flask in complete medium and subsequently 
incubated for 12 h in serum free DMEM. The cells were then treated with GDNF (50 ng/ml) 
or NGF (50 ng/ml) for 0.5 h or 72 h in duplicates. Total RNA was isolated, quantified and 
integrity verified before it was amplified using Ambion Illumina RNA Amplification kit 
(Ambion). Briefly, total RNA (500 ng) was reverse transcribed by ArrayScript in the presence 
of T7 Oligo(dT) primer. Second strand of the cDNA was synthesized by DNA polymerase at 
16°C for 2 h. The cDNA was purified and in vitro transcribed with T7 RNA polymerase and 
biotin-NTPs. Biotin-labeled cRNA samples were purified and quantified by ND-1000 
spectrophotometer (NanoDrop, Fisher Thermo, DE). Each cRNA (750 ng) was hybridized to 
RatRef-12 Expression BeadChip (Illumina, San Diego, CA) containing 22,523 probes for a 
total of 21,910 rat genes selected primarily from the NCBI RefSeq database (Release 16) 
according to instruction provided by Experienced User Card (11286340 Rev A, Illumina). 
After hybridization, washing and blocking, the BeadChip was incubated with Streptavidin-
Cy3 solution (Amersham Biosciences, Piscataway, NJ). Fluorescent signals were obtained 
from scans on the high resolution Illumina BeadArray reader, using a two-channel, 0.8 μm 
resolution confocal laser scanner. The Illumina BeadStudio software (Version 2.0) was used 
to extract fluorescence intensities and the raw fluorescent data was background subtracted and 
used for analysis. Background is defined as the average signal intensity estimated from the 
negative control bead types. Outliers are removed using the median absolute deviation 
method. Detection p-values produced by the BeadStudio software were corrected for multiple 
hypothesis testing. 
 Gene-ontology analysis was carried out with Panther database (261). Regulation of 
gene expression by GDNF or NGF was clustered based on biological processes. A p value 






10.6. Analysis of glioma cell behaviors 
 
10.6.1. Cell proliferation assays 
 For the cell number analysis, C6 cells were seeded in triplicates in 6-well plates at 
100, 000 cells per well and transfected with siRNA for 24 h and 48 h. Cells were then fixed 
with 4% paraformaldehyde and stained with 20 µg/ml propidium iodide (Sigma) and 0.2 
mg/ml RNase (Boehringer Mannheim, Germany). Number of cells in each well was then 
counted under a fluorescent microscope in six randomly defined fields. For analysis of 
proliferating cells, siRNA-transfected cells were fixed and stained with ki-67 antibody as 
described above. Percentage of proliferating cells was calculated by the number of ki-67 
positive cells divided by total number of cells. For fluorescence-activated cell sorting (FACS) 
analysis, cells were harvested by trypsinization 48 h after siRNA transfections. Cells were 
collected by centrifugation at 1,000 g for 3 min and resuspended in PBS. Cells were then 
fixed with 70% ethanol and nucleus were stained with 20 µg/ml propidium iodide and 0.2 
mg/ml RNase. FACS was then performed on BD FACSCanto (BD Biosciences, San Jose, 
CA). FACS digital data was analyzed using WinMDI software version 2.9 (Scripps Institute, 
La Jolla, CA). 
 
10.6.2. Cell elongation analysis 
 C6 cells were either stained with 15 µg/ml fluorescein diacetate (FDA, Sigma) for 5 
min or immunostained with antibody against HA-tag. Cells were examined under fluorescent 
microscope and the cell elongation index was measured as previously described (175). Briefly, 
elongation index of a cell was measured as the ratio of the process length to the cell width. To 
measure the process length, a line was drawn from the center of the nucleus to the furthest 
visible tip of the cell process. To measure the cell width, a second line was drawn across the 
cell passing through the center of the nucleus at a 90° angle to the first line. The length in 
arbitrary units was measured by ImageJ software version 1.41o (National Institutes of Health, 




10.6.3. Cell migration and invasion assays 
 For wound healing assay, 20,000 C6 cells were seeded into 0.22 cm
2
 removable 
culture insert (ibidi GmbH, Martinsried, Germany) after siRNA transfections. The cells were 
grown to confluence and the “wound” was created by removing the culture insert. After 
washing the cells with PBS, the cells were incubated in complete medium. Wound healing 
was assessed 24 h after removing of the insert. For transwell migration assay, 10,000 C6 cells 
were seeded onto Costar transwell inserts (Corning, NY) with polycarbonate filters containing 
8 µm pores in complete medium. For matrigel invasion assay, 100,000 cells were seeded onto 
the transwell insert precoated with 25 µl Matrigel
TM
 basement membrane matrix (BD 
Biosciences) for 30 min at room temperature. The cells were cultured for 24 h at 37˚C. Non-
migrated cells on the upper surface of the insert were removed with cotton swab, and the cells 
on the lower surface were fixed with 4% paraformaldehyde and stained with 20 µg/ml 
propidium iodide and 0.2 mg/ml RNase. Number of migrated and invaded cells in each insert 
was then counted under a fluorescent microscope in at least four randomly defined fields. 
 
10.7. Analysis of neurite outgrowths 
 
10.7.1. Measurements of neurite outgrowths in Neuro2A and NG108-15 cells transfected 
with GFRα1 isoforms 
 Twenty thousand to 50,000 cells per well were seeded on 6 wells plate overnight, in 
DMEM supplemented with 10% FBS.  Cells were then incubated with media containing 0.5% 
FBS, with or without GDNF or NTN (50 ng/ml) and incubated for 3 more days. All-trans 
retinoic acid and forskolin (Sigma, 5 μM) were used as positive controls for inducing neurite 
outgrowth in Neuro2A and NG108-15 cells, respectively. Cells bearing neurite twice the 
length of the cell bodies were scored. More than 600 cells from 3 different fields were 
counted per well. Significance differences between ligand stimulated and control samples 
were calculated using Students t-test. A value of p < 0.05 was considered significant.  
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 For studies of inhibitors effects on neurite outgrowth, 5 µM of MEK1/2 inhibitor, 
U0126 (Promega) were added with or without ligands stimulations. RhoA inhibitor 
Exoenzyme C3 transferase was transfected into cells using Transfectin (Biorad), at 1 µl of 
Transfectin/ 1 µg of C3 transferase per well of 6-well plate, 4 hour prior to start of experiment. 
Cells were treated with exoenzyme C3 transferase (1 µg/ml) or ROCK inhibitor Y27632 (10 
µM) or H-1152 (0.5 µM), with or without presence of differentiating media.  
 To study the roles of RhoA, Rac1 and Cdc42, cells were transfected with the 
dominant negative mutants of RhoA (RhoA-DN), Rac1 (Rac1-DN) and Cdc42 (Cdc42-DN) 
using Transfectin (Biorad), 14-16 hours prior to treatment of differentiation media.  
     
10.7.2. Neurite outgrowths of PC12 cells expressing GFRα and Ret isoforms 
 PC12 cells were initially seeded in completed medium for 24-48 h, and serum was 
depleted (0.5% FBS) for another 16 h. Cells were then stimulated with individual or 
combinations of the following chemicals: 50 ng/ml GDNF, NTN or NGF, 10 µM FK, 100 µM 
dbcAMP, 100 nM PACAP, 50 µM, 100 µM or 200 µM of 2-Me-cAMP or 6-Bnz-cAMP in 
serum-depleted DMEM for 48 h. For inhibitor studies, cells were pre-treated for 1 h with the 
following chemicals before ligand stimulations: 10 µM U0126, 10 µM H89, 10 µM 
LY294002, 10 µM SB203580, 5 µM SP600125, 2 µM PP2, 2 µM SU6656, 2 µg/ml ActD or 
10 µg/ml Chx. Cells were then incubated with inhibitors and ligands for 24 h, 48 h or 96 h for 
neurite outgrowth analyses. To inhibit ERK activation at different time points after ligand 
stimulations, PC12 cells were treated with ligands (NTN and/or FK) for 0, 1 or 3 h followed 
by co-treatment with ligands and 10 µM U0126 for 48 h. Cells bearing neurites twice the 
length of the cell bodies were scored as differentiated cells. 
 For analysis of PC12 neurite outgrowth in transiently infected Ret constructs, PC12 
cells infected with Ret mutants in pQCXI-eGFP retroviruses were stimulated with 50 ng/ml 
GDNF for 48 h. eGFP positive cells bearing neurites twice the length of the cells bodies were 
scored as differentiated. Significance differences between stimulated and control samples 




10.7.3. Neurite outgrowths of BE(2)-C cells 
 BE(2)-C cells were seeded in DMEM with 0.5% FBS for 16 h and then stimulated 
with 50 ng/ml NTN, 10 µM FK, 200 µM 2-Me-cAMP or 200 µM 6-Bnz-cAMP for 96 h. For 
inhibitor studies, wild-type or GFRα2b knockdown BE(2)-C Cells were pretreated with 10 
µM U0126 or 200 µM Rp-8-Br-cAMPS and stimulated with 50 ng/ml NTN for 96 h. Cells 
bearing neurites twice the cell body length were scored as differentiated cells. Significance 
differences between stimulated and control samples were calculated using Students t-test. A 
value of p < 0.05 was considered significant. 
 
10.8. Analysis of intracellular signaling 
 
10.8.1. Antibodies 
 Primary antibodies against pERK1/2, ERK1/2, pAKT, AKT, pJNK, JNK, pp38, p38, 
pMEK, pLIMK1/2, LIMK1, pCofilin, Cofilin, pMLC2, MLC2, pFRS2α (pY196), pFRS2α 
(pY436), pCREB, pSrc (pY416), pRet (pY905), SOD-1, PARP-1 and PathScan® Multiplex 
Western Cocktail I were purchased from Cell Signaling Technologies (Danvers, MA). 
Antibodies for RhoA, Rac1, Cdc42, Ret9 (c-19), Ret51 (c-20), pRet (pY1062) were from 
Santa Cruz Technologies. Antibodies for Actin, NCAM and Flotinin-1 were obtained from 
Millipore (Billerica, MA). Antibodies against GFRα1 and Ret (both isoforms) were purchased 
from R&D Systems (Minneapolis, MN). Ki-67 and anti-HA antibodies were purchased from 
Sigma. Antibody against Transferin receptor was purchased from Zymed (San Francisco, CA). 
Secondary antibodies conjugated with horseradish peroxidase (HRP) were from Pierce 
(Rockford, IL) and secondary antibodies with Alexa Fluor label were from Invitrogen.  
 
10.8.2. Cytoplasmic and nuclear protein extraction 
 Total cytoplasmic and nuclear proteins from treated PC12 cells were extracted with 
NE-PER® Nuclear and Cytoplasmic Extraction Reagents (Perice) according to 
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manufacturer’s instruction. Briefly, treated PC12 cells were washed with PBS and gently 
harvested using a cell scraper. Cells were then pelleted by centrifugation and re-suspended in 
Cytoplasmic Extraction Reagent I (CER I) and incubated on ice for 10 min. Cells were lysed 
with Cytoplasmic Extraction Reagent II (CER II) and centrifuged at 16,000 g for 5 min. The 
cytoplasmic proteins were recovered from the supernatant. The pellet containing nuclei was 
then washed once with PBS and lysed with Nuclear Extraction Reagent (NER) for 40 min on 
ice. After centrifugation at 16,000 for 10 min, the nuclear proteins were recovered from the 
supernatant. Concentrations of both cytoplasmic and nuclear proteins were quantified using 
microBCA assay (Pierce) and stored at -20°C until further use. 
 
10.8.3. Immunoprecipitation 
 Ligand-stimulated NG108-15 cells were first washed twice with ice-cold PBS and 
then lysed with lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 0.5 mM 
sodium orthovanadate, 2 µg/ml pepstatin A, 5 µg/ml leupeptin and 10 µg/ml aprotinin). The 
lysed cells were incubated at 4°C for 20 min with gentle rocking and harvested using a cell 
scraper. Cell lysates were incubated at 4°C for another 20 min and centrifuged at 16,000 g for 
10 min at 4°C. The protein concentration in the supernatant was determined by microBCA 
assay. Five hundred µg of protein samples were incubated with 2 µg antibodies against Ret9 
(c-19) or Ret51 (c-20) for 4 h at 4°C with gentle rocking. Fifty µl of agarose-coupled protein 
A/G 50% slurry (Pierce) was then added to the mixture and incubated for 30 min. The 
mixture was then washed three times with lysis buffer. The immunoprecipitated proteins were 
then resuspended in SDS loading buffer and heated at 95°C for 5 min. Both total cell lysate 
and immunoprecipitated proteins were used for Western blotting. 
 
10.8.4. Extraction of detergent-resistant membrane (lipid rafts) 
 Ligand-stimulated PC12 cells were first washed twice with ice-cold PBS and then 
lysed with lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.5 mM 
sodium orthovanadate, 2 µg/ml pepstatin A, 5 µg/ml leupeptin and 10 µg/ml aprotinin). The 
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lysed cells were incubated at 4°C for 20 min with gentle rocking and harvested using a cell 
scraper. Cell lysates were incubated at 4°C for another 20 min and centrifuged at 16,000 g for 
10 min at 4°C. The detergent-soluble proteins were recovered from the supernatant. The 
detergent-resistant pellet was washed twice with ice-cold lysis buffer and solubilized with 2% 
sodium dodecyl sulfate (SDS). Concentrations of detergent-soluble and –resistant proteins 
were quantified with microBCA and used for Western blotting. 
 
10.8.5. Western blotting 
 Protein samples were separated by SDS-polyacrylamide gel electrophoresis (SDS-
PAGE), transferred onto nitrocellulose membranes, blocked with 5% milk and probed with 
antibodies listed previously. SOD-1 and PARP-1 were used as cytoplasmic and nuclear 
protein markers, respectively. Transferin receptor and flotilin-1 were used as markers for 
detergent-soluble and –resistant proteins, respectively. Blots were stripped with Restore 
Western Stripping Buffer (Pierce) and reprobed with antibodies against either total target 
proteins or house-keeping gene proteins (Actin or eIF4E) to verify equal loading of proteins. 
The protein bands were developed with Immobilon Western Chemilum HRP Substrate 
(Millipore) on ChemiDoc XRS system (Biorad). The band intensities were quantified using 
Quantity One 1-D Analysis software v4 (Biorad). 
 
10.8.6. Immunocytochemistry 
 C6 Cells were fixed with 4% (w/v) paraformaldehyde, permeabilized with 0.5% 
Triton X-100 (Thermo Scientific, Waltham, MA) and blocked with 10% normal goat serum 
(DAKO, Glostrup, Denmark). The cells were then incubated with primary antibodies against 
ki-67 (1:200, Sigma) or HA-tag (1:200, Sigma). Cells were further incubated with secondary 
antibodies conjugated with Alexa Fluor 488 (Molecular Probes, CA). F-actin was visualized 
with TRITC-conjugated Phalloidin (1 µg/ml, Sigma). The nucleus of the cells was stained 
with 1 µg/ml Hoechst 33258 (Sigma) in PBS. The immunofluorescence was visualized and 
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captured with either a Zeiss inverted fluorescent microscope or a LSM 510 Axiovert 200M 
confocal microscope (Zeiss, Thornwood, NY). 
 
10.8.7. RhoA activation assay 
 RhoA activation was examined by GST-Rhotekin pull-down assays (Cytoskeleton, 
Denver, CO). Neuro2A or C6 cells were lysed in lysis buffer containing 50 mM Tris-HCl (pH 
7.5), 300 mM NaCl, 0.1% NP-40, 0.5% sodium deoxycholate, 10% glycerol, 10 MgCl2, 2 
µg/ml pepstatin A, 5 µg/ml leupeptin, 10 µg/ml aprotinin, and 1 mM 
phenylmethanesulfonylfluoride (PMSF). The concentration of cell extracts was determined by 
microBCA assay (Pierce). Five hundred µg of protein extracts were incubated with GST-
Rhotekin immobilized on agarose beads at 4°C for 1 h. The beads were then washed twice 
with cell lysis buffer. Active RhoA was released from the beads by heating at 95°C for 10 
min in SDS loading buffer. Both total and active RhoA was then resolved by 12% SDS-
PAGE and detected by Western blot using RhoA antibody. 
 
10.8.8. Gelatin Zymography 
 C6 cells were transfected with GFRα1 siRNAs. After 24 h, conditioned medium was 
collected and centrifuged at 1,000 g for 3 min. Twenty µl of the medium was subjected to 
gelatin zymography assay. Briefly, the conditioned medium was incubated with 2x sample 
buffer containing 62.5 mM Tris-HCl (pH 6.8), 2% (w/v) SDS and 10% (v/v) glycerol for 10 
min. The samples were then resolved by 10% SDS-PAGE containing 1% (w/v) gelatin 
(Sigma). After electrophoresis, the gel was incubated in renaturing buffer containing 2.5% 
Triton X-100 for 30 min. Gelatin digestion was performed by incubating the gel in developing 
buffer containing 50 mM Tris-HCl (pH 7.8), 150 mM NaCl, 5 mM CaCl2 and 1% Triton X-
100 at 37˚C for 24 h. Gels were then stained with InstantBlue (Expedeon, Cambridge, UK) 
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